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Abstract 
Iron, vitamin A, and protein inadequacies are common in food-aid receiving countries, 
and maximizing nutrient intake and bioavailability are essential treatments. Fortified-blended 
foods (FBFs), are food-aid micronutrient-fortified legume-grain porridges distributed worldwide. 
FBFs have not consistently, effectively treated undernutrition, and it has been suggested that 
formulation and processing changes could improve their nutritional quality. Sorghum is a well 
suited FBF commodity, but high concentrations of ‘antinutritional’ tannin and phytic acid have 
limited its adoption. Iron bioavailability adaptation may be possible after long-term 
antinutritional factor consumption, but adaptive mechanisms are not well understood. In rats, 
salivary proline-rich proteins (PRPs) have been found to chelate tannins to improve iron 
bioavailability, this could be true for people as well. Several research design methods were 
employed to summarize FBF quality outcomes and the effect of tannin and phytic acid 
consumption on iron bioavailability. Extruded sorghum and corn FBFs were developed; protein 
quality, iron, and vitamin A outcomes were compared with a non-extruded corn-soy blend 
(CSB+) in rats.  A narrative literature review and meta-analysis were conducted to determine 
tannin’s antinutritional effects on iron bioavailability, and the potential for adaptation through 
salivary PRPs. Two clinical trials examined the effect of long-term tannin or phytic acid 
consumption on iron bioavailability, salivary protein production, and correlations between PRPs 
and iron bioavailability. There were no differences between iron (hepatic iron 207-300 µmol/g 
*100), vitamin A (hepatic retinol 423-585.5 ng/mg), or protein quality (caloric efficiency: 101.3-
113.3 g/kcal*100) between extruded FBFs regardless of commodity in rats. Compared to 
extruded FBFs, CSB+ caloric efficiency (49.0 ± 2.2 g/kcal*100) and growth (96.3 ± 3.4g vs. 
208.6-236.6) were significantly reduced. A literature review suggested that there were 
  
differences in acute meal and long-term iron bioavailability with tannin consumption; tannic acid 
inhibited iron availability, while food-tannins did not. Meta-analysis suggested that tannin-PRP 
binding could protect iron bioavailability, that long-term tannin consumption did not 
significantly affect hepatic iron or non-heme iron absorption respectively in rats  (d = -0.64-1.84; 
-2.7-0.13), and that PRP expression in rats during tannin consumption was correlated with 
improved iron bioavailability. There were no reductions in iron bioavailability or status based on 
long-term tannin (ps > 0.126) or phytic acid (ps > 0.08) consumption clinically, but basic PRP 
and cystatin subtypes were significantly correlated with improved iron bioavailability during 
tannin (ps < 0.03) and phytic acid (ps < 0.02) consumption. In vitro, it phytic acid-PRP binding 
did not occur, but phytic acid did specifically bind with cystatin SN, a non-enzymatic salivary 
protein. In conclusion, FBF formulation changes may improve protein quality, and provide 
needed macronutrients to food-aid receiving areas. Despite this, this research did not suggest that 
antinutritional factors affected iron bioavailability. In support of this finding, literature, and 
clinical studies presented here suggest that salivary proteins, including PRPs and cystatin, may 
serve as adaptive protective mechanisms against phytic acid and tannin consumption, and that 
further research may be warranted before further recommendations for their removal from food-
aid are made. 
 
  
  
Factors affecting food aid: evaluation of new fortified-blended foods and the impact of tannins 
and phytates in diets 
 
 
by 
 
 
Nicole Marie Delimont 
 
 
 
 
B.S., Kansas State University, 2009 
M.S.N., Vanderbilt University, 2011 
 
 
 
A DISSERTATION 
 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Food, Nutrition, Dietetics, and Health 
College of Human Ecology 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2017 
 
 
 
 
Approved by: 
 
Major Professor 
Brian L. Lindshield 
  
 
Copyright 
© Nicole Delimont 2017. 
 
 
  
  
Abstract 
Iron, vitamin A, and protein inadequacies are common in food-aid receiving countries, 
and maximizing nutrient intake and bioavailability are essential treatments. Fortified-blended 
foods (FBFs), are food-aid micronutrient-fortified legume-grain porridges distributed worldwide. 
FBFs have not consistently, effectively treated undernutrition, and it has been suggested that 
formulation and processing changes could improve their nutritional quality. Sorghum is a well 
suited FBF commodity, but high concentrations of ‘antinutritional’ tannin and phytic acid have 
limited its adoption. Iron bioavailability adaptation may be possible after long-term 
antinutritional factor consumption, but adaptive mechanisms are not well understood. In rats, 
salivary proline-rich proteins (PRPs) have been found to chelate tannins to improve iron 
bioavailability, this could be true for people as well. Several research design methods were 
employed to summarize FBF quality outcomes and the effect of tannin and phytic acid 
consumption on iron bioavailability. Extruded sorghum and corn FBFs were developed; protein 
quality, iron, and vitamin A outcomes were compared with a non-extruded corn-soy blend 
(CSB+) in rats.  A narrative literature review and meta-analysis were conducted to determine 
tannin’s antinutritional effects on iron bioavailability, and the potential for adaptation through 
salivary PRPs. Two clinical trials examined the effect of long-term tannin or phytic acid 
consumption on iron bioavailability, salivary protein production, and correlations between PRPs 
and iron bioavailability. There were no differences between iron (hepatic iron 207-300 µmol/g 
*100), vitamin A (hepatic retinol 423-585.5 ng/mg), or protein quality (caloric efficiency: 101.3-
113.3 g/kcal*100) between extruded FBFs regardless of commodity in rats. Compared to 
extruded FBFs, CSB+ caloric efficiency (49.0 ± 2.2 g/kcal*100) and growth (96.3 ± 3.4g vs. 
208.6-236.6) were significantly reduced. A literature review suggested that there were 
  
differences in acute meal and long-term iron bioavailability with tannin consumption; tannic acid 
inhibited iron availability, while food-tannins did not. Meta-analysis suggested that tannin-PRP 
binding could protect iron bioavailability, that long-term tannin consumption did not 
significantly affect hepatic iron or non-heme iron absorption respectively in rats  (d = -0.64-1.84; 
-2.7-0.13), and that PRP expression in rats during tannin consumption was correlated with 
improved iron bioavailability. There were no reductions in iron bioavailability or status based on 
long-term tannin (ps > 0.126) or phytic acid (ps > 0.08) consumption clinically, but basic PRP 
and cystatin subtypes were significantly correlated with improved iron bioavailability during 
tannin (ps < 0.03) and phytic acid (ps < 0.02) consumption. In vitro, it phytic acid-PRP binding 
did not occur, but phytic acid did specifically bind with cystatin SN, a non-enzymatic salivary 
protein. In conclusion, FBF formulation changes may improve protein quality, and provide 
needed macronutrients to food-aid receiving areas. Despite this, this research did not suggest that 
antinutritional factors affected iron bioavailability. In support of this finding, literature, and 
clinical studies presented here suggest that salivary proteins, including PRPs and cystatin, may 
serve as adaptive protective mechanisms against phytic acid and tannin consumption, and that 
further research may be warranted before further recommendations for their removal from food-
aid are made. 
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This work is dedicated to the poor and malnourished, and to a vision for a world where 
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Chapter 1 - UNDERSTANDING AND OVERCOMING BARRIERS 
TO GLOBAL UNDERNUTRITION 
 Undernutrition 
 Global Prevalence of undernutrition 
The United Nations Children’s Fund (UNICEF) estimates that nearly half of under five 
deaths are attributable to undernutrition, including micronutrient deficiencies (MNDs), stunting, 
or wasting; this equates to almost 3 million children each year 1. Micronutrient deficiencies are 
often referred to as ‘hidden hunger’ because of their significant impact on morbidity and 
mortality despite lack of overt signs and symptoms of deficiency 2. Micronutrient deficiencies 
are commonly found with other nutritional deficiencies, although they are often found alone 2.  
In the first 1000 days of life, poor nutrition is associated with stunting, an irreversible 
deficit in stature associated with cognitive impairment, and wasting, defined as rapid weight loss 
or failure to gain weight 1. An estimated one in four children are stunted (156 million), which is a 
ten percent decrease in the past 15 years. Wasting remains more prevalent than obesity (50 
versus 42 million children in 2015) 3, and the majority (93% and 92%) of the world’s stunted or 
wasted children respectively live in Asia and Africa 3. Most undernutrition occurs in low income 
countries, which are the only areas in the world to experience increases in stunting prevalence in 
the past ten years 3.  
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 Reasons for undernutrition 
Most malnutrition occurs due to inadequate intake or absorption of nutrients, although the 
complexity of this phenomena cannot be overstated 2. For infants and children under five, 
undernutrition may occur due to maternal undernutrition or secondary to rapid growth 4, but the 
primary etiological processes that drive undernutrition are most likely food insecurity, 
inadequate feeding practices, lack of safe drinking water, climate change, and lack of access to 
health services 5. Despite its complexity, undernutrition’s superseding driver is ultimately 
poverty 2, which leads to high rates of stunting, wasting, and micronutrient deficiencies in 
resource poor countries 3.  
 Micronutrient deficiencies and protein-energy malnutrition 
 Micronutrient deficiencies 
Children who have MNDs are at increased morbidity and mortality risk due to fatal 
infections, resultant cognitive, physical and economic losses, and deficits in reproductive 
capability; these factors ultimately lead to multigenerational consequences and the continued 
cycle of undernutrition 1,2. Pregnant women and children under five are commonly micronutrient 
deficient, and the most widespread deficiencies are of iron, iodine, vitamin A, folate, and zinc 2 
(Table 1-1). While iodine 6, and even folate 7 supplementation initiatives have been effective in 
combatting MNDs, vitamin A deficiency remains the leading cause of childhood blindness 8, and 
iron deficiency is the most common nutritional deficiency worldwide 9. 
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Table 1-1 Common micronutrient deficiencies and pathology (adapted from 10) 
Deficiency Prevalence Pathology due to deficiency 
Iron 2 billion Iron deficiency anemia, 
malaise, low birth weight, 
increased infant mortality, 
stunting 
Iodine 1.88 billion 11 Goiter, cognitive deficit, 
hypothyroidism, infant 
mortality, stunting, inhibited 
sexual maturation 
Vitamin A 240-250 million children and 
pregnant women 8 
Xeropthalmia, night 
blindness, increased maternal 
and infant mortality 
Folate Variable, but estimates as 
high as 30-40% of Western 
and non-Western cohorts 7 
Neural tube defects, 
megaloblastic anemia, heart 
disease, depression, stroke 
Zinc Global estimates of ~31% of 
poor children and women 12 
Stunting, decreased resistance 
to infectious disease, genetic 
disorders 
 
 Iron deficiency 
 Prevalence, pathology and etiology 
Iron deficiency is linked to developmental 13, economic, and health 14 related complications. 
Economic losses due to iron deficiency exceed billions of dollars each year globally 15, and an 
estimated one billion people are anemic due to iron deficiency 9. Iron deficiency anemia (IDA) 
rates are more than 30, 42, and 47% in non-pregnant women, pregnant women, and children 
worldwide 16, an improvement of only 4% in total iron deficiency prevalence in the past 20 years 
17. More anemic children are concurrently diagnosed with severe acute malnutrition (SAM) than 
in the general population, exacerbating anemia-mortality risk 18. Simply, iron deficiency occurs 
with imbalances in iron intake, absorption, and demand 16. Children and women are particularly 
vulnerable to iron deficiency due to physical factors such as rapid growth and blood loss 16, 
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respectively, but also because of economic, political, and institutional disadvantages that lead to 
infectious, health care related, and nutritional iron losses compared to their adult male 
counterparts (Figure 1-1) 16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Iron deficiency determinants in women and children. 
Adapted 16. Women and children are particularly vulnerable to economic and political 
disadvantages. Lack of land ownership or agricultural outputs, lower literacy rates, 
decreased equal education and pay, and thus reduced health care coverage lead to less 
wealth and access to iron containing foods, access to healthcare to prevent and treat iron 
deficiency, and increased infectious burden and sanitation related illness. The anemia cycle 
continues as women experience increased fetal need for iron, coupled with blood loss 
during pregnancy and increased nutrient needs during breastfeeding. 
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 Non-heme iron absorption and metabolism 
Ten percent of iron stores are obtained through absorption, while the remainder comes from 
senescent red blood cell recycling 19,20. Total body iron stores, hypoxia, and erythropoiesis 
regulate iron absorption, and these factors are balanced with multifactorial cell loss, 
menstruation, and intestinal iron losses through enterocyte sloughing 21. Duodenal non-heme iron 
absorption occurs at the enterocyte apical cell membrane, where it is first reduced to its ferrous 
form by cytochrome Dcytb 22 and is transported into the cell by divalent metal transporter 1 23. 
Ferrous iron is then transported across the basal membrane of the enterocyte, exported by 
ferroportin 24, oxidized by hephaestin and bound to transferrin for transport and organ use 25.  
 Measurements of iron status and deficiency 
Iron status and deficiency are often measured in context with hemoglobin, which is the iron-rich, 
oxygen-carrier molecule in red blood cells 26. In iron deficiency, heme and red blood cell 
production are decreased 26, leading to an increased number of senescent cells, and later, a low 
proportion of reticulocytes, or immature red blood cells, which contain decreased heme content 
27. Decreased heme-cell availability then leads to decreased cell size and color (denoted 
microcytosis with hypochromia) 26, along with decreased total red blood cell counts, which 
collectively indicate iron deficiency 27. Although anemia is a result of iron deficiency, heme 
production is tightly regulated, red blood cell production is conserved well into marginal iron 
status, and thus anemia itself is not indicative of iron stores 26 (Table 1-2). Serum ferritin, an iron 
storage molecule, coupled with total iron binding capacity, serum free iron, and transferritin 
saturation more accurately reflect iron balance 26,27 than hemoglobin itself. Serum ferritin is 
correlated with iron storage, although production is increased in inflammation, which may mask 
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iron insufficiency. Co-analysis of hemoglobin, which is decreased, along with mean corpuscular 
volume and TIBC, which are normal, in anemia of chronic disease, respectively 26,27, or an acute 
inflammatory biomarker such as C-reactive protein (CRP) can provide context to the 
inflammatory increase in ferritin levels.   
Table 1-2: Trends in iron status markers with iron balance (Adapted 26). 
Measurement Normal 
Negative 
balance 
Depletion Deficiency Anemia 
Bone 
Marrow 
↔ ↓↓ ↓↓ ↓↓ ↓↓ 
Plasma 
Ferritin 
↔ ↓ ↓↓ ↓↓↓ ↓↓↓↓ 
TIBCa ↔ ↔/↑ ↑ ↑↑ ↑↑ 
sTrb ↔ ↔/↓ ↓ ↓↓ ↓↓ 
Plasma iron ↔ ↔ ↔ ↓↓ ↓↓ 
Hemoglobin ↔ ↔ ↔ ↓ /↔ ↓↓ 
MCVc ↔ ↔ ↔ ↓/ ↔ ↓ 
No change (↔), negative change (↓), positive change (↑). a Total iron binding capacity; bSerum 
transferritin saturation, cMean corpuscular volume 
 
 Interventions targeting iron status 
Iron homeostasis is mostly non-modifiable, so much of the nutritional focus around iron 
deficiency treatment has been on a few modifiable factors such as food inhibitors and iron 
absorption enhancers 19. Strategies aimed at improving global iron status have centered around 
iron supplementation, and food fortification 16, although risks of supplementation in low income 
countries include increased malarial burden, iron overload (and related growth suppression), and 
supplement side effects 16. Antinutritional factors, such as tannins and phytates, directly chelate 
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iron to form insoluble complexes 28, and thereby impair absorption. Due to the possibility for 
dietary restriction, and propensity for iron chelation, antinutritional factors have been criticized 
for their contribution to iron deficiency in low income countries 29,30 and are thus an area of 
focus for researchers and health workers.  
 Models assessing iron bioavailability 
Among others, some commonly used iron bioavailability assessment methods include 
radioiron tagging or stable iron isotope ingestion 31, postabsorptive plasma iron measurement 32, 
in vitro Caco-2 cell model33, and the animal model based hemoglobin depletion-repletion 
method 34. Radioiron tagging is often used as an endpoint measurement, meaning that ultimately, 
tagged iron is measured from red blood cells, and absorption is based on expected iron loss 
versus measured red blood cell iron-incorporation 31,34. Postabsorptive plasma iron measures 
changes in plasma iron after oral iron administration 32. Both radioiron tagging and 
postabsorptive iron measurement allow for direct measurement of human iron bioavailability, 
and can be modified to assess for acute or long-term nutrient analysis 31,32,34. Despite their 
advantages, radioiron tagging and post-absorptive plasma iron measurement are costly, time-
consuming, and often, populations of interest (particularly infants and children) are difficult to 
study. 
Non-human iron bioavailability methods include in vitro Caco-2 cell and the animal 
model based hemoglobin depletion-repletion method. Colorectal Caco-2 cells have the ability 
differentiate to enterocytes with normal epithelial cell characteristics, including secretion of 
brush border enzymes 33. After differentiation, Caco-2 cells take up iron like typical enterocytes 
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33. Simulated digestion, and then Caco-2 iron uptake have thus been used to measure acute iron 
bioavailability from meals 33,34.  
Pig, rat, and chickens are all models used to simulate iron bioavailability in vivo 35. Most 
animal studies use variants of the hemoglobin depletion-repletion model, which essentially 
creates increased iron demand to measure iron bioavailability differences in test meals 34. Rats 
are commonly used experimental model for iron bioavailability, are simple and cost effective, 
and have been shown to accurately simulate human digestion 36. Pigs are omnivorous, have 
similar nutrient requirements as humans 37,38, and studies in pigs have demonstrated similar 
pharmacokinetic and bioavailability results as humans 39. Broiler chickens are cost effective, 
have similar intestinal anatomy to humans, mirrors human iron responses during anemia 35, and 
matches iron availability studies in Caco-2 cells 40. While rats, pigs, and chickens present cost-
effective, feasible models for iron bioavailability simulation, there are dissimilarities between 
each model and human digestion that limit their broad application. Rats have been noted to have 
greater iron bioavailability than humans, potentially due to differences in human and rat 
gastrointestinal tracts, energy expenditure, and nutrient metabolism 38. While pigs accurately 
simulate human iron digestion, they are cost prohibitive 39. It is not well understood whether 
avian iron metabolism accurately reflects human bioavailability outside of Caco-2 cell digestion.  
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Vitamin A deficiency 
 Prevalence, pathology, and treatment 
Vitamin A deficiency is the third most common nutritional deficiency in the world 8, and its 
estimated prevalence in South Asia and Sub Saharan Africa nears 40% 41. Morbidity and 
mortality rates due to infectious disease are doubled in deficient children 41, and supplementation 
has been shown to reduce all-cause mortality by as much as 24% in deficient children 6 months – 
5 years 42. Vitamin A deficiency most commonly occurs due to inadequate preformed vitamin A 
intake, as well as diets low in provitamin A-rich carotenoid fruits and vegetables 42. The most 
common interventions to combat vitamin A deficiency include supplementation and food 
fortification with preformed vitamin A, carotenoid rich food consumption, and crop bio-
fortification 43. In 2014, fortification initiatives reached targeted estimates of 80% of East Asian, 
Pacific, and West and Central African nations 44, while Eastern, Southern African, and South 
Asian countries remained nearly 20% below targets 44.  
 Vitamin A absorption, metabolism, and measurement 
Vitamin A is a fat-soluble vitamin commonly consumed as either preformed vitamin A (retinol 
or retinyl esters) or from provitamin A carotenoids 45. Preformed vitamin A is found in animal 
products (dairy, fish, meat), while provitamin A carotenoids are generally plant-based 45. Most 
dietary vitamin A, whether carotenoid or preformed, are transported by chylomicrons and 
converted to retinyl esters for storage in hepatic stellate cells, or are converted to retinol, bound 
to retinol binding protein, and directed to various organs for use 46. Vitamin A (cis-retinal) is 
needed to form rhodopsin, needed for dim light accommodation in rod formation, and vitamin A 
deficiency leads to keratinization of corneal tissue by xeropthalmia 26. Vitamin A deficiency 
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therefore leads to night blindness, and eventually, corneal scarring, and complete blindness 
26.  Serum vitamin A stores are tightly homeostatically regulated by retinol binding protein 
(RBP), and thus, reductions in serum retinol (<0.7 µmol/L) reflect depleted vitamin A stores, and 
deficiency 43. Due to tightly regulated serum vitamin A levels, blood measurement is not directly 
reflective of status, similar to iron metabolism, but is useful in identifying deficiency. Aside from 
overt vitamin A deficiency, hepatic RBP production is decreased during inflammation or illness, 
and thus the clinical picture of vitamin A deficiency based on serum retinol depends on the 
inflammatory state of the individual 47. Hepatic retinol isotope dilution is a technique that allows 
for more accurate estimation of deficiency and moderate or marginal vitamin A status by using a 
small dose of tracer vitamin A followed by measurements of unlabeled vitamin A to tracer 
vitamin A ratios 46, however this technique is not field-friendly due to the need for blood storage, 
and sophisticated lab assessment. Retinol-binding protein has been found to be reflective of 
serum retinol 48, can be adjusted for inflammation 49, and can be performed in a simple ELISA 
from a dried blood spot 50. 
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 Protein-energy undernutrition 
 Prevalence, pathology, and etiology 
Protein-energy malnutrition (PEM) is an umbrella term for a constellation of conditions 
including underweight (<80% weight for age), marasmus (<60% weight for age), kwashiorkor 
(weight for age <80% + edema), stunting, wasting, mild, moderate, and severe acute malnutrition 
(SAM; weight for height, edema, MUAC <80%) 51,52. Edema’s presence in undernutrition 
indicates electrolyte abnormalities encompassed in protein deficiency with, or without, caloric 
deficit 52. Increased vulnerability to gram negative septicemia is common with SAM, and 
treatment is complicated by commonplace and life-threatening refeeding syndrome 52. In 
refeeding syndrome, isocaloric or hypercaloric diets cause functional electrolyte deficits that 
occur secondary to rapid changes in metabolic rate 2.  
Infectious disease burden, impaired dietary absorption, rapid growth, and ultimately 
inadequate protein intake all contribute to PEM prevalence rates among children in low income 
countries 53. Even with adequate PEM recovery, children have been found to be at increased risk 
for relapse or death more than a year after returning to normal anthropometric-for-age scores 54. 
It has been suggested that extended feeding programs may help to prevent relapse 55, but above 
all, energy deficits and subsequent macronutrient imbalances compound the problem of PEM. 
Total, and utilizable, protein may differ among nourished and undernourished individuals; 
positive energy balance uses a significantly higher proportion of total protein for growth than 
negative energy balance 53. Findings from one study estimated that 5% energy deficits in 
underweight men increased protein needs for growth by 10% 56. These findings underscore the 
nuances in energy balance and macronutrient-diet composition that must be considered in 
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childhood PEM, where growth patterns lead to continual and rapid changes in macronutrient 
needs. Unfortunately, it is not well understood how to best treat PEM once a child is 
undernourished. Protein intake in infancy correlates with later total weight gain 53, and animal 
protein intake has been shown to be associated with linear growth with adequate weight for age 
57, but it is not well understood whether protein intake results in improved linear growth or 
obesity later in life 58,59. Amino acid composition and protein quality regulate growth rates 
among a variety of protein sources 60-62, although debate remains about plant versus animal 
source proteins’ adequacy for PEM treatment 63. In food secure areas, PEM may be combated 
effectively through community nutritional education 64 outlining treatment complexity that is 
beyond metabolic nutrition alone.  
 Measurements of protein quality 
Common measurements for protein quality include the protein efficiency ratio (PER), 
amino acid scoring (AAS), the protein digestibility-corrected amino acid score (PDCASS), and 
the digestible indispensable amino acid score (DIAAS). While the PER has been commonly used 
for protein quality assessment, recent recommendations have favored models that more 
accurately simulate human digestion 65. Despite this, it is important to consider models 
independently for their strengths to measure protein quality accurately. 
The PER is a standardized method that measures weight gain for four weeks in weanling 
rats consuming a test diet, and compares efficiency of weight gain to a control, high quality 
(casein) protein diet 65. Final PER values are calculated by dividing weight gain by the amount of 
protein consumed during the study 65. The PER ‘can be used when there is doubt about the 
protein quality of a food or diet,’ but limitations include that animal feeding patterns do not 
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simulate post-prandial and post-absorptive changes in protein and amino acid balances in 
humans, and that the method does not account for caloric maintenance 65,66. Despite questions 
regarding similarity of the method to simulating human digestion, strengths include 1) that the 
PER may be more accurate when considering antinutritional factors 67, and  2) that the PER 
allows for nutritive comparison of foods, outside of human digestion 65,67.  
While the PER perhaps gives context to protein quality of foods independent of human 
digestion, there has been consensus that a method based on human amino acid requirements 
might be a more suitable approach 65. The AAS was developed to score protein quality based on 
the first limiting amino acids in foods 65,68. Despite its attempt to rate quantity needed for human 
amino acid needs, the AAS lacks context for amino acid bioavailability, protein digestion, and 
methodology for amino acid quantification 65,69, limiting its generalizability for human digestion. 
Currently, the FAO/WHO recommend the PDCAAS method for determination of protein 
quality, although the digestible indispensable amino acid score (DIAAS) has been proposed as a 
better measurement 66. While the PDCAAS assesses the quality of protein based on total 
digestibility and amino acid composition, its limitations include measuring effects of 
antinutritional factors, as well as lack of distinct scoring differences among protein sources due 
to score truncation 53,66. By contrast, the DIAAS allows for individual amino acids measurement 
in foods, from ileal digesta, without a truncated score, in age-defined populations 66. These 
factors may be particularly important in low protein diet consumers, like children with PEM. 
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 Strategies to reduce undernutrition: Food aid 
 Global food aid use and distribution 
To combat undernutrition, food aid programs exist for pregnant women, malnourished 
individuals with tuberculosis or HIV/AIDs, school-aged children and children under five 70. In-
kind food aid, local and regional purchase, cash transfers for food, and food vouchers all 
constitute methods for food aid delivery 70. The United States provides most food aid as Title II 
(in-kind) food aid, where U.S. commodities are purchased, processed, and transported to food aid 
beneficiaries 70. In 2012, the World Food Program (WFP) estimated that 2,085,721 metric tons of 
food aid was sent from the United States (more than 50% of total food aid donations); and 
2,976,688 tons of world food aid was received by Sub-Saharan Africa alone 70 (Table 1-3). 
Table 1-3: Food aid received (2012) by region 71 
Country (2012) Food aid received 
 (metric tons) 
Sub-Saharan Africa 2,976,688 
North Africa and Middle East 472,995 
Asia 1,090,719 
Latin America and Caribbean 194,811 
Europe 4,793 
Total 4,740,011 
 
 Commonly distributed food aid products 
Ready-to-use therapeutic food (RUTF) and fortified-blended food (FBF) aid products are 
approved for pediatric food aid, and have proven effectiveness in preventing stunting and 
wasting 72. RUTFs are lipid-based or protein-rich, micronutrient-fortified supplements, while 
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FBFs are micronutrient fortified cereal-legume porridges that are partially precooked 73. High 
energy biscuits, compressed food bars, and micronutrient sprinkle powders provide 
micronutrient-and-protein or micronutrient only fortification to improve nutrition where cooking 
facilities are scarce, and are less commonly distributed 71. The most commonly distributed food 
aid are FBFs, which have been approved for treatment of acute malnutrition and stunting during 
complementary feeding, malnourished individuals on antiretroviral or tuberculosis treatments, 
pregnant and lactating women 71. FBFs’ nutrient-cost benefit has contributed to their widespread 
use 74. It is recommended that FBFs be consumed as <50% of total caloric needs 71, although 
they are often consumed as a higher proportion than recommended. The most commonly 
produced FBF by the United States is CSB, or corn-soy blend 75, but wheat and rice are also 
combined with soy in FBFs 73 (Table 1-4). 
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Table 1-4: Commodities purchased for food aid FY 2014, WFP adapted 76 
Food Type Percentage Amount  
x1000 metric tons 
Maize 16 350.1 
Sorghum 7 169.5 
Rice 16 360.5 
Wheat 7 161.6 
Cereal flours 7 168.9 
Dried Pulses 11 247.9 
Vegetable oil 6 141.1 
Sugar 1 38.8 
RUTF/HEB 10 227.8 
MNP/compressed food bars 1 25.9 
Canned foods 1 33 
Cereal based processed foods 5 114.3 
Family parcels 6 145.9 
Total 100 2185.9 
RUTF: ready to use therapeutic food; HEB: high-energy-biscuit; MNP: micronutrient 
powders/sprinkles 
 History of food aid development and use 
The first FBF, ‘corn-soy milk’ consisted of vitamin and micronutrient powder, dried milk, corn, 
and soy flour, and was used in the 1960’s for its ease and simplicity of delivery that was 
consistent with post-World War II pragmatism for ‘efficient diets’ that were nutrient dense and 
easily digestible 77. FBFs’ benefits, including ease of humanitarian programming around use, 
transport ease, and a ‘one size fits all’ approach 78 have been essential components to their 
continued use. FBFs can be culturally modified in their preparation, and their partially precooked 
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nature allows for recipient control over feeding practices while supplying consistent nutrition 77. 
Consumption of FBFs has been shown to treat moderate acute malnutrition as effectively as 
RUTF 79, at a fraction of the price, which enhances recipient availability. Despite many benefits, 
in-country commodity sourcing, palatability barriers, and product misuse (improper preparation, 
selling or stealing product) complicate FBF use 77.   
After their inception, few modifications were made to FBFs formulations for nearly forty years 
74. In 2004, WFP called for food aid programs that included development of FBFs conceived 
with participatory research for feasible, affordable, and culturally acceptable recipes 80. The 
report noted that while FBFs could provide nutritious, micronutrient dense foods, they 
inconsistently met iron or zinc requirements in a Hatian cohort 80. Five years later, a systematic 
review purported that despite positive effects on recovery from moderate acute malnutrition and 
weight gain due to FBF consumption, there was ‘limited and weak’ evidence for FBF nutritional 
outcomes improvement, including micronutrient status, in children 81. Other reports have claimed 
that FBFs lack macronutrient and micronutrient composition necessary to prevent stunting or 
wasting, and that their composition inherently inhibits micronutrient absorption due to food 
matrix issues (i.e. antinutritional factors) 82. In 2010, a review suggested that both development 
of new products, and improving FBF manufacturing and formulation to enhance delivery 
efficiency would better meet recipient needs 74.  
 Strategies to improve food aid 
A 2011 review commissioned by the United States Agency for International Development 
(USAID) 82 called for formulation of new FBFs that prioritized nutritional improvement at the 
heart of programming. They emphasized in this document that FBFs needed to be  
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“1) energy-dense and rich in micronutrients, 2) easily digestible and palatable, and 3) 
able to be prepared relatively quickly, i.e. with minimal cooking” 82. 
Suggested FBF changes included improvements in nutritional quality to enhance macronutrient 
and micronutrient blend composition, formulation of ‘smart’ food aid that was culturally 
acceptable and palatable to recipients, and use of processing methods and commodities that 
would improve nutritional quality, as well as delivery and availability efficiency for food aid 
beneficiaries 82. Specifically, the report suggested that sorghum could be used for new FBFs, 
noting that it would meet beneficiaries’ needs given its “acceptability in Africa, its relatively low 
price, and its acceptability among host governments 82.” To improve FBFs’ nutritional quality, it 
was suggested that antinutritional factor reductions through processing “including extrusion,” 
could enhance nutrient and energy density, and improve product quality through longer shelf life 
82. In this report, authors suggested that a prototype formula “CSB14” could be compared to 
CSB13, which at the time was the most commonly distributed USAID food aid product (Table 1-
5) 82.  
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Table 1-5: Comparing CSB+, envisioned CSB14, and infant DRI/RNI values 
 
CSB13  
(per 100 g) 
CSB14  
(envisioned, per 100g) 
DRIa/RNIb  
for 6-11 month 
infants 
Energy (kcal) 386.1 387 675 
Protein (g) 15.9 17.7 16 
PDCASS 0.85 0.87 - 
Utilizable protein (g) 13.5 15.4 - 
Animal source 
protein (g) 
0 2.4 - 
Fat (g) 8.7 8.8 31 
Iron (mg) 10.6 15.5 7.7 
Vitamin A (mg) 0.819 0.532 0.46 
PDCAAS: Protein digestibility-corrected amino acid score. Modifications in envisioned CSB14 
compared to CSB13. Recommendations included addition of animal source protein, increased 
blend fat content, decreased preformed vitamin A, and increased iron (as NaFeEDTA) 82. 
aDietary reference intake, bReference nutrient intake 
 Commodities 
 Sorghum 
Sorghum is the fifth most commonly produced cereal crop globally, and the second most 
produced cereal in Africa 83. Due to its propensity for drought-tolerance, sorghum production is 
generally highest in semi-arid parts of India, Sub Saharan Africa, and the Mid-Western United 
States (Figure 1-2) 84. In drought years, sorghum has documented greater yields, and less year to 
year variability, than its grass counterpart, corn 85,86. Sorghum is not a genetically modified 
organism (GMO), and can thus be exported to food aid receiving counties that may not accept 
modified foods, and is often obtained at a lower price than corn 86. One challenge to sorghum 
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production is the lack of post-emergent herbicides (largely due to its non-GMO status), which 
reduces overall crop yield 86. Although most sorghum varieties grown in the U.S. have almost no 
tannin content through breeding 87, higher tannin content in sorghum largely dictates bird, mold, 
and insect resistance 88, and thus may improve crop yields in lieu of herbicide use.  
 
 
 
Figure 1-2: Cropland fraction of sorghum by geographical location with permission 84 
In many parts of Africa, sorghum is consumed as porridge, bread, or whole grain 89, but it is most 
commonly used as animal feed in wealthier countries 83. Compared to corn, sorghum contains 
similar starch, protein, and fiber content 83,90-92, potentially making it a viable alternative to corn 
in complementary foods and FBFs (Table 1-6). Like corn, while sorghum is rich in cysteine and 
methionine, it lacks lysine necessary for complementary feeding (Table 1-6) 90-92. Another 
challenge to its nutritional use is that its starch and protein digestibility when cooked are 
reduced, often up to 25 and 50% less than corn, respectively 91. Strategies to improve sorghum 
digestibility include soaking, fermentation, and heat processing 91. 
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Table 1-6: Comparing sorghum and corn nutritional composition adapted 83,87,91-94 
Composition  Sorghum  
(whole, dry) 
Corn  
(whole, dry) 
Kcal (per 100g) 358 329 
Starch (%) 63-68 60-64 
Protein (%) 9-11 9-11 
Fat (%) 1-1.5 3-5 
Fiber (%) 1-2 1-2 
Iron (mg/100g) 5.4 2.7 
Cysteine/Methionine (mg/100g) 26.3 28.6 
Lysine (mg/g)a 14.6 26.1 
Polyphenols (mg/100g) 10-68 69-71 
aDIAAS 6-30 month: 57 mg/g 90 bDIAAS 6-30 month: 27 mg/g 90. DIAAS: Digestible 
indispensable amino acid score. 
 Cowpea 
Cowpeas, also known as black-eyed peas, are drought-tolerant and nitrogen-fixing legumes often 
used for intercropping in arid and sub-tropical regions 95. Sub-Saharan Africa produces 96% of 
global cowpea hectacres 96, where the legume is consumed as an important source of zinc and 
iron 97. In addition to legume consumption as either fresh or dried seeds, cowpea leafy greens are 
commonly consumed 98. Cowpea’s relative lysine abundance to sorghum, coupled with cysteine 
and methionine deficiency 99, make it a complementary protein source to both sorghum and corn. 
Compared to soy, cowpea has similar lysine content, however, total protein, and fat content are 
lower, while starch content is higher 97,100,101 (Table 1-7). 
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Table 1-7: Comparing cowpea97,101 and soy 100 nutrient composition  
Composition  Cowpea (whole) Soy (whole) 
Kcal (per 100g) 336 382 
Starch (%) 35-55 30 
Protein (%) 18-30 42.6 
Fat (%) 1-1.5 20 
Fiber (%) 6.3 5.3 
Iron (mg/100g) 6-7.6 15.7 
Cysteine/Methionine 
(mg/100g) 
9.6-11.1 25.9 
Lysine (mg/g)a 47.7-67.8 63.8 
Proanthocyanidins (mg/100g) 2.2-6.3 20-65 
aDIAAS 6-30 month: 57 mg/g 90 bDIAAS 6-30 month: 27 mg/g 90. DIAAS: Digestible 
indispensable amino acid score. 
 
 Food inhibitors common in cereal and legume products: antinutritional factors 
Antinutritional factors are food factors that inhibit macronutrient and micronutrient 
absorption, and can be found within foods, or are sometimes the result of protein processing 102. 
Trypsin inhibitors, hemmaglutinins, glucosinolates, gossypol, tannins and phytates occur 
naturally in legumes, grains, and oils; manufactured antinutritional factors often come from 
Maillard reactions 102. Antinutritional factors are often discussed because they reduce food 
protein quality and inhibit mineral absorption 102. 
 Tannins 
Tannins are water-soluble polyphenolic compounds, either hydrolyzable, or condensed (also 
known as proanthocyanidins) 103 (Figure 1-3). Due to their hydrophilic nature, tannins tend to 
form complexes with proteins and minerals most predominately in solutions 102. Hydrolyzable 
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tannins are generally gallic acid esters of polyols, are easily hydrolyzed by acidic or basic 
conditions 104, and are rarely consumed 103 (Figure 1-3). Condensed tannins are comprised of 
oligomers and polymers of flavan-3-ols linked by carbon bonds 105, are difficult to hydrolyze 104 
(Figure 1-3), and are commonly consumed, often found in sorghum, wine, tea, dark chocolate 
and berries 103. Both hydrolyzable and condensed tannins have a multidendate nature that allows 
for precipitation of multiple cationic compounds to polyphenol hydroxyl groups, and complexes 
are generally insoluble during digestion 106,107. Larger tannin molecules tend to bind to cationic 
metals with greater affinity, and acidic environments favor precipitation and binding, thereby 
reducing mineral bioavailability 106-108. In general, tannins are heat-resistant, and processing 
treatments aimed at their removal from foods are often expensive and ineffective 102. Despite 
cited antinutritional effects, condensed tannins may confer antioxidant 109, cancer fighting 110, 
and cardiovascular 111 health benefits.  
 
Figure 1-3: A: Condensed tannin Yikrazuul/ Wikimedia Commons / Public Domain and B: 
Tannic Acid Ronhjones/ Wikimedia Commons / Public Domain 
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 Phytic acid 
Phytic acid (myo-inositol hexakisphosphate) is a phosphorous storage compound for most plants, 
including grains and legumes, that often accounts for the majority of a plant’s phosphorous 
content 112 (Figure 1-4). The myo denotation refers to the hydroxyl conformation around the 
inositol ring, and is the most commonly consumed phytate form 112. Like tannins, phytic acid 
compounds are multidendate, meaning that they can bind to multiple sites on a given compound 
113. Increased inositol size leads to increased metal cation affinity and chelation 112, however, 
unlike tannins, both increased and decreased pH leads to increased precipitation depending on 
the bound agent pKa 114. Negatively charged phosphates around the inositol ring chelate metal 
cations, exerting an ‘antinutritional effect 112.’ When metal ions are bound to phytic acid, the 
resultant insoluble compound is called a phytate 112. Wheat and sorghum phytic acid content is 
generally highest in the grain bran, and thus the food matrix in which phytic acid is consumed 
plays a direct role in its antinutritional effect 112. The phytic acid to iron molar ratio plays a role 
in iron bioavailability specifically, and amounts less than or equal to 10:1 phytic acid: iron tend 
to have less effect on absorption 115. Phytic acid-iron chelation is less prone to stay precipitated 
during digestion than tannic acid, and can be reversed by ascorbic acid or certain iron salts 112,116. 
Increased metal ion: phytic acid ratio (often other than iron: Ca2+, Mg2+, Cu2+, Zn2+) increases the 
propensity of phytate formation 117, meaning that increased food-mineral content increases the 
likelihood of iron precipitation regardless of food-iron content. Strategies aimed at phytic acid 
reduction in foods include milling, soaking, phytase treatment, and recently, genomic reduction 
112. Despite its general denotation as an antinutritional factor, phytic acid has potential cancer 
fighting antioxidant mechanisms 112, is antiviral 118, may lower glucose 119, and cholesterol 120. 
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Figure 1-4: Chemical structure of phytic acid (myo-inositol hexakisphosphate) 
Harbinary/Wikimedia Commons/ Public Domain 
 Strategies aimed at reducing antinutritional content of foods 
Bio-fortification, soaking, fermentation, milling, extrusion, enzymatic food treatment, and 
cooking are all used to overcome, destroy or denature antinutritional factors. Bio-fortification 
uses crop-gene modification or conventional plant breeding in commonly consumed plants to 
reduce negative food components (tannin or phytate plant content, for example) or improve 
positive attributes (increase iron or zinc content) 121. Processing, including heat or plant protein 
hydrolysis has also been shown to reduce soybeans’ antinutritional effect 122. Phytates, which are 
not completely destroyed with cooking, are often reduced by application of phytase enzyme 
treatment 123,124, which is often only partially effective, and is a costly measure. Household 
strategies aimed at improving nutrient availability include grain and legume germination, 
fermentation, cooking, and soaking, as well as increased ascorbic acid consumption 125. Despite 
multiple approaches aimed at antinutrient reductions, socio-cultural and economic factors may 
render household use unlikely 125.  
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 Extrusion processing 
Extrusion processing uses a combination of milling, steam and pressure to process foods with 
enhanced nutrient retention, and antinutritional factor reduction at a high rate of productivity 126. 
An added benefit to extruded foods for undernourished children is that foods can be produced 
with a high caloric density 82. From an ecological standpoint, extruded products are ‘pre-cooked’, 
meaning that they take less time and energy to prepare foods that must be boiled or cooked over 
a stove. Mechanical shearing, high temperature, and short times for processing allow for tannin 
or phytic acid polymer covalent bond destruction 126. It is the processing and food-protein 
denaturation, through decreased temperature 127, screw speed 128, and pressure 129, that may allow 
for increased digestive enzyme binding to proteins, and thus better protein bioavailability 126. 
Iron content in extrudates is actually enhanced, potentially due to metallic screws wear during 
processing 130.  
 Effects of extrusion processing on protein quality and iron bioavailability 
Many studies have cited improvements in protein and iron-related outcomes with extruded 
compared to conventionally prepared foods. In weanling pigs, soy-meal extrusion significantly 
improved average daily gains and gain to feed ratios compared to roasted soybeans by nearly 
31% over a 14-day feeding period 131. Mineral bioavailability and protein digestibility 
significantly increased compared with roasting and malting in extruded soybeans in the in vitro 
Caco-2 digestion model (75-79 and 79-82% vs. 47-53 and 70-72% iron and protein in extruded 
vs. malted/roasted common beans, respectively) 132. In vitro digestion of extruded vs. raw lentils 
was significantly improved from 60 to 90%, and polyphenol and phytic acid content were 
significantly reduced by more than half 133. Extrusion of pearl millet significantly enhanced in 
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vitro iron bioavailability by 3.5 times, and protein digestibility by 10% compared to roasted 
millet 134. Extruded, iron-fortified rice reduced anemia prevalence similar to ferrous sulfate 
fortification in Philipino children aged 6-9 135. Despite these results, findings citing improvement 
in iron incorporation into hemoglobin with extruded vs. non-extruded products have been mixed. 
In a study of 30 normal men and women consuming extruded vs. non-extruded wheat bran and 
flour, there were no differences in iron bioavailability measured by iron absorption after 
consuming meals 136. Similarly, rats consuming extruded chickpeas had similar hemoglobin and 
hepatic iron levels at end line compared to their non-extruded meal consuming counterparts 
despite similar food intake 137.    
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Chapter 2 - AN EVALUATION OF IRON, VITAMIN A, AND 
GROWTH OUTCOMES IN RATS CONSUMING EXTRUDED 
FORTIFIED-BLENDED FOODS COMPARED TO CORN-SOY 
BLEND PLUS 
# Originally Published: NM Delimont, NM Fiorentino, AB Opoku-Acheampong, MV Joseph, Q 
Guo, S Alavi, and BL Lindshield. (2017).  Newly formulated, protein-quality enhanced, 
extruded, sorghum, cowpea, corn, soy, sugar and oil containing fortified-blended foods lead to 
adequate vitamin A, iron outcomes and improved growth compared with non-extruded CSB+ in 
rat in Journal of Nutritional Science (in press) 
 Abstract  
Corn and soybean micronutrient fortified-blended foods (FBFs) are commonly used for food aid. 
Sorghum and cowpeas have been suggested as alternative commodities because they are 
drought-tolerant, can be grown in many localities, and are not genetically modified. Change in 
formulation of blends may improve protein quality, vitamin A and iron availability of FBFs. The 
primary objective of this study was to compare protein quality, iron, and vitamin A availability 
of newly formulated, extruded, sorghum, cowpea, soy, and corn based FBFs, along with a 
current, USAID corn and soy blend FBF (CSB+). A second objective was to compare protein 
quality of whey protein concentrate (WPC) and soy protein isolate (SPI) containing FBFs to 
determine whether WPC inclusion improved outcomes. Eight groups of growing rats (n = 10) 
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consumed two white and one red sorghum-cowpea (WSC1, WSC2, RSC), white sorghum-soy 
(WSS), corn-soy (CSB14), white sorghum-cowpea with SPI (WSC1+SPI) extruded FBFs, 
CSB+, and AIN-93G, a weanling rat diet, for 4 weeks. There were no significant differences in 
protein quality, iron or vitamin A outcomes between WPC FBFs groups. The CSB+ group 
consumed significantly less food, gained significantly less weight, and had significantly lower 
caloric efficiency, protein efficiency, and length, compared to all other groups. Compared with 
WSC1, the WSC1 + SPI FBF group had significantly lower caloric efficiency, protein efficiency, 
and weight gain. These results suggest that a variety of commodities can be used in formulation 
of FBFs, and that newly formulated extruded FBFs are of better nutritional quality than CSB+. 
 
 Background 
Protein-energy malnutrition, iron, and vitamin A remain some of the most common 
nutritional deficiencies worldwide 1, and food aid targeted at improving both food security and 
foreign agricultural development is necessary to create sustainable and effective programs to 
treat undernutrition. Fortified blended foods (FBFs), have traditionally consisted of micronutrient 
fortified, partially precooked blends of milled cereals and pulses, and the most commonly 
distributed micronutrient-fortified food aid by the United States Department of Agriculture 
(USDA) is the FBF corn soy blend (CSB). Hundreds of thousands of metric tons of CSB are 
distributed annually 2, and the most widely distributed is CSB+, a roasted CSB blend 3. A recent 
report cited the importance of formulating new food aid products to improve treatment of 
malnutrition, which included suggestions to utilize crops that are adapted to climate change, 
locally-available, and utilizing processing methods that may destroy anti-nutritional factors 
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thereby improving the nutritional quality of FBFs 4. Despite recommendations calling for new 
formulations, there is little research assessing nutritional outcomes from these changes compared 
with previous FBF formulations.  
Corn, soy, sorghum, and cowpea are all crops suitable for food aid due to their availability 
and acceptability worldwide. In 2012, The World Food Program (WFP) invested 62% of its food 
aid efforts to support Sub-Saharan African nations5, and sorghum and cowpea are appealing 
crops for use in FBFs here due to common consumption, drought-tolerance, and regional and 
local availability 6-9. Sorghum porridge is an already acceptable and widely consumed staple in 
many areas throughout Africa, and from 1993-2013, 36% of global sorghum production came 
from African nations 9,10. Cowpea is a nitrogen-fixing, drought-tolerant legume that can be 
utilized in intercropping because it is tolerant to shade 8,11, and Africa produces 96% of global 
cowpea hectares 6. The combination of sorghum with cowpea in FBFs has potential to enhance 
low levels of cysteine and methionine found in cowpeas, and cowpeas’ amino acid composition 
complements traditionally low lysine levels in sorghum 6,11. Formulating new blends with 
sorghum and cowpea may allow for local and regional procurement aimed at improving local 
agricultural markets and nutritional outcomes in food aid receiving countries 4. 
When consumed in large quantities, antinutritional factors such as trypsin and 
hemagglutinins in legumes, and phytates and tannins in cereals, may negatively affect the 
bioavailability of amino acids and minerals such as zinc and iron that may contribute to stunting, 
wasting and micronutrient deficiencies in low income countries 12,13. Extrusion is a processing 
technique that has been shown to decrease antinutritional factors and improve protein and iron 
bioavailability 14-16 by an operation that first grinds, then partially cooks, and finally applies 
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pressure to products to promote expansion to a desired density 17. Additionally, because density 
of extruded products is controlled, a unique benefit of this processing is its ability to create solids 
compositions that enhances caloric and micronutrient density of FBFs 4. Extrusion may further 
benefit food aid consumers because it can create pre-cooked porridges, which take less energy to 
prepare and consume. In addition to suggestions to use alternative commodities and processing 
methods, it has been proposed that lack of animal source protein may be a reason that FBFs have 
not traditionally adequately prevented stunting and wasting 4, although this has not been 
supported in a recent review 18. Limitations to utilizing animal proteins isolates like whey protein 
concentrate (WPC) include: they are costly, may not provide the protein quantity to support 
linear growth in suggested amounts, and may lack beneficial bioactive components reported as 
important components of supporting growth 19. A recent field trial comparing CSB+ against an 
animal protein complementary food product found no difference in linear growth, iron status, or 
lean mass between protein sources in children consuming them as complementary food at 6 
months of age for 9 months 20. Utilization of soy based proteins may be a safe, cost-effective, 
and efficacious alternative to WPC 21, and therefore, whey and soy protein may similarly 
enhance protein quality of FBFs by providing amino acids that are highly bioavailable.  
The primary objective in this study was to assess protein, iron, and vitamin A outcomes of 
newly formulated, (according to United States Agency for International Development (USAID) 
guidelines 4 extruded, sorghum, cowpea, corn and soy based FBFs, along with a current, non-
extruded USAID corn and soy blend FBF, CSB+. Combinations of corn, soy, sorghum, and 
cowpea were chosen as commodities to assess whether sorghum or cowpea, recommended as 
alternative to corn or soy in the Food Aid Quality Report (FAQR), could be utilized with similar 
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or better protein, vitamin A, or iron outcomes. A second aim was to compare the protein quality 
of a whey protein concentrate (WPC) containing FBF to a soy protein isolate (SPI) containing 
FBF 18,19. 
 Methods  
 Ethical Standards 
We chose weanling rats, which are a well-known nutritional model, to allow for assessment of 
FBF protein quality, vitamin A, and iron bioavailability during a linear growth period. The 
Institutional Animal Care and Use Committee (IACUC) at Kansas State University approved all 
animal procedures (protocol 3399). Welfare assessments were carried out prior to and during the 
experiment.  
 Diets 
 In order to compare nutritional outcomes related to recommended formulation, six FBFs 
were developed according to USAID food aid recommendations 4, and were later reformulated to 
meet viscosity requirements. In reformulation, sugar replaced 15% grain and legume flours, and 
additional WPC or SPI and oil were added to meet protein and fat requirements (Table 2-1). 
Vitamin and mineral premixes were formulated according to recommendations by the FAQR 4, as 
3.2% of FBFs (Research Products Company, Salina, KS). Blends were created by extruding grain 
and legume flours, milling to powder, then adding sugar, vitamin and mineral premix, oil and whey 
protein concentrate 80% (WPC80) (Davisco Foods, Eden Prairie, MN) or SPI 80% (Organic Puris 
1060, World Food Processing, Turtle Lake, WI). For comparison of commodity types within FBF 
formulation, two white (Fontanelle 4575, 738Y), one red (217X Burgundy) sorghum with cowpea 
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(WSC1, WSC2, RSC, respectively), a white sorghum (Fontanelle 4575) soy (WSS), and corn soy 
blend (CSB14), with whey protein concentrate, along with white sorghum (Fontanelle 4575) 
cowpea with soy protein isolate (WSC1+SPI) extruded blends, were developed. WSC1, WSC2, 
RSC, WSS, and CSB14 were formulated to compare outcomes related to consumption of different 
commodity types (sorghum-cowpea blends, sorghum-soy, and corn-soy). Further, CSB14 was 
developed to compare new formulation and extrusion of blends to a current USAID FBF (CSB+). 
WSC1+SPI was formulated to compare soy to whey protein in WSC1. CSB+ was purchased from 
a USDA producer (Bunge Milling, St. Louis, MO), with standard preparation, which includes 
utilization of heat treated corn and soybeans which are mixed, and micronutrient fortified. AIN-
93G, which is a diet formulated to meet the National Research Council (NRC) requirements for 
growing rats, was included as a control diet group to facilitate assessment of adequacy of the FBFs. 
Of note, iron forms and concentrations, as well as vitamin A concentrations were different between 
the CSB+, extruded FBFs, and AIN-93G. AIN-93G contained ferric citrate (6.6g/100g), while 
extruded FBFs and CSB+ contained sodium iron EDTA iron/ferrous fumarate, although at 
different concentrations, vitamin A concentrations in CSB+ were nearly twice those in newly 
formulated FBFs, and more than 40 times the levels in AIN-93G (Table 2-2). Sodium-ETDA iron 
was chosen to reduce mineral-antinutrient interactions found in ionized iron forms, to improve 
bioavailability 4. Therefore, iron availability of FBFs was expected to surpass AIN-93G (ferric 
citrate alone).  
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 Fortified Blended Food Production 
Sorghum-cowpea, sorghum-soy and corn-soy flours were extruded on a single screw extruder 
X-20 (Wenger Manufacturing Co., Sabetha, KS, USA). The dry feed rate was 200 kg/h for 
formulations made from commercially sourced flours and 166 kg/h for formulations that were 
obtained from flours produced from pilot milling (cowpea flour containing FBFs). 
Steam and water were added in the preconditioner, where discharge temperature was maintained 
above 85°C, and screw speed ranged from 500-550 rpm. In-barrel moisture content ranged 
between 18-20%, the die had a single circular opening of 4.1 mm. After cutting, extrudates were 
dried using a double pass dryer/cooler (Series 4800, Wenger Manufacturing Co., Sabetha, KS, 
USA) operating at 104°C, where they were retained for 10 minutes, before being cooled for 5 
minutes at room temperature. Vitamins and minerals were mixed in with other dry ingredients in 
steps to ensure mixing uniformity. Once dry ingredients were mixed combined through this 
process, oil was added and mixed. 
 Diet, Macronutrient, and Antinutrient Analysis 
FBFs were analyzed by AOAC official methods by the University of Missouri Agricultural 
Chemical Laboratories. Methods included measurement for total calories (by calculation: protein 
= 4kcal/g, carbohydrate = 4kcal/g, fat= 9kcal/g), protein (LECO; AOAC 990.03, 2006), fat (acid 
hydrolysis, 954.02, 2006), carbohydrates (by calculation: 100% - % crude protein + ash + crude 
fat + moisture), and amino acids including available lysine (cEIC- HPLC; spectrophotometry 
AOAC 982.30E; 975.44). Phytate and tannin content of blends were analyzed as described in 
reference 22. Briefly, phyates and tannins were assessed using a Megazyme kit (Megazyme 
International, Ireland) and methods described previously 23, respectively. 
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 Study Design 
Weanling, 21-23 day old male Sprague-Dawley rats (Charles River, Wilmington, MA) were 
randomized into 8 diet groups (n=10, 80 total). Animals were housed individually in wire-
bottomed cages (to prevent corporophagy) with a resting board beneath food and water feeders, 
in a temperature controlled facility with 12-hour light and dark cycles. Rats were provided food 
and water ad libitum, fed every other day when food intake was measured, and weighed weekly 
for four weeks. Study length and size were based on the preventative prophylactic 24, and protein 
efficiency ratio (PER) 25 methods, respectively.  
 Data and Sample Collection 
At study end, rats were anesthetized by CO2 inhalation, weights and lengths were recorded, 
and they were euthanized by exsanguination. Length from nose to base of tail was measured as a 
comparison of overall linear growth. Blood collected from cardiac puncture was divided into 2 
ml EDTA-K2 vacuum tubes (Fisher) and 2 ml microcentrifuge tubes for hemoglobin and serum, 
respectively. EDTA tubes were immediately placed on ice and subsequently stored at 4°C for 48 
hours before analysis. Blood samples in microcentrifuge tubes collected for serum analysis were 
allowed to rest at room temperature under aluminum foil to protect them from light. They were 
then centrifuged at 3000 x G for 15 minutes, supernatant was pipetted into microcentrifuge tubes, 
flash frozen in liquid nitrogen, and stored at -80°C. Following blood collection, liver tissue was 
collected, weighed, flash frozen in liquid nitrogen, and stored at -80°C. After hepatic samples 
were collected, bone density and total body fat mass were measured via a PIXIMUS 
densitometer (Lunar, Madison WI) following manufacturer instructions. Prior to the study, it was 
54 
 
 
 
 
verified that hepatic removal had a consistent, and minimal effect, on fat mass and bone density 
measured. 
 Iron Quantification 
 Hepatic and Diet Iron 
Hepatic iron analysis was determined by wet ashing before quantification by flamed atomic 
absorption spectrometry (AAS) (Perkin Elmer AAnalyst 100, Waltham, MA). Briefly, 1g of 
hepatic tissue was placed into a 50 ml acid washed beaker, 10 ml of full strength nitric acid was 
slowly added and left for one hour for chemical decomposition. Samples were then brought to 
boil, reduced to 1 ml over 2-3 hours, titrated to 10 ml with dd H2O, and quantified in duplicate 
(n=10) by atomic absorption spectrophotometry (AAS). Iron content of blends were analyzed in 
duplicate (n=1) by AAS (Great Plains Analytical Laboratory AACC method 40-70.01, 
Manhattan, KS). 
 Hemoglobin 
Hemoglobin samples were prepared in triplicate (n=10) using Drabkin’s reagent for 
cyanmethemoglobin measurement (Sigma Aldrich, St. Louis). Samples were compared with a 
standard hemoglobin curve prepared with lyophilized bovine hemoglobin and measured by 
spectrophotometer at an absorbance of 540 nm according to manufacturer instructions.  
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 Retinol Quantification 
 Hepatic Retinol 
Hepatic retinol concentrations were analyzed in duplicate (n=10) using an adapted protocol 
26,27. In initial samples analyzed, BHT was not found to protect retinol from oxidation, and was 
not included in the protocol. 0.1 g of liver sample was weighed and homogenized by vortexing 
well with 0.25 g ascorbic acid in 5ml ethanol 27,28. Samples were placed on ice, and 1 ml of 
supersaturated KOH was added. After vortexing, samples were heated for 30 minutes in a water 
bath (70°C), vortexing every 10 minutes for 30 seconds. After ensuring that tissue was totally 
dissolved, samples were cooled on ice for 10 minutes. Six ml of hexane was added, the sample 
was vortexed, supernatant was removed, and samples were dried down in a Vacufuge 
(Eppendorf Vacufuge, Hamburg Germany) at 20°C. This process was repeated twice more. 
When approximately 1 ml of sample remained, it was vortexed for 30 seconds, pipetted into 
Eppendorf tubes, dried under nitrogen, and stored at -20C overnight (<24 hours). Samples were 
reconstituted into 400 L of mobile phase, vortexed well, and 20 µl was injected into the HPLC. 
 Serum Retinol 
Serum for all rats was pooled and prepared in duplicate (n=1), because of low volumes of 
CSB+ serum due to small body size. Pooling has been shown to be highly representative of 
individual serum samples in vivo 29. Serum was extracted using a modified protocol 27,30. Serum 
samples (150 µl) were added to an equal volume of ethanol with ascorbic acid (0.25 g per 5 ml), 
vortexed, and extracted three times with 1 ml of hexane, with the supernatant removed after each 
extraction. Supernatant samples were dried down under nitrogen, and stored at -20°C overnight 
56 
 
 
 
 
(<24 hours). Samples were reconstituted into 40 L of mobile phase, vortexed well, and 30µl 
was injected into the HPLC. 
 Diet Retinol 
Vitamin A content of blends was analyzed as described previously in duplicate 31. 0.25 g of 
blend was weighed, transferred into a 50 ml glass centrifuge tube, then 3.5 ml of ethanol and 1.5 
ml dd H2O were added to the sample with 0.25g ascorbic acid, followed by 1 ml of 
supersaturated KOH. Samples were vortexed, then placed in a 60°C water bath for 30 minutes, 
vortexing every 10 minutes, then 2 ml of dd H2O was added, and samples were cooled on ice. 
Seven ml of hexane was added, the sample was vortexed, supernatant was removed, and samples 
were dried down in a Vacufuge (Eppendorf Vacufuge, Hamburg Germany) at 20°C. This process 
was repeated twice more. When approximately 0.5 ml of sample remained, it was vortexed for 
30 seconds, pipetted into Eppendorf tubes, dried under nitrogen, and stored at -32°C overnight 
(<24 hours). AIN93-G, extruded FBFs, and CSB+ were reconstituted in 40 µl, 80µl, and 160 µl, 
respectively, with 20µl injected into the HPLC. Different reconstitution volumes were utilized to 
obtain similar retinol values, across blends with a wide range of vitamin A content. 
  Sample Analysis 
Samples were run on an Agilent Eclipse XDB 5m C18 (250mm x 4.6mm, Santa Clara, 
CA,USA) analytical column at a flow rate of 1ml/min for 20 minutes at 23.4◦C with an 
autosampler (Shimadzu SIL) on a HPLC system containing a LC20AB pump (Shimadzu), and a 
Shimadzu SPD-M20A PDA system. Mobile phase consisted of 47/47/6 methanol, acetonitrile, 
and chloroform. Samples were analyzed against an external standard curve prepared using retinyl 
acetate (U.S. Pharmacopeia, Rockville, MD); standards were prepared in duplicate daily from 
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stock solutions after analysis on spectrophotometer at 325 nm to quantify absorbance. 
Concentration was calculated using an absorbance coefficient of 0.155 for retinyl acetate in 
ethanol 32. 
 Calculations  
Due to differences in protein, fat, carbohydrate and total caloric content between blends, as 
well as evidence suggesting that protein intake may not directly relate to linear growth as protein 
reaches a certain concentration in the diet 33, caloric efficiency was calculated along with protein 
efficiency as an indicator of protein quality.  
𝐶𝑎𝑙𝑜𝑟𝑖𝑐 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑤𝑒𝑖𝑔ℎ𝑡 𝑔𝑎𝑖𝑛 𝑝𝑒𝑟 𝑘𝑐𝑎𝑙 𝑐𝑜𝑛𝑠𝑢𝑚𝑒𝑑) =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑔𝑎𝑖𝑛 (𝑔)
𝐹𝑜𝑜𝑑 𝑖𝑛𝑡𝑎𝑘𝑒 (𝑔)𝑥(100𝑔×(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑙𝑜𝑟𝑖𝑒𝑠 𝑝𝑒𝑟 𝐹𝐵𝐹 𝑖𝑛 100𝑔))
   
Protein efficiency (weight gain per gram of protein consumed) = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝐺𝑎𝑖𝑛 (𝑔)
𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑖𝑛𝑡𝑎𝑘𝑒 (𝑔)
  
Lean mass was calculated to monitor for weight gain related to adiposity rather than linear or lean mass. 
𝐿𝑒𝑎𝑛 𝑚𝑎𝑠𝑠 (𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑛𝑜𝑛 − 𝑓𝑎𝑡 𝑚𝑎𝑠𝑠 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑) = 𝑊𝑒𝑖𝑔ℎ𝑡 −𝐹𝑎𝑡 𝑀𝑎𝑠𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 
    
Blends were compared with Digestible Indispensable Amino Acid Score (DIAAS) 
recommendations for protein quality assessment. DIAAS was utilized to analyze protein quality 
because of limitations of the Protein digestibility-corrected amino acid score (PDCAAS) as an 
estimate of crude protein digestibility, and the recent recommendation of the Food and 
Agricultural Organization (FAO) that DIAAS replace PDCAAS 21. 
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 Statistical Analysis 
Group differences were assessed using one-way ANOVA with Tukey’s test after satisfying 
Levene’s test for homogeneity. Significance was set at p <0.05; statistics were performed using 
SAS version 9.3 (Cary, NC).  
 Results 
 FBF composition 
CSB+ contained 8.3% fewer total kcals, 6.9% more carbohydrate, 23.9% less protein, and 
41.5% less fat compared to newly formulated, extruded FBFs (Table 2-3). Lysine and sulfur- 
containing amino acids did not meet DIAAS requirements for children aged 6 months to 4 years 
in CSB+ and WSC1+SPI diets, respectively 21. CSB+ and AIN-93G (6.6 mg/100g) contained 
48% and 58% less iron than the newly formulated, extruded FBFs, respectively. Vitamin A 
content of blends was higher and lower in CSB+ and AIN-93G, respectively, compared with 
newly formulated, extruded FBFs. WPC containing FBF groups had comparable macronutrient 
and micronutrient compositions (Table 2-3). CSB+ mean phytate content was more than three 
times greater than newly formulated, extruded FBFs (Table 2-3) 22. Phytate content of WSC2, 
WSC3, and WSS were similar, and more than 1.5 times greater than CSB14; WSC1 mean 
phytate content was 1.2-2.5 times greater than other newly formulated blends 22. 
 
  
59 
 
 
 
 
 Food intake, anthropomorphic and micronutrient outcomes 
Food intake, weight gain, final body weights, caloric efficiency, protein efficiency, and linear 
growth changes were not significantly different between WPC-containing FBF groups (Table 2-
4, Figures 2-1, 2-2). The CSB+ group’s total intake was significantly reduced by 30%, final body 
weight, protein efficiency were significantly decreased by greater than 50%, caloric efficiency 
was significantly decreased by 20%, and length was significantly reduced by greater than 20% 
compared to all groups (Table 2-4). During week 1, all groups consumed the same amount of 
FBF, while weight gain was significantly decreased (>50%) in the CSB+ consuming group. In 
subsequent weeks, CSB+ consumption and growth were significantly decreased (Figures 2-1, 2-
2). Compared with the AIN-93G group, the WSC1+SPI group gained significantly less total 
weight (Figure 2-2). Compared with the WSC1 and AIN-93G groups, the WSC1+SPI group had 
significantly lower caloric and protein efficiency (Table 2-4). 
 
There were no differences in lean mass, bone mineral density, hemoglobin, hepatic iron, 
serum retinol, or hepatic iron in newly formulated, extruded FBFs groups. Bone mineral density 
was significantly lower in the CSB+ group compared to the AIN-93G group. Liver weight as a 
percentage of body mass was significantly lower in the CSB+ group compared with all groups 
(Table 2-5). The AIN-93G group had significantly, and CSB14 non-significantly, lower hepatic 
iron levels compared to remaining groups (Table 4). WSC2, RSC, and WSC1+ SPI groups had 
significantly lower hemoglobin levels than the CSB+ group (Table 2-6). Serum retinol levels 
were not significantly different between groups, while CSB+ and AIN-93G had significantly 
higher and lower hepatic retinol concentrations than all groups, respectively (Table 2-6).  
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 Comparing FBFs to National Research Council Recommendations 
Due to significantly different anthropometric outcomes, WSC1+SPI and CSB+ 
macronutrient and micronutrient content were compared with NRC recommendations for 
growing rodents 34. WSC1 content is also included as a representative WPC-containing FBF 
given its similarity in formulation to WSC1+SPI. Comparing WSC1 composition to the NRC 
recommendations assisted in identifying composition differences that may not have contributed 
to significant outcomes observed in the CSB+ and WSC1+SPI groups. Micronutrient and 
macronutrient formulation of CSB+ and WSC1+SPI met or exceeded recommended 
requirements for weaning rodents with the exception of vitamin B12 (Table 2-7). CSB+ and 
WSC1+SPI levels were below requirements for sulfur-containing amino acids (53% and 48% of 
recommendation, respectively), and CSB+ lysine concentration was 15.2% less than 
requirement. WSC1 met all NRC recommendations 34. 
 
 Discussion 
In this study, consumption of newly formulated blends resulted in improved protein quality, 
vitamin A, and iron availability outcomes compared to a current FBF (CSB+) and a control diet 
formulated for growing rats regardless of cereal or legume combination. Further, there were no 
differences in protein quality, vitamin A, and iron outcomes among newly formulated, extruded 
FBFs. This suggests that cowpea and sorghum based FBFs support protein, vitamin A, and iron 
outcomes as effectively as the newly formulated corn and soy FBF blends. 
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CSB+ consumption resulted in poor protein quality outcomes. The CSB+ group consumed 
less FBF, had weight and length suppression, lower caloric and protein efficiency compared to 
all groups. The SPI containing FBF consuming group also had significantly lower caloric 
efficiency, protein efficiency, and weight gain compared to a similar FBF group with WPC. 
Adiposity did not differ between FBF groups, micronutrient outcomes were similar among 
extruded FBFs, however, the CSB+ group’s vitamin A and iron hepatic levels were significantly 
greater than other groups. 
Several factors likely led to changes in growth observed in the CSB+ group, and to a lesser 
extent, the SPI consuming group. Blends met requirements of total protein and fat intake when 
compared with NRC recommendations for rodents 34, however, selected amino acids were lower 
than recommendations, including methionine + cysteine (WSC1+SPI and CSB+) and lysine 
(CSB+, Table 2-7). While severe limitations in lysine may reduce rodent growth, it was unlikely 
the only cause of growth restriction in the CSB+ consuming group. For example, up to 50% of 
lysine recommendations in feed did not reduce growth in 6-week-old Sprague-Dawley rats 35. 
Relative deficiency of methionine is a well-known growth inhibitor in weanling rats 36, but given 
that the methionine content was lower in WSC1+SPI than CSB+, it is unlikely that lack of 
methionine was the cause of observed growth suppression. These findings may however, explain 
the small but significant decreases in weight gain and caloric efficiency in the WSC1+SPI group 
compared to the WSC1 group.  Some of growth impairment in the CSB+ group may have been 
due to several limiting amino acids (methionine, cysteine, lysine, leucine, and tryptophan), or 
more likely, reduction in protein and starch digestibility. The NRC recommends that protein 
sources be “high quality” 34, and while individual protein sources and amino acid content were 
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adequate, protein digestibility may have been poor in the CSB+ group compared with the newly 
formulated, extruded FBFs. One noteworthy consideration is that CSB+ is partially cooked, but 
its preparation requires boiling to complete cooking, while extruded blends are considered 
completely cooked. Complete cooking improves starch and protein digestibility, supported by 
multiple observations that extrusion improves cereal and legume amino acid digestibility 37-39. 
Perhaps more importantly, antinutritional content of blends was greatly reduced in newly 
formulated, extruded blends. CSB+ phytate content were more than three times the levels found 
in newly formulated, extruded blends 22, and inhibition of growth may be attributed in part to 
reductions in amino acid bioavailability and enzyme activity of dietary and mucosal proteins, 
found in vivo with consumption of tannins 40. 
In the SPI consuming group, it is possible that reduced protein digestibility when compared 
with WPC may have accounted for the small decrease in growth. It is unlikely that when 
consuming a varied diet, changes in growth would be observed with SPI inclusion in FBFs for 
complementary foods for children. For example, no differences in growth were found in 6-12-
month-old infants consuming soy, casein, or rice formula along with complementary feeding 41. 
In field trials, CSB+ has been as efficacious as other ready-to-use foods for growth 20,42,43, 
despite possibly poor protein quality identified in our study. Dietary variety beyond food aid may 
contribute to these findings as well. A 2014 review found that FBFs containing isocaloric, 
isonitrogenous sources of animal source proteins did not enhance linear growth compared to 
plant proteins, suggesting that animal protein itself may not be needed to be included in FBFs 18. 
Our study supports that a WPC containing FBF did not significantly enhance linear growth 
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compared to a SPI containing FBF. Given the higher cost of WPC when compared with SPI, it 
may be prudent to further explore the use of SPI, or other plant protein sources within FBFs.  
It is possible that animal feeding behaviors had effect on growth in the CSB+ group. 
Certainly, significant reduction in CSB+ consumption contributed to growth suppression, but 
growth was inhibited with similar food intake to other groups from week 1. Although reductions 
in growth were seen in the first week of feeding, when intake was consistent with other groups, 
CSB+ intake in subsequent weeks was significantly less than all other groups. One possibility is 
that the CSB+ group did not consume CSB+ as well as other FBFs groups because they 
contained sugar. Given that lean mass and food intake were unchanged in newly formulated, 
extruded FBFs groups compared to the AIN-93G group, which also did not contain sugar, it is 
unlikely that sugar led to overeating of blends. It is possible that sugar enhanced taste, or masked 
unappealing flavors of the extruded FBFs. For example, some studies have cited improved taste 
of corn and soy blended foods with enhanced sweetness 44. 
Similarities in the micronutrient outcomes make it unlikely that micronutrient differences 
were responsible for the observed growth suppression. While extrusion has been demonstrated to 
enhance micronutrient bioavailability 45,46, the combination of higher levels of vitamin A in 
CSB+ and subsequently less demand for micronutrients due to slower growth rates likely 
resulted in elevated hepatic iron and retinol levels observed. Additionally, animals in the CSB+ 
group did not show overt signs of other micronutrient deficiencies, and their livers were not 
enlarged compared with other groups. Given that circulating retinol and hemoglobin differences 
were not observed among groups, vitamin A or iron toxicity were also unlikely causes for growth 
suppression. Despite these findings, given the non-significant relationship between hepatic iron 
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and grain types, it may be most important to consider availability, cost, and preference of 
consumers of these products rather than small changes in biochemical markers when selecting 
commodities for FBFs.  
Interestingly, our findings do not support further differences in protein quality or in 
biochemical markers with consumption of newly formulated blends containing varying levels of 
antinutritional factors regardless of grain type. For example, WSC1 contained more tannins and 
phytates than its sorghum cowpea counterparts, but had similar caloric, protein efficiency, and 
micronutrient outcomes. Our results may suggest that differences in digestibility and 
bioavailability of nutrients in sorghum and cowpea may be negated by reductions in 
antinutritional factors. Further, lack of differences in outcomes between groups consuming 
newly formulated, extruded blends regardless of antinutritional factor level may suggest possible 
threshold, or dose-mediated adaptation to antinutritional factors such as tannins and phytates, 
cited previously 47-49. 
 Limitations 
Given consumption level and composition differences, it is not possible to specifically 
identify factors that contributed to inhibition of CSB+ growth outcomes compared with other 
groups. FBFs were consumed as dry powders rather than cooked porridges. Sorghum protein 
digestibility has been reported to decrease after cooking in water 50, although our blends are 
cooked during extrusion, and it is possible that protein digestibility would not be decreased with 
addition of hot water during their preparation. Lack of cooking may have contributed to poor 
protein and starch digestibility of CSB+. We did not obtain antinutritional information for 
WSC1+SPI, so our interpretation of findings in this group is limited. Newly formulated, 
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extruded FBF prepared porridges contain increased solids when compared with CSB+ (20% and 
13.79%, respectively), which is not a difference we were able to assess for in this study. This 
study was limited to a rapid growth period, but did not follow animals through transitions into 
later life. This limits the ability to ascertain whether newly formulated, extruded FBFs support 
long term growth. Additionally, the study was limited to FBF consumption only, rather than 
“complementary” consumption along with other food items. 
 Conclusions 
These results suggest that a variety of commodities can be used in newly formulated, 
extruded FBFs, which are of better nutritional quality than CSB+. Further studies that compare 
prepared FBF porridges to gain a better understanding of poor growth outcomes in the CSB+ 
group are warranted. Given the potential cost savings of using plant protein sources, further 
research comparing soy, or other plant proteins, versus whey protein in FBFs is warranted. A 
field trial is currently assessing the efficacy of these newly formulated, extruded porridges in 
combating micronutrient deficiencies and supporting linear growth in children. Lastly, long-term 
studies exploring protein and micronutrient adaptation may enhance understanding of FBF 
quality and efficacy over the lifespan. 
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 Tables 
 
Table 2-1:  Newly Formulated Extruded FBFs, CSB+, and AIN-93G Formulations (%)  
 Sorghum 
flour 
Cowpea 
flour 
Soy 
flour 
Corn 
Flour 
Sugar 
Whey 
protein 
Soy 
protein 
Vegetable 
oil 
Micronutrient 
Premix 
WSC1+WPC, 
WSC2+WPC, 
RSC+WPC 
24.7 38.6 0 0 
15 9.5 0 9.0 3.2 
WSS+WPC 47.6 0 15.7 0 
15 9.5 0 9.0 3.2 
WSC1 + SPI 24.7 38.6 0 0 
15 0 9.5 9.0 3.2 
CSB14+WPC 0 0 15.2 48.1 
15 9.5 0 9.0 3.2 
CSB+: Whole corn (78.4), whole roasted soy (20), vitamin mineral (0.2), tricalcium phosphate (1.16), potassium chloride 
(0.17) 
AIN-93G: corn starch (39.7), casein (20), maltodextrin (13.2), sucrose (10), soybean oil (7), powdered cellulose (5), AIN-93 
vitamin and mineral mix (4.5), L-cystine (0.3), choline bitartrate (.25), t-buylhydroquinone (0.001) 
White sorghum-cowpea 1 with whey protein concentrate (WSC1+WPC), White sorghum-cowpea 2 + WPC (WSC2+WPC), 
Red sorghum-cowpea + WPC (RSC+WPC), WSC1+ + soy protein isolate (SPI), White sorghum-soy + WPC (WSS+WPC), 
Corn-soy blend 14 + WPC (CSB14+WPC), Corn soy blend Plus (CSB+). 
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Table 2-2:  Newly formulated, extruded FBFs and CSB+ vitamin and mineral forticant 
levels (mg per 100g) 
adapted 51. 
Newly formulated, extruded FBF  CSB+  
Vitamin A Palmitate 0.488  Vitamin A Retinyl Ester 1.04 
Thiamin Mononitrate (B1) 0.652  Thiamin Mononitrate (B1) 0.2 
Riboflavin (B2) 0.933  Riboflavin (B2) 1.4 
Niacinamide (B3) 9.07  Niacinamide (B3) 8 
Calcium D-Pantothenate (B5) 3.646  Calcium D-Pantothenate (B5) 1.6 
Pyridoxine Hydrochloride (B6) 0.752  Pyridoxine Hydrochloride 1 
Folic Acid (B9) 0.087  Folic Acid (B9) 0.11 
Vitamin B12 0.0015  Vitamin B12 0.002 
Vitamin D3 0.0292  Vitamin D3 0.011 
Vitamin E 13.224  Vitamin E 8.3 
Vitamin K 0.033  Vitamin K 0.03 
Coated Ascorbic Acid 40.0  Coated Ascorbic Acid 90 
Calcium (Tri-Calcium Phosphate) 279.08 Calcium (Tri-Calcium Phosphate) 452 
Iron 
Sodium Iron EDTA                                          
Ferrous Fumarate 
13.0                       
2.0              
11.0 
 Iron  
 Sodium Iron EDTA 
 Ferrous Fumarate 
6.5      
2.5     
4.0 
Iodine (Potassium Iodide) 0.23  Iodine (Potassium Iodide) 0.04 
Magnesium Oxide 9.47  Phosphorus (Tri-Calcium 
Phosphate) 
290 
Phosphorus (Tricalcium Phosphate) 290.97  Potassium (Potassium Chloride) 140 
Potassium (Potassium 
Monophosphate) 
163.19  Zinc Sulphate Monohydrate 
5 
Sodium Chloride 225.67 Sodium Chloride 326 
Zinc Sulfate 5.50   
*Amount of iron the forticant is providing 
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Table 2-3: Analyzed FBF macronutrient, micronutrient, and antinutrient content 
 
White Sorghum 
Cowpea Variety 
1  
(WSC1+WPC) 
White Sorghum 
Cowpea Variety 
2   
(WSC2+WPC) 
Red Sorghum 
Cowpea 
Variety  
(RSC+WPC) 
WSC1 + 
Soy Protein 
Isolate 
(SPI) 
Sorghum 
Soybean  
Blend 
(WSS+WPC) 
Extruded  
Corn-Soybean 
Blend 
(CSB14+WPC) 
Corn-
Soybean 
Blend + 
(CSB+) 
Total Calories 
(kcal/100g) 
394.6 396.5 397.1 395.1 392.19 392.4 361.64 
Carbohydrate 
(g/100g) 
60.8 (61.6%) 59.6 (60.1%) 60.7 (61.1%) 
59.9 
(60.6%) 
60.7 (61.9%) 61.1 (62.3%) 
64.7 
(71.6%) 
Protein (g/100g) 19.0 (19.2%) 19.7 (19.9%) 19.5 (19.6%) 
19.2 
(19.4%) 
19.4 (19.8%) 19.3 (19.7%) 
14.7 
(16.3%) 
Fat (g/100g) 8.4 (19.2%) 8.8 (20%) 8.5 (19.2%) 8.7 (20%) 8.0 (18.3%) 7.7 (18%) 4.9 (12.1%) 
Lysine (mg/g) 74.1 70.9 72.2 60.5 69.5 68.3 52.9a 
Cysteine + 
methionine (mg/g) 
33.1 30.9 32.2 24.5a 35.0 35.7 35.3 
Available lysine 
(mg/g)+ 
72.0 67.9 68.6 58.9 67.4 66.2 52.2 
Iron (mg/100g) 15.2 15.9 15.2 16.3 15.6 15.6 8.2 
Vitamin A 
(µg/100g) 
598.9 496.9 527.7 488.4 553.7 462.6 846.0 
Phytates 
(mg/100g)* 
832.0 561.0 689.0 ND 557.0 318.0 1885.0 
Tannins 
(mg/100g)* 
0.00 0.00 0.00 ND 0.00 0.00 0.00 
a. Does not meet recommended mg/g amino acid content for children aged 6 months-3 years [20] 
+ by HPLC 
* From Reference[21], ND Not Determined 
Note: AIN-93G is formulated to contain 6.6 mg/100g iron; 23.1 µg/100g vitamin A; Macronutrient and micronutrient content analyzed in duplicate. 
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Table 2-4: Food intake, food efficiencies, and length (n=10) 
 AIN-93G 
WSC1+ 
WPC 
WSC2+ 
WPC 
RSC+WPC 
WSC1 
 + SPI 
WSS+ 
WPC 
 CSB14+ 
WPC 
CSB+ 
Total Food 
intake (g) 
432.6 ± 15.7a 414.3 ± 15.3a 414.4 ± 11.4a 429.7 ± 12.5a 415.6 ± 14.8a 414.3 ± 8.9a 412.7 ± 9.2a 293.0 ± 10.0b 
Total 
weight 
gained (g) 
195.9 ± 6.7a 188.7 ± 6.9a 184.3 ± 6.7ab 188.5 ± 6.9ab 168.9 ± 7.5b 194.4 ± 3.2ab 189.0 ± 4.2ab 54.1 ± 2.6c 
Final Body 
Weight (g) 
238.1 ± 8.0a 228.5 ± 8.4a 225.8 ± 7.3a 230.6 ± 8.0a 208.6 ± 9.1a 236.3 ± 4.2a 228.9 ± 4.7a 96.3 ± 3.4b 
Caloric 
Efficiency 
(g/kcal* 
100) 
113.2 ± 4.0a 111.8 ± 1.9a 109.1 ± 2.9ab 107.6 ± 2.5ab 101.3 ± 1.8b 114.7 ± 1.4a 113.3 ± 1.6a 49.0 ± 2.2c 
Protein 
Efficiency 
(g/g)  
2.40 ± 0.08a 2.40 ± 0.04a 2.22 ± 0.06ab 2.19 ± 0.05ab 2.14 ± 0.04b 2.35 ± 0.28ab 2.29 ± 0.03ab 1.16± 0.17c 
Length 
(cm) 
21.8 ± 2.3a 21.6 ± 0.3a 21.4 ± 0.3a 21.5 ± 3.2a 20.7 ± 3.1a 21.8 ± 0.2a 21.9 ± 2.3a 16.8 ± 0.4b 
White sorghum-cowpea 1 (WSC1+WPC), White sorghum-cowpea 2 (WSC2+WPC), Red sorghum-cowpea (RSC+WPC), WSC1+ + soy 
protein isolate (SPI), White sorghum-soy (WSS+WPC), Corn-soy blend 14 (CSB14+WPC). Food intake: measured every other day by 
subtracting food remaining from food given (g). Total weight gained: cumulative weight gain from weeks 1-4 (g). Caloric efficiency: total 
weight gain (g) divided by total caloric content of food intake per gram consumed (calculated). Protein efficiency: total weight gained (g) 
divided by total protein consumed (g).  
Data are mean ± SEM; values with different letters are statistically different (p<0.05). 
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Table 2-5: Anthropometric outcomes 
 AIN-93G WSC1+WPC WSC2+WPC RSC+WPC WSC1 +SPI WSS+WPC CSB14+WPC CSB+ 
Lean mass 
(%) 
89.9 ± 0.5a 90.0 ± 0.4a 89.6 ± 0.3a 89.7 ± 0.4a 88.1 ± 0.6a 90.3 ± 0.3a 89.5 ± 0.5a 90.4 ± 0.5a 
Bone 
Mineral 
Density 
(g/cm
2
) 
x1000 
87.4 ± 3.1a 80.4 ± 2.2ab 78.3 ± 1.7ab 82.0 ± 2.5ab 77.3 ± 1.0ab 79.0 ± 1.3ab 80.7 ± 4.6ab 73.7 ± 1.6b 
Liver 
weight/bod
y weight 
(%) 
5.63 ± 0.2a 5.46 ± 0.1a 5.50 ± 0.2a 5.47 ± 0.2a 4.90 ± 0.2a 5.58 ± 0.2a 5.73 ± 0.2a 4.00 ± 0.1b 
White sorghum-cowpea 1 (WSC1+WPC), White sorghum-cowpea 2 (WSC2+WPC), Red sorghum-cowpea (RSC+WPC), WSC1 + soy 
protein isolate (SPI), White sorghum-soy (WSS+WPC), Corn-soy blend 14 (CSB14+WPC). Lean mass: total weight minus fat mass and 
divided by total weight x100. Liver weight/body weight%: liver weight divided by body weight x100. Data are mean ± SEM; values with 
different letters are statistically different (p<0.05). 
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Table 2-6: Circulating and hepatic iron and vitamin A levels 
 AIN-93G 
      WSC1+ 
   WPC 
    WSC2+ 
 WPC 
RSC+ 
WPC 
WSC1 + 
SPI 
WSS+ 
WPC 
CSB14+ 
WPC 
CSB+ 
Hemoglobin 
(g/dl) 
18.6 ± 0.6ab 17.9 ± 0.5ab 17.7 ± 0.9a 17.9 ± 0.6a 17.3 ± 0.5a 18.3 ± 0.4ab 18.7 ± 0.9ab 20.2 ± 0.4b 
Hepatic Iron 
(µmol/g 
*1000) 
142.4 ± 16.8 a 293 ± 29.3b 272 ± 30.2b 300 ± 26.5 b 271.8 ± 32.1b 207 ± 29.1ab 277 ± 32.1b 310.5 ± 25.2b 
Serum 
Retinol 
(ng/µl) 
89.6 ± 3.5a 73.9 ± 11.2a 74.5 ± 2.2a 77.9 ± 2.7a 82.6 ± 1.8a 71.3 ± 1.2a 67.4 ± 10.1a 55.7 ± 5.3a 
Hepatic 
Retinol 
(ng/mg) 
78.1 ± 5.0a 479.4 ± 17.8b 473.8 ± 27.8b 482.5 ± 20.4b 585.5 ± 28.6b 423.8 ± 19.4b 460.9 ± 28.9b 1478.8 ± 95.2c 
White sorghum-cowpea 1 (WSC1+WPC), White sorghum-cowpea 2 (WSC2+WPC), Red sorghum-cowpea (RSC+WPC), 
WSC1 + soy protein isolate (SPI), White sorghum-soy (WSS+WPC), Corn-soy blend 14 (CSB14+WPC). Data are mean ± 
SEM; values with different letters are statistically different (p<0.05). 
 
  
72 
 
 
 
 
Table 2-7: Comparison of NRC growing rodent dietary needs versus formulation per 100g of corn soy blend 
plus (CSB+), white sorghum cowpea-1 with soy protein isolate (WSC1+SPI), and white sorghum cowpea 1 
(WSC1+WPC).  
 NRC CSB+ WSC1 +SPI WSC1+WPC  NRC CSB+ WSC1+ SPI WSC1+WPC 
Vitamin A 
(g) 
70 1038 488 488 Total Fat (g) 5 4.88 8.74 8.37 
Vitamin D3 
(g) 
2.5 11.04 29.2 29.2 Protein (g) 15 14.74 18.53 19.02 
E (mg) 1.8 8.3 13.2 13.2 Arginine (g) 0.43 0.93 1.33 0.99 
K (g) 100 30 33 33 
Aromatic 
amino acidsa 
(g) 
1.02 1.17 1.21 1.42 
Thiamin(m
g) 
0.4 0,2 0.652 0.652 Histidine (g) 0.28 0.41 0.53 0.49 
Riboflavin(
mg) 
0.3 1.4 0.933 0.933 
Isoleucine 
(g) 
0.62 0.61 0.87 0.98 
B6 (mg) 0.6 1 0.752 0.752 Leucine (g) 1.07 1.34 1.59 1.82 
Pantothenic 
acid (mg) 
1 1.6 3.646 3.646 Lysine (g) 0.92 0.78 1.16 1.41 
Folic acid 
(g) 
100 110 87 87 
Methionine 
+ Cysteine 
(g) 
0.98 0.52 0.47 0.63 
Niacin 
(mg) 
1.5 8 9.07 9.07 
Threonine 
(g) 
0.62 0.54 0.68 0.94 
B12 (g) 5 2 1.5 1.5 
Tryptophan 
(g) 
0.2 0.18 0.25 0.28 
Iodine (g) 15 40 23 23 Valine (g) 0.74 0.74 0.98 1.04 
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Total Iron 
(mg) 
3.5 6.5 13 13 
 
    
Zinc (mg) 1.2 5 5.5 5.5      
aAromatic amino acids: phenylalanine, tyrosine, tryptophan 
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 Figures 
 
Figure 2-1: Average weekly food intake. The CSB+ group’s average weekly food intake was 
significantly decreased during weeks 2-4 compared to extruded fortified blended food 
(FBF) groups and AIN-93G (n=10; *p<0.05).  
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Figure 2-2: Weekly average body weights. The CSB+ group’s average body weight was 
significantly reduced compared with extruded fortified blended food groups; the WSC1 
+SPI group’s body weight was reduced compared with AIN-93G and WSC1+WPC (n=10; 
*p<0.05 CSB+ versus comparison to all groups, ** p<0.05 WSC1 +SPI versus WSC1 
+WPC and AIN-93G). 
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 Abstract  
Iron deficiency remains a global health issue, and antinutritional factors, such as tannins, are 
often cited as contributors to the high prevalence of deficiency. Despite this, tannin-rich diets 
may have potential beneficial cardiovascular and cancer fighting properties due to tannins’ 
antioxidant activity. Further, epidemiological studies and long-term trials involving participants 
who consumed diets rich in antinutritional factors, particularly tannins, conflict with single-meal 
bioavailability studies. The purpose of this narrative review is to determine tannins’ effects on 
iron bioavailability and status, and establish whether adaptation to tannins reduces tannins’ 
antinutritional effects over time. We also aimed to compare tannins used in iron studies. 
Common themes related to iron bioavailability and iron status with tannin consumption were 
collected and collated for summary and synthesis based on models and subjects used. Overall, 
there was dissonance among iron bioavailability and status in studies. Single meal studies with 
hydrolyzable and oligomeric catechin/epicatechin tannins (tea and tannic acid) generally support 
reductions in bioavailability with tannin consumption compared to condensed tannin’s 
consumption, although condensed tannins are more commonly found in food. Long term animal 
models, epidemiological data, and multi-meal studies generally do not support changes in iron 
status related to tannin intake. Studies suggest that long-term tannin consumption may reflect 
iron status differently than single meal studies or bioavailability iron models predict. Further, 
iron bioavailability studies employing condensed tannins, which are more commonly consumed, 
may better predict mealtime iron bioavailability. More research is needed to develop 
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representative antinutritional-iron studies, as well as the possibility of, and mechanisms 
underlying the adaptation to tannins and other antinutritional factors that occurs over time. 
Key Words: iron bioavailability, antinutritional factors, tannins, proanthocyanidins, iron    
deficiency anemia 
  Introduction 
Iron deficiency is common worldwide, and nearly 1 billion people suffer from iron 
deficiency anemia (IDA) 1. Adequate iron stores are required for normal growth and 
development, and IDA has been associated with loss of productivity, reduced cognitive 
functioning 2, increased prematurity, and perinatal, childhood, and maternal mortality 3. While 
the World Health Organization (WHO) approximates that IDA contributes to 3% of all disability 
life years lost, more recent estimates suggest that 2013 economic losses related to IDA in Indian 
children 6-59 months alone were nearly 24 billion U.S. dollars 4. Populations with higher 
prevalence of IDA include women, children, people consuming a vegetarian or meatless diet, and 
those consuming insufficient iron in developing countries 1, and an estimated 30-40% of women 
and children younger than 5 years develop IDA without iron fortification 1. Despite prevalence 
rates and multiple initiatives aimed at improvement of IDA, an estimated 29% of non-pregnant 
women were anemic in 2011, a reduction of only 4% from 1995 5.  
The absorption, incorporation, and use of iron in the body is a strictly regulated process in 
which the homeostatic regulation of iron is primarily mediated through absorption and recycling 
6. Nearly 90% of iron stores are retained through senescent red blood cell recycling; nutritional 
intake accounts for the remaining 10% 7. While a multitude of genetic and disease related factors 
influence the pathophysiology and prevalence of IDA (6), interest in its treatment has been 
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largely focused on readily modifiable factors, such as nutritional enhancement and iron 
absorption inhibitors. Inhibitors found in diets rich in legumes and grains (termed ‘antinutritional 
factors’) are particularly criticized as contributors to the high prevalence of deficiency in 
developing and low income countries 8,9, despite cited health benefits of diets rich in these 
staples 10,11. Antinutritional factors, such as tannins and phytates, in cereals have been found to 
negatively impact the bioavailability of minerals, such as iron, when consumed in large 
quantities 12,13. It is accepted that tannins reduce iron availability before absorption through the 
formation of insoluble antinutritional-mineral complexes 14, and reported exacerbation of IDA by 
foods high in phytates or tannins is common 15-17. Single meal studies have confirmed iron 
bioavailability inhibition with phytate 12,18,19, and tannin 20-22 consumption.  
 The term ‘tannin’ denotes a broad class of compounds, which can be further classified 
into hydrolyzable, or the more commonly consumed, condensed tannins (also known as 
proanthocyanidins) 23 (Figure 1). Tannins’ ability to precipitate proteins has been linked to the 
sensation of astringency 24, and plant tannin content is linked to insect, animal, and mold 
resistance 25. It may be these defense mechanisms that lead to antioxidant 26, cancer fighting 27, 
and cardiovascular benefits 28 derived from antioxidant properties tannin-rich foods, such as 
wine and tea. Considering both the potential detrimental and beneficial properties of tannins, a 
dichotomy exists between limiting the tannin consumption of those at risk of IDA and the 
potential health benefits derived from tannin-rich diets. 
Due to tannins’ iron absorption inhibition, prudent food system and agricultural efforts have 
been made to reduce tannin content of grains, legumes, and foods in an effort to enhance the iron 
status of those consuming them 29. Despite this, there is a wealth of information that refutes 
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conventional ideology that tannins contribute to chronic changes in iron deficiency. In studies 
that have supported reduction in bioavailability through tannin consumption, individual iron 
absorption has been highly variable 30,31, and the majority of individuals consuming diets with 
high concentrations of tannins, as well as antinutritional factors in general, have reported normal 
iron status 32,33. Further, removal of antinutritional factors has not been shown to improve iron 
bioavailability 34, nor have diets rich in tannin content 35,36.  
Evidence suggests that individuals can adapt to antinutritional factors over time. Repeated 
consumption of antinutritional factors has been shown to blunt reductions in iron bioavailability 
in animal 37-39 and clinical 40,41 models alike. Interestingly, tannins administered per rectum 42 or 
topically 43 have been linked to hepatotoxicity, while oral consumption of condensed tannins has 
not, suggesting that inherent defense mechanisms may exist that respond to tannins consumption 
over time. While adaptation to antinutritional factors may be plausible, it is not currently well 
understood whether 1) tannins at commonly consumed levels are linked to changes in iron status, 
2) short term tannin-mediated reductions in iron bioavailability continue over time, 3) tannins 
alone (rather than consumed with phytates) reduce iron status, and 4) single meal study 
inhibition levels result in meaningful reductions in iron status. The focus of this review is to 
explore tannins’ effects on iron bioavailability and status.  
 Methods 
Interventional and epidemiological studies that examined the relationship between tannin 
consumption on iron bioavailability, or iron status was identified using PubMed, Web of 
Science, and Google scholar databases using the search terms “iron availability AND/OR iron 
bioavailability” AND “tannin AND/OR polyphenol AND/OR antinutritional factors”, “iron” 
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[Mesh] AND “bioavailability” [Mesh] AND “tannin” [Mesh], “polyphenol” AND iron 
bioavailability. Terms also included were “sorghum AND/OR tea” due to the common citation of 
these tannin containing factors on iron bioavailability. In addition, the method of snowball article 
collection (citations from relevant journal articles) was also utilized. 
In vivo articles were included that gave some indication of bioavailability/iron status at the 
end of the study. Studies excluded were ecological, rather than human nutrition application, in 
vitro, or focused on special populations (genetically defined illness), or did not attempt to 
quantify tannins’ effects alone when consumed with other antinutritional factors. 
  Results 
The original search terms generated 497 articles, which were narrowed first by inclusion of at 
least 2 search terms (217). Exclusions for in vitro studies (133), review articles (38), for 
specialized populations (9), were conducted during abstract reviews. A second abstract review 
excluded studies for manual combing of duplicates (34). Full article review of the 64 remaining 
studies was conducted, and further exclusion for non-iron outcomes (13), as well as lack of direct 
assessment of tannins’ effects on iron status (16), were applied. In total, 37 studies were 
reviewed (Figure 2). 
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 Iron bioavailability, iron status in tannin consumers 
 Animal Studies 
Animal studies using tea to measure inhibition of iron status or bioavailability often 
exceeded or met levels that could be expected in common consumption. For example, one cup of 
tea may contain about 25-80 mg tannins per 150 ml 21,22, and three cups of tea daily would mean 
consumption of anywhere from 75 – 240 mg tannins per day. Most studies exceeded this, 
especially when accounting for weight/weight dosing in animals. The majority studies isolating 
the influence of tannin consumption over time without confounding antinutritional factors have 
been in animals. This enabled comparison of tissue level iron depletion/repletion, and the direct 
comparison of bioavailability versus iron status with tannin consumption.  
 
 Studies supporting reduced iron bioavailability and/or iron status in animals 
consuming tannins over time 
Studies supporting reductions in iron bioavailability and/or iron status in animal models 
have typically employed use of tannic acid or tea as study interventions (Table 1). The 
consumption of 100g/L green tea polyphenols compared to water consumption in rats over eight 
weeks 44, resulted in a significant reduction in hepatic iron and hemoglobin (25% and 10%, 
respectively), although food intake was also significantly reduced. A 28-day pig study, 
consumption of 125, 250, 500, or 1000 mg/kg tannic acid in feed resulted in significant and 
linear depletion of serum iron levels, as well as hemoglobin. In this study, there was a significant 
decline in erythrocyte count, hemoglobin, and hematocrit seen in the control group similar to the 
125, 250, and 500 mg/kg diet consuming groups, and mean corpuscular volume was unaffected 
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by tannic acid consumption 45. Interestingly, there were significant reductions in gain to feed 
ratios seen in days 0-14 that were normalized during days 15-28, suggesting adaptation to the 
diets over time. Serum and hepatic iron levels were significantly reduced in rats consuming diets 
containing a 5, 10, 15, or 20% tannic acid/kg diet for 3 weeks 46, but there were no significant 
differences in other tissue iron levels, body weight gain, or food intake with increasing tannin 
dose. Despite reductions in iron stores, rats consuming tannic acid in weeks two and three had 
non-significant improvement in hematocrit levels, possibly suggesting adaptation or demand 
facilitated increases in uptake to blunt iron losses. Another depletion-repletion rat study utilizing 
a bean ragout meal with green or black tea compared to water for 14 days found that iron 
bioavailability and change in hemoglobin decreased significantly with tea intake when iron and 
food intake were similar, but hepatic iron and total hemoglobin levels were not significantly 
different at study end 47. In a study examining effects of habituated versus black tea naïve diet on 
iron bioavailability in rats (n = 6), iron bioavailability, along with final body weight and food 
consumption of rats consuming a powdered black tea diet was significantly reduced compared to 
control, although hepatic iron stores were normal 48. In the long-term tea consuming group, food 
intake and iron bioavailability from baseline to end line significantly improved over time, 
suggesting adaptation.  
 Studies supporting no differences in iron bioavailability or status with tannin 
consumption over time 
Many animal studies have not reported differences in iron status after consuming tannin-
rich diets (Table 2). In iron replete and depleted rats consuming a diet containing 20 mg of 
condensed tannin/kg body weight + phytoferritin for 4 weeks in a hemoglobin depletion-
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repletion model, a significant reduction in hemoglobin, weight gain, and serum iron in the 
condensed tannins + phytoferritin consuming, compared to phytoferritin alone-consuming rats 
was observed 49. Despite reductions in overall iron absorption, ferritin was not reduced, rats were 
not iron deficient, and achieved similar iron repletion to control while consuming condensed 
tannins with adequate iron intake. Food intake was not measured in this study. It is important to 
note that anemic rats consuming condensed tannins died by study end, pointing to toxicity at the 
daily dose of 20 mg/kg. In both 16 and 30-day rat studies comparing 0.35, 1.17, or 3.50% weight 
per weight black tea consumption, or green tea oral and powdered diet (daily dose of 20 mg/kg) 
to control diets, there were no differences in tissue iron levels or hemoglobin at study end 38,50. In 
the study employing a green tea challenge, iron absorption was similarly unchanged among tea 
consumers compared to control without changes in body weight or feed intake 38. A study in 
weanling rats looked at differences in iron availability with condensed tannin habituated vs. 
naïve animals. Both habituated and naïve rats did not have significant differences in iron status at 
study end 51. A 4-week hemoglobin depletion-repletion study in piglets consuming meals with 
significantly different tannin levels from red or white bean feed found no differences 
hemoglobin, hemoglobin repletion-efficiency (hemoglobin replaced per iron intake), or weight 
gain at endpoint 36.  Interestingly, this study did find initial downward trends in hemoglobin 
repletion efficiency at day 7 (49.9% versus 55.6% in red versus white bean consumers, 
respectively) that were compensated for by endpoint, potentially indicating adaption to tannin 
consumption over the study period. In pigs consuming grape meal or hops polyphenol-rich diets 
compared to control diet for 4 weeks, there were no significant differences in plasma iron, total 
iron binding capacity, transferrin saturation, tissue iron, or fecal iron compared to control 52. 
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 Human studies 
While many studies have linked tannin consumption to iron bioavailability, there are a 
paucity of human studies directly examining the relationship between tannin intake and iron 
status. Studies are presented by their methodology to accurately portray the information available 
from the design. Single meal studies using tea often used a standard dose of 150 – 300 ml of tea, 
while the majority of studies using condensed polyphenols exceeded the 75 – 240 mg polyphenol 
per day that could be expected with tea consumption three times daily 21,22. 
 Epidemiological studies 
The majority of epidemiological studies that included isolated tannin-iron interactions 
focused on tea consumption, and have not found an influence of tea consumption on iron status 
(Table 3). One study collected two 24-hour recalls from 173 Indian, premenopausal, parous 
women, and found that in multiple regression analysis, tannin intake was not a significant 
regression factor correlated with anemia 53. Similarly, tea consumption in 2573 French men 
(954) and women (1639) had no influence on iron status 54. Another cross-sectional study with 
157 Indian participants did not find differences in anemia prevalence between men and women 
consuming “high” and “low” tannin-containing diets 55. Notably, condensed tannin/polyphenol 
consumption varied widely in these studies (from 36 mg tannin intake daily to greater than 5000 
ml of tea per week); however, none of them found an impact of tannin consumption levels on 
iron status.  
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 Single meal studies 
Since the 1970’s, researchers have found statistically significant reductions in iron 
absorption measurements with tannin consumption in single meal studies. The majority of these 
studies have been in iron-replete individuals, both male and female, who consume a meal with 
tannin compared to the meal alone. Almost all single meal bioavailability studies use radioactive 
iron, most use hemoglobin incorporation, and fewer use direct measurement of iron absorption 
through area under the curve serum iron levels to understand iron uptake. Additionally, most 
studies have used iron absorption ratios to compare tannin-containing meals to control.  
In premenopausal anemic and non-anemic Indian women (n =10) consuming either 200 
ml of black tea or warm tap water with a control meal on two consecutive days reduced iron 
absorption by 21%, although this inhibition was reduced when tea was consumed with milk 20. 
These findings have been since supported in a variety of foods, but generally, reductions in 
bioavailability of iron with tannin consumption are linked to consuming black tea (Table 4) 22,56-
63. These studies all reported notable iron absorption variability between participants. Further, 
iron absorption between studies varied, from as little as 1% 63 to as much as 50% 31, pointing to 
the wide variability in maintenance iron homeostasis through iron absorption.   
Contrary to the previous studies mentioned, other single meal studies in men and women 
have suggested that tannin consumption alone, particularly of condensed tannins, may not 
contribute to reductions in iron bioavailability (Table 5). One study in anemic and non-anemic 
Indian men found that while there was a two-fold reduction in iron absorption after consumption 
of a phytate and tannin-rich sorghum meal (20 versus 136 mg/100g and 160 vs. 273 mg/100g 
tannin and phytates in low and high tannin meals, respectively), there was no significant 
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difference in iron absorption when meals were normalized for phytic acid (n = 12, 4.0 vs. 3.1% 
iron absorption in low and high tannin meals) 35. A comparison of red to white cowpea meals 
found no differences in iron bioavailability with a two-fold increases in tannin levels in 
premenopausal Dutch women 64, and another study found that despite similar tannic acid 
equivalents, spinach consumption resulted in a two-fold increase in iron bioavailability compared 
to black tea (n = 9, 5, respectively) in 19-51-year-old Swedish men and women 56. Other studies 
have supported minimal 16,61,65, no reductions 66, or enhanced uptake in iron absorption 67 with 
tannin consumption.  
Phytate content may conflate findings in these studies. Women consuming low 
polyphenol beans (29 versus 180 mg/100g in low versus high polyphenol beans) did not 
significantly increase iron absorption, while high phytate beans significantly reduced iron 
bioavailability (n = 20) 68. Similarly, adding polyphenol oxidase to high tannin sorghum meals 
did not improve iron bioavailability in iron replete women consuming them, suggesting that 
tannins were not the cause of reduced iron bioavailability (n = 16,18) 62. 
 Long-term/multi-meal clinical studies 
Few multi-meal antinutritional factor iron bioavailability studies have been conducted 
(Table 6).  In 19- to 32-year-old German vegetarian (n = 6, 8 in black and green tea groups, 
respectively) and omnivorous (n = 10, both groups) men and women consuming green or black 
tea for 4 weeks, ferritin was significantly decreased in omnivorous women consuming black tea, 
or in a subgroup analysis of anemic women consuming black or green tea, respectively. There 
were no changes in ferritin in men or non-anemic vegetarian women consuming tea, nor did total 
iron binding capacity, hemoglobin, serum iron, or hematocrit change in groups from baseline to 
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end line 69. In a study comparing iron status of Indian men and women aged 20-25 years old (n= 
46), polyphenol-rich leafy vegetable supplement diets did not significantly impact individuals’ 
hemoglobin levels after three weeks of supplementation compared to a control meal with no 
green leafy vegetables 70. 
Confounding antinutritional diet factors make intervention increases in tannin 
consumption alone difficult. Two studies that followed 31 healthy men aged 32-56 40 and later 71 
36 premenopausal women consuming a “high” or “low” bioavailability diet for more than 12 
weeks. High bioavailability diets consisted of meat and poultry, refined cereal and grain 
products, no coffee or tea, and foods with > 75 mg ascorbic acid in each meal, while low 
bioavailability diets consisted of whole grains, with limited meat, tea, and 60 mg/d ascorbic acid 
equivalent. Iron and calcium content of diets were similar and researchers conducted two, 24-
hour iron absorption studies comparing iron bioavailability between the two groups before and 
after the study period was complete. While tannin burden of diets was not measured, it was noted 
that absorption efficiency of the low bioavailability diets significantly increased over time, while 
absorption efficiency of the high bioavailability diets decreased 40,71. This was supported in 2015, 
when marginally iron deficient women consuming a high phytate (and tannin, although this was 
not measured) diet for 8 weeks (n = 16) significantly increased iron absorption from a high 
phytate test meal, while iron absorption in low phytate diet consumers was non-significantly 
decreased. In this study, consumers’ iron status was not changed by high or low phytate diets 41.  
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 Discussion 
 Tannins’ effect on iron bioavailability 
Studies reviewed that noted reductions in iron bioavailability with tannin consumption 
commonly used hydrolyzable tannins (tannic acid) or epicatechin and catechins monomers, 
dimers and oligomers found in tea. Animal or single meal studies that resulted in significant 
reductions in iron bioavailability or iron status almost exclusively used tannic acid 31,45,46,60,63, a 
mixture of hydrolyzable gallo-tannins that are “virtually absent from our diet” 23, or tea 
20,22,44,50,56,58,61,72, which contains thearubigins and a low density of condensed tannins found in 
most foods 73. Of studies reviewed, only four that utilized condensed tannins supported 
reductions in iron bioavailability during single meals (out of 16 total). No studies reviewed using 
multi-meal animal or clinical models, or epidemiological analysis found reductions in iron status 
or bioavailability with condensed tannin consumption, which may point to a limitation of single 
meal studies to assess iron bioavailability and status for long-term outcomes. This could 
highlight the importance of using condensed, rather than hydrolyzable tannins or tea to assess 
bioavailability of iron in tannin containing meals. It is also interesting to note that some 
significant findings have used polyphenol beverages, rather than food, which may increase 
tannin-iron interaction in the food matrix 24. Plants such as sorghum contain proteins rich in 
proline, similar to salivary proteins that may protect consumers from antinutritional properties of 
tannins 24. It may be that consumption of such plants may result in an inherent mediation of 
tannin-nutrient binding with whole plant or food consumption, not found with tannin extracts or 
beverages. Phytic acid may be another factor that affects outcomes describing tannin induced 
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reductions in iron availability, considering negation of antinutritional effects in the setting of 
normalized phytate levels found in two studies reviewed 35,68. 
 It may be important to also consider outcome measures from single meal studies. While 
several single meal studies reviewed noted reductions in iron bioavailability, these findings were 
often non-significant until data was adjusted into iron absorption ratios. Often, total iron 
absorption differences were less than 10% between tannin consumers and non-consumers, which 
may not impact iron status long-term.  This is an important normalizing factor given the wide 
variability of iron absorption, but may point to significant outcomes that make little meaningful 
impact on iron status when consuming tannin-rich diets over time. It is similarly important to 
take into consideration population, iron status, and study design when determining whether this 
research will result in meaningful outcomes in the context of global nutrition. Studies 
considering iron bioavailability from iron replete and deplete populations, who fully randomize 
their interventions order may carry more significant weight in this context.   
 Tannins’ effect on iron status 
Although tannin consumption impairs iron bioavailability, the majority of epidemiological 
and long-term human studies reviewed have not supported reductions in iron status with 
consumption of tannin-rich diets over time. In epidemiological studies, tannin compounds that 
inhibit iron bioavailability in single meal studies have not been correlated with iron status 
changes 54, or iron deficiency 53,74. Further, four week or more studies focused on tannin-rich 
foods have not found alterations in iron status 69,70. Some animal 75,76, and human 40,41 studies 
reviewed point to the idea that long-term adaptation to antinutritional factors, including tannins, 
instead. It is important to notice that these findings are confused by several factors, including 
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lack of control for concurrent antinutritional, or iron enhancing factors in diets, as well as 
assessment of iron deficiency, rather than adequate iron stores. More importantly, there are few 
studies that have looked into long-term antinutritional effects on either iron bioavailability or 
iron status, and no studies that we found have isolated the effects of condensed tannin 
consumption over time.  
 Conclusion 
The focus of this review was to determine tannins’ effects on iron bioavailability and status, 
and attempt to answer to whether possible adaptation to tannins could reduce the antinutritional 
effects of tannin consumption over time. Evidence from animal and single-meal studies suggests 
that tannic acid and tea consumption more consistently impair iron bioavailability than 
condensed tannins, although the connection between these studies’ findings and individual iron 
status findings are not established. Certain tannins may inhibit iron bioavailability, but a lack of 
long-term studies and confounding factors in most studies reviewed assessing tannins’ effects 
limit this generalizability. Additionally, epidemiological studies and long-term trials reviewed 
suggest that individuals’ iron status is often not affected by tannin consumption, although there is 
a dearth of this type of research conducted compared to single meal studies. Future studies 
focusing on the long-term effects of condensed tannins (proanthocyanidins) on iron status are 
needed to determine their impact on iron bioavailability and status, and whether adaptation is the 
missing piece to explain the inconsistency between single meal and longer-term studies. In 
addition, further studies are needed to characterize the mechanism that results in adaptation. 
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 Tables 
Table 3-1: Studies reporting reductions in iron bioavailability in animal models 
Reference n Model Intervention 
Tannin 
type 
Intervention 
length 
Outcome 
46 6 Rat 
5, 10, 15, 20 g tannin/kg 
diet vs. control  
Tannic 
acid 
3 weeks 
Significant linear reduction in hemoglobin (up 
to 27%) and hepatic (up to 61%) iron levels 
with tannic acid consumption 
45 9 Pig 
125, 250,500, 1000 mg 
tannin/kg diet vs. 
control 
Tannic 
acid 
4 weeks 
Significant linear reduction in hemoglobin (up 
to 21%; p = 0.028) and serum iron levels 
(29%, p = 0.12) with tannic acid consumption  
44,  7 Rat 
100 g tea consumption 
vs. 100 g tea (beverage) 
with various levels of 
aluminum and control 
Green 
tea 
8 weeks 
Significant reduction in hemoglobin (11.0 vs. 
10.0 g/L; 9% reduction) and hepatic (750 vs. 
250 µg/liver; 71% reduction) iron with tea 
consumption compared to control 
47. 8 Rat 
Green or black tea 
decoction with bean 
ragout meal 
Green 
or 
black 
tea 
14 days 
Significant depletion of hemoglobin (-1.1 and 
-0.95 g/L black and green tea) and iron 
bioavailability (19.6% and 14.9% in black and 
green tea, respectively) compared to control 
during the study. Normal hepatic iron in tea 
groups compared to control (65, 89.4 and 66.3 
µg/g in control, black, and green tea) 
76 6 Rat 
Black tea powdered diet 
as 25 g/kg vs. control 
Black 
tea 
12 days 
Significant reduction (26%) in iron absorption 
compared to control, although there was 
significant increase over time (24 vs. 42% at 
baseline and end line among tea consumers). 
No reduction in hepatic iron levels. 
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Table 3-2: Studies reporting no or inconsistent reductions in iron bioavailability or iron status in animal models 
Reference n Model Intervention 
Tannin 
type 
Intervention 
length 
Outcome 
50   6 Rat 
Control vs. 
various types 
of tea in food 
Black tea 16 days 
No significant differences in iron absorption or 
hepatic iron compared to control 
75 6 Rat 
Green tea 
diet, or 
gavage vs. 
control  
Green tea 30 days 
No significant differences in iron absorption (3.7 
vs. 5.6 over time and 43 vs. 63% in control vs. tea, 
p = 0.292) or hepatic iron (60.9 vs. 54.2 control 
vs. tea, p = 0.521) compared to control 
49 10 Rat 
Meal with 
phytoferritin 
vs. condensed 
tannins (PA) 
and 
phytoferritin 
Condensed 
tannins 
4 weeks 
Significant reduction in hemoglobin (11.9 vs. 10.0 
g/L); serum iron (10.33 vs. 21.43) control vs. 
proanthocyanidins). Iron repletion and ferritin 
(23.4 vs. 20.98) not significantly different from no 
proanthocyanidin group. 
51 7 Rat 
Casein, soy, 
chickpea, red 
kidney bean 
flour based 
meals  
Condensed 
tannins 
1 week 
No significant differences in iron retained, total 
hemoglobin from meals containing various levels 
of polyphenols and control, no difference between 
iron retention in high and low tannin kidney bean 
meals 
52 16 Pig 
Grape meal, 
hops diets vs. 
control 
Condensed 
tannins 
4 weeks 
No significant differences in iron, TIBC*, 
transferrin, hepatic iron, fecal iron between groups  
36 8 Pig 
Red vs. white 
bean meal 
Condensed 
tannins 
4 weeks 
No significant difference in 
hemoglobin/hemoglobin repletion efficiency in 
white and red bean (26 vs. 30%) 
*TIBC: Total iron binding capacity 
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Table 3-3: Epidemiological study outcomes related to iron status 
Reference n Intervention Analysis Tannin type 
Conflation 
of phytates 
Iron status affected? 
53 173 
2- 24 hour 
recalls  
Multiple 
regression 
“Dietary tannin” 
including tea and 
other polyphenol 
yes 
No IDA correlated with “tannin” 
intake. No significant effect in 
regression model 
74 143 
24 hour diet 
recall 
Multiple 
regression 
“Dietary tannin” 
including tea and 
other polyphenol 
yes 
No significant IDA correlation with 
“tannin” intake  
54 1639 
3- 24 hour 
diet recall, 
venous 
blood draw 
Multiple 
regression 
Black, green, and 
herbal tea 
yes 
IDA, or marginal iron status not 
correlated with “tannin” intake (ferritin 
48, 50, 49 compared to 50, 47, 46 µg/l 
in control, regular black, green, and 
herbal tea drinkers, respectively; p = 
0.71, 0.34, 0.36 in premenopausal 
women with green, black, and herbal 
tea) 
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Table 3-4: Single meal bioavailability studies showing reductions in iron bioavailability with tannin consumption 
Reference N 
Iron 
status 
Population Intervention Tannin type Outcome 
20 10 Replete Women 
Control meal with 
water vs. with 
meal with tea 
Black tea  
Significant reduction in iron bioavailability by 
20% 
56 10 
Replete 
and 
deplete 
Men and 
Women 
Oregano, spinach, 
coffee, tea, or 
tannic acid vs. 
control  
Black tea, tannic 
acid, 
polyphenol/ 
condensed 
tannin 
Tannic acid significantly reduced iron 
bioavailability; oregano, tea, and coffee % 
inhibited bioavailability by greater than >60, 
which was less than their respective equivalent 
tannic acid doses. Spinach reduced bioavailability 
by 30% despite similar tannic acid equivalents to 
its tannic acid, tea, coffee, oregano counterparts. 
57 
6 
(C), 
13 
(I) 
Replete 
Men and 
Women 
High vs. low 
availability meal 
in vegetarian vs. 
non vegetarians 
Polyphenol/ 
condensed 
tannin 
Significant impairment of iron absorption from 
low bioavailability meals in vegetarian and non-
vegetarian consumers. Similar iron bioavailability 
between vegetarian (1.4% vs. 14.9 in bran vs. 
whole wheat rolls) and non-vegetarian (22.3 vs. 
2.2%) despite higher average phytate intake in 
vegetarian group 
22 10 
Replete 
and 
deplete 
Women 
Meal with black 
tea, ascorbic acid, 
vs. control meal 
Black tea 
Significant reduction in iron bioavailability with 
tea consumption (18.2 vs. 7.1% in control vs. 150 
ml, and 19.7 vs. 5.6% in control vs. 300 ml tea 
drinkers), not dependent on polyphenol burden (1 
vs. 2 cups tea) 
58 8 
Replete 
and 
deplete 
Men and 
Women 
10 different 
beverages  
Black tea, 
herbal tea, 
cocoa, or coffee   
Significant reduction in iron bioavailability with 
tannin consumption (tea); ranges in reductions tea 
compared to water: 3-27% dependent on whether 
food consumed.  
59 13 
Replete 
and 
deplete 
Men and 
Women 
Control breakfast 
vs. coffee, tea 
Black tea, 
polyphenol 
Significant reduction in bioavailability with tea or 
coffee consumption compared to control (60-90% 
reduction compared to control, average 10% less 
iron absorbed) 
61 22 Replete Women 
Control meal vs. 
meal with tea 
Black tea 
Non-significant differences in iron absorption with 
tea consumption (reduction 1.7%), although 
effects of tea noted with ascorbic acid 
consumption (20% reduction vs. ascorbic acid 
alone) 
60 8 Replete Women 
Broccoli with 
tannic acid 
(500mg) or 
Tannic acid 
Significant reduction (10% vs. 0.3%) iron 
absorption in broccoli vs. broccoli + tannic acid 
meal 
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broccoli alone vs. 
control 
31 
14 
(C), 
15 
(I) 
Replete Women 
Control meal with 
5mg FeSO4 vs. 
tannic acid, phytic 
acid, or pectin  
Tannic acid 
16-25% significant reduction in iron absorption 
with tannic acid vs. no tannin consumption 
63 
10 
(C), 
16 
(I) 
Replete Women 
Bread baked with 
tannic acid (12-
884 mg) vs. 
control 
Tannic acid 
Significant reduction in iron absorption ratio, 
serum iron with tannic acid consumption in bread 
(average reduction of iron absorbed 3-10%) 
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Table 3-5: Single meal bioavailability studies showing no or minimal reductions in iron 
bioavailability with tannin consumption 
 
 
 
  
Reference n 
Iron 
status 
Population Intervention Tannin type Outcome 
65 14 Replete Women 
Meal with green tea, 
meal with rosemary 
extract, control meal 
Green tea or 
polyphenol 
No significant differences in iron absorption 
12.1 vs 8.9% (control vs. green tea) and 7.5 vs. 
6.4% (control vs. rosemary oil) 
66, 8 
Replete 
and 
deplete 
Men and 
Women 
Meal with orange 
juice or tea compared 
with control (water) 
Black tea 
No significant differences in iron bioavailability 
between tea and control, ascorbic acid and 
control 
35 
7 (D), 
12 
(R) 
Replete 
and 
deplete 
Men 
Vegetable and low or 
high tannin sorghum 
roti 
Polyphenol/ 
condensed 
tannins 
Significant 5.2% reduction in absorption of iron 
in anemic men, normalized and non-significant 
when adjusted for phytates (0.83%). No 
significant difference in iron replete men (5.05 
vs. 3.81% in low and high tannin sorghum) 
62 
16 
(C), 
18 (I) 
Replete Women 
Meal with white vs. 
polyphenol rich 
sorghum 
Condensed 
tannins 
5.2 and 5.8% significant reduction (p < 0.001) 
in iron bioavailability from high/medium tannin 
sorghum compared with low tannin sorghum. 
No differences noted with polyphenol oxidase 
addition to meal 
64 16 Replete Women 
Meal containing red 
or white cowpea 
Condensed 
tannins 
No significant differences in iron bioavailability 
between red and white cowpea (11%, both 
groups, p = 0.69) 
67 16 Replete 
Men and 
Women 
Maize meal 
compared to algae 
containing maize 
meal 
Polyphenol/ 
condensed 
tannins 
Dose-dependent, significant enhancement of 
iron bioavailability with algae polyphenols (6.8-
17.8% more iron absorbed with algae compared 
to maize meal)  
68 20 
Replete 
and 
deplete 
Women 
2x2 factorial 
structure with low 
phytate, low 
polyphenol, high 
phytate, or high 
polyphenol bean 
meals 
Polyphenol/ 
condensed 
tannins 
Polyphenol-rich, low-phytate beans non-
significantly increased iron bioavailability 
(6.14, 95% CI: 2.57-14.65 vs. 3.99; 95% CI 
1.83-8.71), compared to low-polyphenol, low-
phytate beans. High-phytate beans significantly 
reduced iron bioavailability (6.14, CI 2.57-
14.65% vs. 3.84, 1.76-8.38).  
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Table 3-6: Long-term studies investigating the impact of tannin consumption on iron 
bioavailability 
Reference n 
Iron 
status 
Intervention Tannin type 
Intervention 
length 
Outcome 
69 
9 (D), 
25 (R) 
Deplete 
and 
Replete 
Green or black tea 
supplementation in 
either vegetarian or 
omnivorous 
participants  
Green or 
Black Tea 
4 weeks 
Significant decrease in ferritin in 
anemic and omnivorous women 
consuming black tea without 
change in TIBC*, Hb+, serum iron 
70 
11 (C), 
12 (I) 
Replete 
Green leafy vegetable 
supplementation vs. 
standard meal 
Polyphenol/ 
condensed 
tannins 
3 weeks 
No significant inhibition of iron 
bioavailability after 
supplementation of tannin 
containing meal compared to 
control; significant increase in Hb+ 
by 11% compared to baseline with 
leafy vegetable intake 
40 
14 (C), 
17 (I) 
Replete 
“High” or “Low” 
bioavailability diet 
Polyphenol/ 
condensed 
tannins 
12 weeks 
Trends toward increases in 
bioavailability of low bioavailable 
diet over time with reduction in 
bioavailability of high bioavailable 
diet. No significant differences in 
non-heme iron absorption between 
groups at study end 
71 9 Replete 
“High” or “Low” 
bioavailability diet 
Polyphenol/ 
condensed 
tannins 
12 weeks 
Significant 8.8% greater iron 
absorption efficiency in high 
bioavailability group (p < 0.0001) 
compared with low bioavailability 
group.  
41 16 Deplete 
“High” or “Low” 
phytate diet with high 
phytate diet challenge 
at baseline and 
endpoint 
Polyphenol/ 
condensed 
tannins 
8 weeks 
Significantly increased uptake of 
iron in high phytate diet (29.3% 
increase) despite no changes in iron 
markers (ferritin, TIBC*, hepcidin) 
compared to low phytate group. 
Decrease in absorption of iron to 
high phytate meal with low phytate 
consuming group 
+ Hb: Hemoglobin; *TIBC: Total iron binding capacity;  
(C) Control; (D) Deplete participants; (I) Intervention; (R) Replete Participants 
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 Figures 
Figure 3-1: A: Condensed tannin Yikrazuul/ Wikimedia Commons / Public Domain and B: 
Tannic Acid Ronhjones/ Wikimedia Commons / Public Domain 
 
 
Figure 3-2: Inclusion and exclusion criteria for review. Articles were excluded related to 
key terms, in vitro analysis, lack of tannin assessment in dietary analysis, and analysis of 
non-iron outcomes iron bioavailability, iron status in tannin consumers  
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 Abstract  
Background: Tannins are often cited for antinutritional effects, including chelation of non-heme 
iron. Despite this, studies exploring non-heme iron bioavailability inhibition with long-term 
consumption have reported mixed results. Salivary proline-rich proteins (PRPs) may mediate 
tannin-antinutritional effects on non-heme iron bioavailability.  
Aim: To review evidence regarding biochemical binding mechanisms and affinity states between 
PRPs and tannins, as well as effects of PRPs on non-heme iron bioavailability with tannin 
consumption in vivo.  
Method: Narrative systematic review and meta-analysis. Common themes in biochemical 
modeling and affinity studies were collated for summary and synthesis; data were extracted from 
in vivo experiments for meta-analysis.   
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Results: Thirty-two studies were included in analysis. Common themes that positively influenced 
tannin-PRP binding included specificity of tannin-PRP binding, PRP and tannin stereochemistry.  
Hydrolyzable tannins have different affinities than condensed tannins when binding to PRPs. In 
vivo, hepatic iron stores and non-heme iron absorption are not significantly affected by tannin 
consumption (d = -0.64-1.84; -2.7-0.13 respectively), and PRP expression may increase non-
heme iron bioavailability with tannin consumption. 
Conclusions: In vitro modeling suggests that tannins favor PRP binding over iron chelation 
throughout digestion. Hydrolyzable tannins are not representative of tannin impact on non-heme 
iron bioavailability in food tannins because of their unique structural properties and PRP 
affinities. With tannin consumption, PRP production is increased, and may be an initial line of 
defense against tannin-non-heme iron chelation in vivo.  More research is needed to compare 
competitive binding of tannin-PRP to tannin-non-heme iron complexes, and elucidate PRPs’ role 
in adaption to non-heme iron bioavailability in vivo. 
Key words: iron bioavailability, antinutritional factors, tannin, proanthocyanidins, salivary 
proline-rich proteins 
 Introduction 
 Non-heme iron-tannin binding  
Tannins are defensive metabolites classified as either hydrolyzable or condensed 1, that 
protect plants from insect, animal predators, and mold 2. Hydrolyzable tannins are esters of 
polyols with phenolic acids (generally gallic acid) that are readily hydrolyzed by acidic or basic 
conditions 1, and are “virtually absent from the diet” 3 (Figure 1a). Condensed tannins, also 
known as proanthocyanidins, are more commonly consumed in sorghum, wine, tea, dark 
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chocolate and berries 3, and are comprised of oligomers and polymers of flavan-3-ols linked by 
carbon bonds 4 that are difficult to hydrolyze 1 (Figure 1b).   
While tannin-rich foods may confer potential antioxidant 5, cancer fighting 6, and 
cardiovascular 7 health benefits, a potential drawback to their consumption is that they inhibit 
non-heme iron bioavailability 8-20. However, the studies supporting this antinutrient function 
have mostly been single meal studies utilizing hydrolyzable tannic acid or oligomeric 
epigallocatechin gallate found in tea. Studies that have explored long-term consumption of 
tannins 21,22 and other antinutritional factors 23,24, as well as epidemiological studies 25-27 have 
questioned whether potent tannin-non-heme iron inhibition is sustained over time.  
Traditionally, protein-tannin binding has been cited as a major contributor to the 
antinutritional effect of tannins outside of mineral metabolism. It is tannins’ predilection toward 
protein interaction that may mediate non-heme iron-chelation by salivary proline-rich proteins 
(PRPs), which bind to tannins in lieu of non-heme iron to make the mineral more bioavailable. 
Tannins’ ability to interact with proteins varies widely, and it has been noted that protein 
characteristics that increase binding include large protein size, amino acid sequences that are rich 
in proline, and a lack of protein structure 28. Due to their specific preference for tannin binding, 
PRP’s have been studied in disciplines that have aimed to understand adaption to seasonally 
tannin-rich diets in animals 29-32. Salivary PRPs have been of interest in sensory studies due to 
their ability to irreversibly precipitate tannins, contributing to the sensation of astringency 28. 
Tannin-PRP complexes have been found to be insoluble throughout the gastrointestinal tract 33,34, 
thus complexes are maintained during digestion. Moreover, like non-heme iron absorption, PRP 
profiles tend to show high intrapersonal, rather than interpersonal variability 35, that is 
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genetically linked 36,37, which may explain why some individuals have enhanced capacity for 
‘antinutritional’ consumption without impaired iron status. Increases in PRP secretion with 
tannin consumption have been shown to improve protein 38, and non-heme iron availability 39,40, 
in rats, and hamsters without capacity to enhance PRP synthesis tannin consumption resulted in 
poorer protein availability 31,41. 
This systematic review aims to explore whether tannin-PRP complexes may reduce 
tannin-non-heme iron chelation during digestion, and to determine whether biochemical 
mechanisms behind tannin-PRP binding could reduce tannin-non-heme iron chelation during 
digestion. This review will identify in vitro and in vivo research exploring biochemical 
mechanisms and outcomes related to tannin-PRP binding and non-heme iron. Secondary aims 
are to compare potential differences in non-heme iron bioavailability attributed to hydrolyzable 
versus condensed tannins PRP-binding mechanisms in order to explore whether food, or 
condensed tannins, may affect non-heme iron chelation differently than hydrolyzable tannins 
commonly used in non-heme iron absorption studies.  
 Methods 
 Primary outcomes and search strategy  
Primary search subjects included non-heme iron and/or salivary proline-rich proteins 
exposed to tannins, both condensed and hydrolyzable. Search outcomes were targeted toward 
research exploring biochemical modeling for binding methods, binding strength, mechanism of 
binding comparatively, effects of binding of one compound on another, and long-term effects of 
tannin consumption on PRP and non-heme iron availability. Studies were not excluded for 
sample or effect size. To capture as many relevant citations as possible, medical and scientific 
122 
 
 
 
 
databases were used (Pubmed, Web of Sciences Core Collection, Cochrane Database, Medline, 
Proquest Nursing, and CABI), as well as snowball article collection (citations from relevant 
journal articles) and internet search engines (Google Scholar) to look for other references. All 
publication dates were included and searches were completed by July 2016. Articles reviewed 
were in English. 
 Search terms and inclusion  
Article searches in PubMed included ("Salivary Proline-Rich Proteins"[Mesh] AND 
"Non-heme iron"[Mesh]) AND "Tannins"[Mesh];("Salivary Proline-Rich Proteins"[Mesh] AND 
"Non-heme iron"[Mesh]) 2012; ("Salivary Proline-Rich Proteins"[Mesh] AND "Tannins"[Mesh] 
2009-2014; ("Non-heme iron"[Mesh]) AND "Tannins"[Mesh] 1945-2015; ("Salivary Proteins 
and Peptides"[Mesh]) AND "Non-heme iron"[Mesh] 1983-2015; (("Salivary Proteins and 
Peptides"[Mesh]) AND "Non-heme iron"[Mesh]) AND "Tannins"[Mesh];("Proline-Rich Protein 
Domains"[Mesh]) AND "Tannins"[Mesh] 2009-2016;"Proline-Rich Protein Domains"[Mesh] 
AND "Non-heme iron"[Mesh] ("Tannins"[Mesh]) AND "Salivary Proteins and Peptides"[Mesh] 
1983-2015; (salivary protein[All Fields] OR salivary proteinase[All Fields] OR salivary 
proteins[All Fields]) AND ("non-heme iron"[MeSH Terms] OR "non-heme iron"[All Fields]) 
1966-2016; salivary[All Fields] AND ("proline"[MeSH Terms] OR "proline"[All Fields]) AND 
rich[All Fields] AND ("proteins"[MeSH Terms] OR "proteins"[All Fields] OR "protein"[All 
Fields]) 1973-2016. Filters included searches for in vivo, in vitro, human and animal models. 
Web of Science Core Collection and CABI search terms included “salivary proline-rich proteins 
AND tannins (condensed OR proanthocyanidins AND/OR hydrolyzable) AND/OR non-heme 
iron”; “tannins AND non-heme iron” (All years). Proquest nursing and MEDLINE (all years; 
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terms included: "salivary proline-rich protein*" AND proanthocyanidins; "salivary proline-rich 
protein*" AND non-heme iron; ("salivary protein*" AND non-heme iron) AND tannin; 
("salivary protein*" AND tannin); ("salivary protein*" AND non-heme iron) (All years). 
Cochrane search terms were: #1 MeSH descriptor: [Non-heme iron] explode all trees 1785 #2 
MeSH descriptor: [Proanthocyanidins] explode all trees; #3 MeSH descriptor: [Salivary Proline-
Rich Proteins] explode all trees (all years). 
 Selection, quality assessment, data extraction and analysis  
Articles retrieved were collected into an online database, and duplicates were removed. 
Remaining articles were included with the presence of at least two key terms, and then by 
abstract reviews for relevance to study outcomes. After initial inclusion criteria were met, 
articles were collected for full review. Quality assessment of data was completed using the 
Cochrane Quality Guide 42 adapted for in vitro studies (Appendix A). In brief, articles were 
reviewed for risk of bias based on methodology, results presented and discussion. They were 
classified as having high, unclear, or low risk of bias based on their overall study characteristics. 
Studies with overall high or unclear risk of bias were excluded from the review. Data from 
remaining articles were collated into summary tables (biochemical study characteristics, 
Appendix B). For biochemical binding analysis, a narrative synthesis approach was chosen due 
to the heterogeneity of studies explored and lack of studies exploring tannin-non-heme iron: 
tannin-PRP binding comparisons. This process included developing a theory of how study 
interventions worked, developing a preliminary synthesis of findings in included studies, 
exploring relationships within and between studies, and assessing the robustness of the synthesis 
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formulated (Figure 2) 43. For analysis, studies were grouped primarily by study question, then by 
subgroup topics.   
  
For in vivo analysis, study outcomes were collected, mean outcome measurements and 
standard deviations were used to calculate Hedges’ g estimates, and results were used to 
calculate effect size (40). Upper and lower confidence limits of effect size were calculated using a 
95% confidence interval, and total effect size was calculated from normalized values 44. PRP 
synthesis relative to control gave reference to PRP production with non-heme iron-tannin 
outcomes using the equation: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑃𝑅𝑃 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑃𝑅𝑃 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 (𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛)
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑃𝑅𝑃 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 
 Results 
 Inclusion Criteria  
Original search terms generated 1220 articles that were added into an electronic database 
(Figure 3). After duplicates were automatically removed, 752 articles were reviewed for title, 
abstract, and key term relevance. Articles were removed without presence of at least two key 
terms in abstracts (one of two key subject terms; non-heme iron and/or salivary proline-rich 
proteins) AND an intervention term (tannin exposure). Excluded studies at this stage included 
validity studies for measurement tools, assessment studies (including tannin content of foods, 
food non-heme iron content), studies in ruminant animals, research exploring topic subjects in 
specialized conditions (burning mouth syndrome, Sjogren’s syndrome, Appendix C). The 107 
articles remaining were manually combed for duplicates, and a second review of abstracts for 
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specific population intervention comparison and outcomes (PICO) specified further narrowed 
articles. Articles were obtained for full article review from online journal archives, printed 
journals, and interlibrary loan. Because of the heterogeneity of remaining studies available to 
answer the research question, full text review of the remaining 81 articles was divided into two 
groups: biochemical mechanisms for tannin binding, and in vivo comparisons of non-heme iron 
status with tannin consumption and PRP production. For biochemical mechanisms, articles were 
excluded that did not address PRP interactions with tannins specifically. This exclusion criterion 
was applied due to suggestion that PRPs have different binding capacity and mechanisms than 
other proteins, limiting efficacy of substitute models 45. Other reasons for exclusion at this stage 
were that articles did not include biochemical mechanisms explaining tannin-PRP binding. 
Remaining in vivo articles were excluded that did not include all three outcomes related to the 
study question: non-heme iron, tannins, and salivary PRPs. Full text review of articles was 
completed including analysis for internal and external bias. Final analysis included 32 studies 
(for biochemical modeling: 30in vitro and 2 in vivo, both animal studies). 
 Part I: Mechanisms behind tannin-PRP binding, effects of tannin and PRP 
characteristics on binding affinity 
Of studies reviewed, three themes potentially important to considering binding and 
affinity of PRPs to tannins were identified. The first was that tannin-PRP binding mechanisms 
are specific, and that binding affinity and efficiency are affected by tannin and PRP 
concentration. Next was that ionic and digestive influences favor tannin-PRP complex formation 
throughout digestion. Finally, the stereo-chemical makeup of tannins and PRPs themselves is 
important to preferential binding and affinity of tannin-PRP connections.  
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 Tannin-PRP binding specificity  
PRPs are randomly structured, unfolded proteins 46 where open and flexible conformation 
of helical and extended coils allows for binding of tannins to proline-rich residues (Figure 4) 47-
49. Interactions between PRPs and tannins first occur through hydrogen bonds between 
compounds enhanced by glycine, arginine, and alanine 46,48,50. It is important to note that PRPs 
bind specifically to tannins 46,50-55 (Table 1), and with an increased affinity compared to digestive 
enzymes and proteins 4,56, which supports the role of PRPs serving as biological protectors 
against tannins. Selectivity is regulated by both tannin and PRP properties enhancing affinity of 
binding; high-affinity tannin molecules are bound first, then lower affinity molecules are bound 
at higher concentrations 57. Enzyme activity inhibited by tannins is enhanced in the presence of 
PRPs, pointing to tannin-PRP preferential binding 55, and similarly structured compounds to 
PRPs have not been found to bind to tannins with the robust affinity found in tannin-PRP binding 
53.  
As tannins bind to and saturate proline-rich residues, their multidendate, or self-
associating nature 54, leads to cross-linked binding between tannin molecules, formation of 
hydrophobic tannin-PRP bonds 46, and more efficient and stable precipitation of tannin-PRP 
complexes 52,54. The concept of affinity and eventual tannin-PRP precipitation may explain the 
effectiveness of tannin-PRP complexes in preventing tannin-iron chelation. In a non-precipitated 
state, tannins are highly bound to PRPs, however, lack of saturation of proline-rich residues 
increases the likelihood that tannin-PRP complexes will dissociate 46,54. This may lead to tannin-
iron chelation later during digestion. Tannin-PRP binding at low tannin concentrations may 
follow a ‘poisoned growth model,’ wherein aggregation of tannins through crosslinking is 
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limited by PRPs that do not have sufficient saturated proline residues to continue the process 54. 
In this model, a lack of saturated proline-rich residues on PRPs favors redistribution of tannin 
molecules among all PRPs, reducing the crosslinks formed by tannins and leading to dissociation 
and ‘freeing’ of tannins from PRPs 54. 
 Concentration effects 
High tannin concentrations support almost immediate formation of hydrophobic bonds 
and tannin crosslinks with PRPs, along with subsequent precipitation 46. In contrast, lower tannin 
concentrations resist precipitation due to lack of tannin crosslinking and hydrophobic bonds in 
favor of weaker hydrogen bonds that may later dissociate (Table 2) 50,54,56,58-62. Thus, as 
concentration of tannin increases, PRPs have the ability to bind tannin molecules beyond the 
number of proline residues that they contain 50,54, leading to more efficient tannin ‘capture’ by 
PRPs. After concentration-dependent hydrophobic interactions and tannin-crosslinking is 
established, conformational changes in the PRP molecule provides additional stability of tannin-
PRP complexes, further reducing likelihood of digestive dissociation 51,63. 
Thus, the process of tannin-PRP binding is proposed in three stages: first, proline 
residues are saturated by tannins that bind selectively, and hydrogen bonds strengthen the tannin-
PRP complex. Next, tannins self-associate and hydrophobic stacking of multiple tannins 
promotes crosslinking of tannin-PRP complexes via tannin-tannin bonds, and conformational 
PRP changes stabilize the bond. Last, tannin-PRP complexes aggregate and separate from 
solution (precipitation, Figure 5) 46,52. 
  
128 
 
 
 
 
 Ionic Effects  
Ionic concentration and solvent effects also affect tannin-PRP binding affinity. 
Hydrophilic 56 and basic 55,62,64-66 environments tend to reduce tannin-PRP affinity, partly due to 
reductions in hydrogen and hydrophobic binding 56,66 (Table 3). Potential of hydrogen (pH) in 
gastric compared to enteric environments significantly increases precipitation of PRPs 65, and 
lower ionic concentrations may inhibit secondary structural changes needed for PRP-tannin 
association 54,67. Tannic acid is more soluble in acidic environments 62, suggesting that 
precipitation may be necessary for PRP-induced protective mechanisms against tannins. Food 
matrix components, carbohydrates and ethanol particularly 56,66, disrupt precipitation of tannin-
PRP aggregation, necessitating increased concentrations of tannins to precipitate PRPs. It is 
important to note that matrix disrupted interactions may limit tannin-iron exposure as well. 
 Digestive Effects 
In vitro digestion experiments have shown that tannin-PRP bonds are highly resistant to 
digestion 55,58,59,65,68. Tannin-PRP bonds are resistant to trypsin cleavage 58, and in the presence 
of enteric digestive protease enzymes, tannin-PRP complexes are more likely to stay insoluble 
than in their absence 65. Gastric digestion and pH favor precipitation of tannin-PRP aggregates 
55,58,59,65,68, although smaller tannin size and lower concentration reduce stability in gastric 
digestion 59. PRPs are also highly bound and recovered in enteric digestion 59, and may block 
enteric absorption and digestion of tannins themselves 55,65. Binding affinity of tannin-PRP 
complexes seems to remain specific outside of the mouth; addition of PRP to hydrolyzable 
tannin has been found to reduce tannin absorption 2-3 fold in Caco-2 cells 68. 
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 PRP characteristics and tannin interactions 
Many classifications of PRPs have been identified in saliva, and are grouped according to 
their biochemical properties. When referencing their ability to precipitate tannins in whole saliva, 
acidic PRPs (aPRP) tend to bind to tannins with the highest affinity, followed by basic (bPRP), 
and glycosylated PRPs (gPRPs) 58,59. While tannin-PRP affinity may explain the predilection for 
complex formation, this does not always correlate to the ability to efficiently precipitate tannins. 
Greater proline content in bPRP 65,69, and gPRP 69 is associated with increased ability to 
precipitate higher concentrations of tannins compared to their acidic counterparts. Longer PRP 
sequences found in bPRP and gPRP with more proline-rich residues result in more tannin-
proline-rich residue interactions 70, and allow for secondary conformational changes around 
tannin molecules 50, likely reducing complex dissociation compared with shorter PRP sequences 
48. Glycosylation may increase the threshold for precipitation of tannins without impeding 
tannin-PRP affinity 61, although this finding has been inconsistent 71. 
In vivo, PRP profiles differ among regular tannin consumers and non-consumers. For 
example, gPRP have been found more prevalently in tannin consumers’ salivary profiles, and 
tannins are precipitated at a lower rate (30%) in consumers than in non-consumers (85%), 
possibly due to increased capacity of PRP types produced 4. Types of PRPs that were 
precipitated also varied between tannin and non-tannin consumers. Tannin consumer PRP 
profiles consisted of higher prevalence of bPRP and gPRP, which were most commonly 
precipitated 4. 
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 Tannin Polymerization, galloylation, and hydroxylation 
Tannin polymerization, galloylation, and hydroxylation play a role in tannin-PRP affinity 
and precipitation (Table 4). Increased polymerization, or increases in the relative size of tannin 
molecules, may favor tannin-PRP affinity through hydrophobic interactions and subsequent 
increases in self-association of tannin molecules to form precipitating complexes 51. Increased 
galloylation 69,72, as well as hydroxyl group positioning 53,70, may increase affinity, as well as 
binding strength of tannins to PRPs through promotion of hydrogen bonds. Perhaps less 
importantly, the location of carbon-carbon bonds within polymers may improve stability of 
precipitates formed by tannin-PRP complexes 72. 
Tannin polymerization affects tannin-PRP affinity and dissociation more than either 
tannin galloylation or hydroxylation 52,53; larger tannin molecules precipitate PRPs more 
efficiently 51-53,59,61,61,70,72, and selectively 4, than smaller molecules. Smaller molecules do bind 
PRPs, but do not crosslink 72, and the lack of tannin self-association increases the likelihood that 
tannin-PRP complexes dissociate 50,54,65,69, found in vitro 59. In vivo, tannin polymerization has 
been shown to be positively correlated with precipitation; however, tannin consumers’ saliva is 
able to precipitate smaller tannins, and given that greater polymer size is bound preferentially, 
does not leave tannins unbound. Non-consumers, on the other hand, may bind only large 
tannins4. 
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 Binding of hydrolyzable vs. condensed tannins 
PRP binding to hydrolyzable versus condensed tannins is influenced both by differences 
in binding affinity 50,64,65,69 and subsequent likelihood of bond dissociation during digestion 
50,51,65,66 (Table 5). PRP affinity toward hydrolysable tannins is greater than condensed tannins 
50,64,65,69. Affinity of hydrolyzable tannins toward PRPs may reduce the number of available 
proline residues for tannin-binding compared with condensed tannins 50,65,69. It has been noted 
that there is a greater stability of PRP with quebracho (a condensed tannin), measured by 
precipitation, in both gastric and enteric conditions compared to tannic acid 65. This may be due 
to weaker hydrogen bonds that hold hydrolyzable tannin-PRP complexes together 50,51 compared 
with more prominent hydrophobic bonds found in condensed tannin-PRP precipitates 66. The 
ring structure in condensed tannins may favor a more stable hydrophobic bond compared with 
hydrolyzable tannins 72. It has been suggested that hydrolyzable tannins may not crosslink 
compared to their condensed counterparts 51, reducing bond stability and increasing likelihood of 
complex dissociation. Differences in binding mechanisms described above may also reduce the 
physiological stability of hydrolyzable compared to condensed tannin-PRP complexes 
throughout the digestive process 50,51,65,66.   
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 Part II: Effect of tannin consumption on PRP expression and non-heme iron 
bioavailability 
 In vivo comparisons 
Two studies have explored the interaction of chronic tannin ingestion, PRPs and non-
heme iron bioavailability 39,40 (Table 6). Due to the similarities of the two studies, it is possible 
to compare effects of several treatments to control conditions in order to isolate findings for 
synthesis. Thus, PRP production and the effects of tannin consumption on non-heme iron 
absorption versus hepatic iron status are highlighted. Further, isolation of experiments employing 
chronic ingestion of tannins is included to give context to effect of tannin ingestion over time. 
 Study characteristics: 
Both of the studies reviewed included a diet challenge after either acute or chronic 
ingestion of a tannin-rich diet in weanling Sprague-Dawley rats, however they employed 
different diet mechanisms to attempt to explore the effect of PRP expression on non-heme iron 
absorption and hepatic iron stores. The first (Study 1) study provided tannin-containing green tea 
powder or a control diet, fed for 7 or 30 days, compared with a tannin-containing gavage (green 
tea) diet. In the gavage diet, exposure of tannin to the oral cavity was bypassed with the goal to 
reduce expression of PRPs 39. This study included a diet challenge at either day 1 (acute) or day 
24 (chronic) to measure non-heme iron absorption, after collection of baseline bloodwork. Green 
tea powder and control diets were given as powdered diets, or without green tea powder; animals 
in these groups were given a twice daily phosphate buffered saline gavage. Green tea gavage 
groups were given a control powdered diet with green tea gavages twice daily throughout the 
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study 39. Tannin concentration in gavage diets was based on oral tannin consumption of green tea 
diets by rats. 
The second (Study 2) study included a control or tannin-containing diet (as black tea, half 
the amount of tannin given at challenge) with tannin challenge at midpoint (day 11) for all 
groups. Substitution of protein with gelatin (proline-rich) in separate chronic and acute ingestion 
groups aimed to assess the effects of PRPs on non-heme iron absorption with proline addition 40. 
In study 2, intervention groups were given a diet with brewed black tea that was made into a 
slurry with powdered diets. Slurry diet components were then freeze dried and milled into 
powdered diets 40. Diets consumed in both studies contained similar tannin and iron content 
(Table 6). Study 2 diet intake was not significantly different between groups with chronic 
consumption, but was ~3x less days 1-3 of the study. Both studies used a 2 g test meal for iron 
absorption, which was totally consumed by rats. 
 Comparison I: Effect of tannin on non-heme iron absorption and stores with acute 
and chronic tannin ingestion 
Data are presented in means ± SEM. Study 1 hepatic iron stores were not significantly 
different among treatment groups (p = 0.521) 39. Acute treatment outcomes were not different 
from chronic outcomes in control (53.5 ± 11.1 vs. 61.0 ± 4.0 µg Fe/g liver), gavage (58.4 ± 2.0 
vs. 57.6 ± 7.6 µg Fe/g liver), or green tea powder (47.2 ± 2.7 vs. 54.2 ± 7.5 µg Fe/g liver) groups 
39 (Table 7, Figure 3). Study 2 hepatic iron stores were not significantly different among 
treatment groups (p-value not presented). Acute and chronic groups’ hepatic iron levels were not 
significantly different (58.5 ± 5.2 and 58.8 ± 6.9 vs. 43.5 ± 3.4 and 46.6 ± 3.6 µg Fe/g liver) in 
challenge and long-term tea and gelatin diets, respectively, (Figure 1) 40. Calculated confidence 
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intervals supported that overall, there was a non-significant, but positive, effect of tannin 
consumption on hepatic iron stores (calculated effect size d= 0.57, 95% CI -0.64 to 1.84 in favor 
of treatment; Table 7). This trend was more positive in chronic tannin consumers (calculated 
effect size d= 1.16, 95% CI -0.18 to 2.51 in favor of treatment).  
Data for non-heme iron absorption are also presented in means ± SEM. Non-heme iron 
absorption percentage was not significantly different among treatment groups in study 1 (p = 
0.104, p= 0.292 acute and chronic, respectively). Acute non-heme iron absorption was much 
higher than chronic non-heme iron absorption in all groups, possibly due to sufficient iron stores 
in the rats at study end, but absorption among treatment groups were not significantly different in 
control (43.1% ± 4.9 vs. 5.6% ± 1.0), gavage (56.5% ± 7.5 vs. 6.0% ± 1.0), or oral (63.8% ± 6.4 
vs. 3.7% ± 1.2) groups (Table 8, Figure 4) 39. Non-heme iron absorption was significantly 
reduced in Study 2 tannin-consuming groups, although there was significantly greater absorption 
of non-heme iron from groups consuming tannins over time (7.5% ± 2.3 and 25.1% ± 7.4 vs. 
6.8% ± 1.6 and 20.8% ± 4.5) in challenge and long-term tea diet and gelatin diets, respectively, 
(Figure 4) 40. Calculated confidence intervals supported that overall, there was a non-significant 
but negative effect of tannin consumption on non-heme iron absorption (calculated effect size d= 
-1.30, 95% CI -2.73 to 0.13 in favor of treatment; Table 8). This trend was slightly more positive 
with chronic tannin consumption (calculated effect size d= -1.11, 95% CI -2.37 to 0.16 in favor 
of treatment).  
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 Comparison II: Effects of PRP production on non-heme iron bioavailability 
While study 1 presented a more detailed analysis of PRP production relative to control, 
study 2 presented total PRP production for each chronically consuming tannin group and control. 
Because total PRP production was assessed differently by studies, and is presented in relative 
amounts compared to control analysis (Table 9). In study 1, total PRP production in oral-tannin 
ingestion groups was greater than either control or gavage groups 39. Chronic oral tannin 
ingestion resulted in reduction of PRP production relative to acute ingestion.  In study 2, there 
were no significant differences in PRP production between control and intervention groups 40.  
Given that direct tannin precipitation of PRPs would most likely affect non-heme iron 
absorption with proposed biochemical binding mechanisms, relative PRP production to control 
was calculated and compared to experimental non-heme iron absorption. Given the somewhat 
qualitative nature of the findings in both studies, statistical analysis has not been applied. 
Overall, relative PRP expression is greater in groups that found greater non-heme iron 
absorption, although this is not true in gavage groups, where PRP induction was low and non-
heme iron absorption was generally improved compared with control (Table 8, Figure 6). 
Groups where PRP induction was low (chronic tea and chronic gelatin ingestion) trended toward 
lower non-heme iron absorption.  
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 Discussion  
 Comparison of tannin non-heme iron and tannin PRP binding 
 PRP tannin binding and affinity  
Comparing the nature of tannin-PRP binding elucidates mechanisms that may deter 
tannin-non-heme iron chelation throughout digestion. Tannin exposure to PRPs in the mouth 
allows for selective complex formation in lieu of tannin-iron chelation on first contact with the 
food bolus, and conformational changes, along with tannin-crosslinking, effectively allows PRPs 
to efficiently bind tannins. The strength of hydrophobic bonds formed with tannin-crosslinking, 
along with secondary PRP conformational changes with residue saturation, may prevent tannin 
dissociation during digestion and limit the number of unbound hydroxyl groups with the 
potential to chelate iron throughout the alimentary tract 55,63. 
Similarly to tannin-PRP binding, non-heme iron species are bound to hydroxyl groups of 
polyphenols 73, and tannins with greater affinity toward non-heme iron (such as tannins with 
galloyl groups, or larger tannin-polymers) 74 may bind to tannins more efficiently (and thus 
fewer tannins chelate more non-heme iron molecules). Because PRPs favor binding to higher 
order (higher polymerization) polyphenol complexes, it may be that PRPs specifically precipitate 
tannins most likely to bind to iron during digestion.  Beyond the nature of tannin-PRP binding, 
production of PRPs that better bind tannins (such as bPRP or gPRP) 58,59 with common tannin 
consumption 4 may facilitate adaptation to tannin-iron chelation over time.  
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 Digestion and ionization 
At physiological conditions, tannins tend to be deprotonated 75, forming Lewis bases that are 
stabilized with Lewis acids, such as Fe3+, and to a lesser extent, Fe2+ 73,76). In acidic conditions, 
protonated tannins, and can be stabilized after bound ferric iron is reduced to its ferrous state, 
and reduce another ferric iron molecule 73. Acidic conditions where iron is easily oxidized 
therefore favor tannin-iron affinity. Interestingly, gallate complexes oxidize at a much higher rate 
than catecholate complexes 77, which may be why tannic acid strongly chelates non-heme iron 
compared with condensed tannin-containing foods. Reductions in iron bioavailability are found 
at higher pH environments, where polyphenol-non-heme iron complexes prevent Fe3+ reduction 
to Fe2+ 78, possibly reducing the amount of non-heme iron that can be taken up by the enterocyte.  
Similar tannin-iron and tannin-PRP properties regarding pH may explain why pH 
strongly influences the nature and strength of tannin-PRP bonds. Condensed tannins and bPRP 
tend to precipitate within similar, more basic ionic conditions 79; aPRP tend to precipitate closer 
to the pH of saliva 58, suggesting that PRPs may have different functions at different stages of 
digestion 80. Tendencies of aPRP to precipitate at salivary pH may also favor immediate tannin-
PRP binding before non-heme iron can be chelated in the mouth. Importantly, the affinity of 
tannin-PRP binding is resistant to digestion, thereby reducing exposure of tannins to non-heme 
iron throughout the digestive tract 55,58,59,65,68. Compared with the more basic isoelectric point of 
condensed polyphenols, tannic acid is deprotonated at a pH closer to 5 81, where tannin-non-
heme iron precipitation is highest 74. This may explain why tannic acid has more potent affinity 
and efficient binding than condensed tannins for both PRP and non-heme iron complexes.  
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 Hydrolyzable versus condensed tannins 
Effective PRP protection against hydrolyzable and condensed tannins may be different 
due to multiple factors. Tannic acid binds more efficiently to non-heme iron as compared to 
catechins or food polyphenols 74,82,83, increasing efficiency of tannin acid-iron chelation 
comparatively. As mentioned previously, larger tannin polymers increase non-heme iron-tannin 
binding 74. Condensed tannin polyphenols tend to be higher order polymers 59 than tannic acid 68, 
are more likely to cross-link 51, and less likely to dissociate in digestion. By comparison, tannic 
acid is not as efficiently bound by PRPs during digestion, increasing the antinutritional potency 
of these tannins. The overall smaller molecular size of hydrolyzable tannins (especially in tannic 
acid) decreases non-heme iron binding relative to higher order condensed tannin polymers, but 
an increased number of galloyl groups on tannins increase affinity compared to condensed 
tannins 74. Subsequently, a higher concentration of small monomeric compounds may allow 
hydrolyzable tannins to more efficiently bind PRPs and non-heme iron, leading to an increased 
burden on salivary glands to produce PRPs, as well as more effective chelation of non-heme iron 
when PRPs cannot meet tannin demand. In digestion, the hydrolyzable tannins may more likely 
dissociate from PRPs 65, further increasing potential non-heme iron chelation compared with 
their condensed counterparts. In vivo, PRP production is more highly upregulated with exposure 
to a mix of condensed and hydrolyzable tannins compared to tannic acid alone 84, suggesting that 
PRPs may not be an effective defense mechanism against this compound. It may be important to 
consider these differences when comparing accommodation of non-heme iron status and 
availability between food tannins (condensed tannins) and hydrolyzable tannins (tannic acid).  
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 Limitations in protective Tannin-PRP binding  
Despite attributes that potentially favor tannin-PRP binding as a mechanism to prevent 
tannin-non-heme iron chelation, inefficiencies seem to exist. Similar to tannin-PRP interactions, 
low concentrations of polyphenols associate with non-heme iron more efficiently than higher 
concentrations 82. This phenomenon may importantly explain the inefficiency of tannin-PRP 
complexes in preventing tannin-non-heme iron chelation, especially in adaption. Following the 
‘poisoned growth model,’ tannins must be highly bound, and possibly precipitated in order to 
prevent tannin-non-heme iron chelation 50,54. As PRP profiles change due to tannin consumption, 
favoring bPRPs and gPRPs 4 that may bind a greater number of tannins before crosslinking leads 
to complex formation, molecules that randomly dissociate may chelate non-heme iron in 
digestion. This may be more commonly found in tannins of lower affinity (lower polymerization, 
galloylation, or hydroxylation).  
 In vivo findings 
 In vivo, it is interesting to note that overall PRP production closely follows non-heme 
iron absorption (Figure 5). Protective benefits of PRP production against tannins have been 
particularly highlighted in hamsters, which do not produce PRPs 85. Other studies have shown 
that PRPs play a role in acclimation to tannins 86-89, although this is not always without 
reductions in growth overall compared to control 30. Non-heme iron absorption is generally 
impacted by tannin intake, although major limitations, including interaction of tannins and non-
heme iron in solution before exposure to PRPs 40, reductions in overall chronic non-heme iron 
absorption 39, and differences in measurement of PRPs between both studies limits the 
generalizability of these findings. It is particularly important to point out that non-heme iron 
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absorption was highly variable in all experiments presented, highlighting the importance of 
individual variability in non-heme iron absorption and the need to understand mechanisms 
behind non-heme iron inhibitors and enhancers from a physiological point of view. Interestingly, 
non-heme iron absorption and non-heme iron status (measured by hepatic non-heme iron) were 
not correlated in these studies, possibly indicating that either non-heme iron supplied was greater 
than the burden of tannin supplied, or that numerical non-heme iron absorption may be a poor 
indicator of non-heme iron status (in this limited model). Adequate hepatic non-heme iron stores 
likely impacted non-heme iron absorption percentage changes when comparing acute to chronic 
tannin challenges 39, although there was an increase in non-heme iron absorption suggesting that 
there was accommodation to poor non-heme iron absorption in acute challenges 40. Perhaps more 
interestingly, rats gavaged with tannins had similar non-heme iron absorption and hepatic status 
compared to those with oral tannin exposure, suggesting that mucosal or endocrinological 
protection mechanisms are additionally important to non-heme iron bioavailability with tannin 
consumption. It may be that immediate tannin accommodation starts with PRPs, but is more 
efficiently dealt with elsewhere.  
 Conclusion 
Similarities in binding mechanisms to tannins may support the hypothesis that PRPs play a role 
in protecting against tannin-non-heme iron chelation during digestion. Additionally, PRP 
production is linked to non-heme iron absorption, although absorption is poorly correlated with 
non-heme iron status in studies reviewed. More research is needed to explore changes in PRP 
production in humans related to tannin-non-heme iron chelation, and in vitro studies specifically 
modeling tannin-non-heme iron chelation in the presence of food tannins. Further in vivo 
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research should explore the differences between condensed and hydrolyzable tannins on non-
heme iron status, and explore potentiating effects of antinutritional factors when consumed 
together.  
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 Tables 
Table 4-1 Tannin-PRP specificity 
Reference Method Tannin type 
PAC-TA 
comparison? 
Conditions of assay Outcome 
Mechanism 
agreement 
51 NMR 
B2, PGG, 
TGG, PAC 
monomer, 
epicatechin 
yes 
40 mM B2, other 
assays 50 mM; either 
0.5 ml of 2mM or 
4mM PRP from 
mouse; pH 3.8 
N-terminal proline residues 
linked to amide and amino 
structures bind tannin, then 
secondary interactions with 
galloyl groups changes structure 
of open conformation around 
PRP (specific binding) 
Yes 
52 NMR 
PAC as B1, 
B3, C2 
No 
0.5-20mM PRP 
(IB9) with 15.7 mM 
tannin; pH 3.5 
Tannin-PRP binding is specific 
to a certain concentration of 
tannin; then becomes random 
Yes 
53 ESI-MS 
EgCG, ECG, 
B2, B2 3-O 
gallate, 
reserpine 
No 
1:10 ratio protein: 
polyphenol; pH 3.2 
Tannin-PRP binding is specific; 
PRP-reserpine did not bind 
(similar structure to studied 
tannins) 
Yes 
54 
ESI-MS; 
DLS, SAXS 
EgCG No 
0.336 mM (1-3.5 
mg/ml) PRP (IB5); 
2:1 protein: 
polyphenol; pH 5.5 
Tannin-PRP interaction is 
specific and dependent on 
tannin interactions; PRP sites 
for tannin binding are 
independent and have free 
energy; at a threshold, 
multidendate tannin crosslinks 
strengthen Tannin-PRP bonds 
Yes 
46 DLS, ITC EgCG No 
6.4 or 12.8 EgCG 
with 0.25-2 mg IB5; 
pH 3.5 
Tannin-PRP interaction is 
concentration dependent; there 
is slow and specific binding of 
tannins followed by rapid and 
non-specific aggregation as 
Tannin-PRP binding sites are 
saturated. 
Yes 
55 
In vitro 
digestion, 
SDS-
PAGE, 
HPLC 
EgCG No 
0.05-0.5 mM EgCG, 
Human salivary 
PRPs; protein: tannin 
ratio 3:1; pH gastric 
2.07; duodenal pH 
7.8 
Preferential tannin-PRP binding 
compared to lipase, alpha 
amylase, chymotrypsin, trypsin, 
lactase 
Yes 
90 DLS, ITC EgCG No 
1:5 ratio saliva: wine 
in 1% TFA 
compared to 
physiological 
conditions 
Salivary PRP ‘moderately’ 
bound tannins 
Yes 
50 NMR, DLS 
EgCG, EGC, 
PGG 
Yes 
20 mM polyphenol 
with 2 mM mouse 
PRP; pH 3.8 
There is preferential binding of 
tannin to proline residues of 
PRPs vs. alternative amino acids 
Yes 
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NMR: Nuclear magnetic resonance imaging; ESI-MS: electrospray ionization mass spectrometry; DLS: dynamic light scattering; SAXS: small angle 
X-ray scattering; ITC: isothermal titration calorimetry; SDS-PAGE: sodium dodecyl polyacrylamide gel electrophoresis; HPLC: high performance 
liquid chromatography. B1, B2, B3: proanthocyanidin B1, B2, B3; PGG: pentagalloylglucose; TGG: tetragalloylglucose; PAC- proanthocyanidin; 
EgCG: epigallocatechin gallate; ECG: epigallocatechin; PRP: proline-rich protein 
 
Table 4-2: Effects of tannin, PRP concentration on binding 
Reference Method Tannin type 
PAC-TA 
comparison 
Conditions of 
assay 
Outcome 
Concentration 
effect 
56 DLS 
PAC as 
tetramers, 
pentamers, 
gallates 
No 
31.2 mg/L GSE: 
0.5-5 mg/L IB-8c 
or 3.12 mg/L IB-
8c: 19.5-46.8 
mg/L GSE; pH 
5.0, 12% ethanol 
Increase in PRP concentration 
increases aggregation and 
precipitation of tannins to a 
maxima, then increased 
protein concentrations favors 
dissociation due to reductions 
in tannin-cross linking 
Tannin stacking 
and crosslinking 
at higher 
concentrations 
58 
SDS-PAGE, 
HPLC, 
tryptic 
digestion 
PAC as 
dimers, 
trimers, 
tetramers 
No 
0.00-1.5 mM 
GSE in saliva; pH 
5.0, 12% ETOH 
At higher tannin 
concentrations, less PRP are 
required for similar binding at 
lower tannin concentrations. 
Tannin stacking 
and crosslinking 
at higher 
concentrations 
59 ESI-MS 
EgCG, ECG, 
B2, B2 3-O 
gallate, 
reserpine 
No 
1:10 ratio protein: 
polyphenol; pH 
3.2 
Higher tannin concentration of 
tannins favor Tannin-PRP 
stability in gastric digestion 
Stability of 
tannin-PRP 
binding  
54 
ESI-MS; 
DLS,SAXS 
EgCG No 
0.336 mM (1-3.5 
mg/ml) PRP 
(IB5); 2:1 
protein: 
polyphenol; pH 
5.5 
At lower concentrations, PRP 
are bound to tannins, but 
soluble. At higher 
concentrations, more tannin is 
needed to effectively bind the 
same amount of PRP; this 
happens as binding occurs 
regardless of proline terminal 
residue numbers. 
Tannin stacking 
and crosslinking 
at higher 
concentrations 
60 HPLC-DAD 
PAC as 
monomers, 
dimers, 
trimers 
No 
1-8 ml saliva 
mixed with 40 ml 
GSE or 20 or 40 
ml sipped 
Increased tannin concentration 
increases precipitation. 
Tannin stacking 
and crosslinking 
at higher 
concentrations 
61 ITC 
GSE as 
catechin, 
epicatechin, 
epicatechin 3-
O gallate 
No 
5-25 µg PAC and 
40 µl saliva with 
10% ethanol 
Increased tannin concentration 
increases precipitation. 
Tannin stacking 
and crosslinking 
at higher 
concentrations 
50 NMR, DLS 
EgCG, EGC, 
PGG 
Yes 
20 mM 
polyphenol with 
2 mM mouse 
PRP; pH 3.8 
The number of PRP binding 
sites does not correlate with 
the corresponding decrease in 
tannin concentration after 
Tannin-PRP binding at higher 
concentrations 
Tannin stacking 
and crosslinking 
at higher 
concentrations 
62 NMR Tannic acid No 
1:0-1:5.6 ratio of 
PRP to tannic 
acid 
More Tannin-PRP complexes 
that are bound, the less that 
the complexes dissociate 
Stability of 
tannin-PRP 
binding 
NMR: Nuclear magnetic resonance imaging; ESI-MS: electrospray ionization mass spectrometry; DLS: dynamic light scattering; 
SAXS: small angle X-ray scattering; ITC: isothermal titration calorimetry; SDS-PAGE: sodium dodecyl polyacrylamide gel electrophoresis; 
HPLC: high performance liquid chromatography. B1, B2, B3: proanthocyanidin B1, B2, B3; PGG: pentagalloylglucose; TGG: 
tetragalloylglucose; PAC- proanthocyanidin; EgCG: epigallocatechin gallate; ECG: epigallocatechin; PRP: proline-rich protein 
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Table 4-3: Effects of pH on tannin-PRP solubility 
Reference Method Tannin type pH Effect 
64 
Diffusion precipitation 
interaction assay 
Hydrolyzable and 
condensed wine extracts, 
catechin, tartaric acid, gallic 
acid 
3.5 vs. 7.0 ↓pH ↑precipitation  
65 Competitive binding assay Quebracho and tannic acid 2.0 vs. 7.4 ↓pH ↑precipitation 
55 
In vitro digestion precipitation 
interaction assay, HPLC, SDS-
PAGE 
EgCG 
2.07, 7.8, 
5.0-9.0 
↓pH +  ↑ tannin = 
enzyme inhibition, 
blunted by PRP 
62 NMR 
Galloyl rings from tannic 
acid 
3.5 vs. 1.7 ↓pH ↑precipitation 
66 SDS PAGE Wine or tannic acid 2.9, 3.0, 3.6 
↓pH ↓solubility of 
tannin-PRP 
NMR: Nuclear magnetic resonance imaging; SDS-PAGE: sodium dodecyl polyacrylamide gel electrophoresis; HPLC: high performance liquid 
chromatography. EgCG: epigallocatechin gallate; PRP: proline-rich protein 
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Table 4-4: Effect of tannin polymerization, galloylation, and hydroxylation on PRP affinity 
and precipitation 
Reference Method Tannin type 
Polymerization 
(1) 
Galloylation 
(2) 
Hydroxylation   
 of the B ring (3) 
53 ESI-MS 
EgCG, ECG, 
B2, B2 3-O 
gallate 
↑↑↑ ↑↑ ↑ 
51 NMR 
B2, PGG, 
TGG, PA 
monomer 
↑↑↑ ↑↑ nd 
72 nephelometry 
B1-9, C1, B2 
3-O gallate, E 
↑↑↑ ↑↑ nd 
52 NMR 
PAC as B1, 
B3, C2 
↑↑↑ ↑↑ ↑ 
70 ESI-MS 
B1, B2, B3, 
B4, C2, C, E, 
quercetin 
derivatives 
↑↑↑ nd ↑↑ 
59 ESI-MS 
EgCG, ECG, 
B2, B2 3-O 
gallate, 
reserpine 
↑↑↑ nd nd 
61 ITC 
GSE as 
catechin, 
epicatechin, 
epicatechin 3-
O gallate 
↑↑↑ nd nd 
69 
Competitive 
binding assay 
5GG, gallic 
acid, EGC 
nd ↑↑↑ nd 
NMR: Nuclear magnetic resonance imaging; ESI-MS: electrospray ionization mass spectrometry; ITC: isothermal titration calorimetry; B1, B2, 
B3, B4, C1: proanthocyanidin B1, B2, B3, B4, C1; PGG: pentagalloylglucose; TGG: tetragalloylglucose; PAC- proanthocyanidin; EgCG: 
epigallocatechin gallate; ECG: epigallocatechin; PRP: proline-rich protein 
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Table 4-5: PRP binding to hydrolyzable vs. condensed tannins 
Reference Method Tannin type Bond stability Binding affinity 
69 
Competitive 
binding assay 
5GG, gallic acid, 
EGC 
nd 
Hydrolyzable tannin > 
condensed tannin 
65 
Competitive 
binding assay 
Quebracho and 
tannic acid 
Hydrolyzable: 20% 
greater dissolution of 
bonds in gastric and 
enteric digestion 
Hydrolyzable tannin > 
condensed tannin 
51 NMR 
B2, PGG, TGG, 
PAC monomer 
Hydrogen bonds 
associated with 
hydrolyzable tannins 
B2>PGG>TGG> 
50 NMR, DLS EgCG, EGC, PGG 
Hydrogen bonds 
associated with 
hydrolyzable tannins 
Hydrolyzable tannin > 
condensed tannin 
66 SDS PAGE Wine or tannic acid 
Condensed tannins 
associated with 
hydrophobic bonds 
nd 
64 HPLC 
Hydrolyzable vs. 
condensed wine 
extracts 
nd 
Increased precipitation 
of condensed tannin at 
pH 7.5 c/t hydrolyzable 
tannin 
NMR: Nuclear magnetic resonance imaging; DLS: dynamic light scattering; SDS-PAGE: sodium dodecyl polyacrylamide gel electrophoresis; 
HPLC: high performance liquid chromatography. B2: proanthocyanidin B2; PGG: pentagalloylglucose; TGG: tetragalloylglucose; PAC- 
proanthocyanidin; EgCG: epigallocatechin gallate; ECG: epigallocatechin; PRP: proline-rich protein. nd= not done 
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Table 4-6: In vivo studies comparing PRP expression and non-heme iron availability with 
tannin ingestion 
Study Model 
Interventi
on 
Study 
conditions 
Tannin 
concentration in 
challenge diet 
(g/kg) 
Fe(diet) n 
Study 
duration 
Measurement 
of 
bioavailability 
PRP 
measurement 
39  
 
 
 
Sprague 
Dawley rats 
Green tea  
Control 
(acute and 
chronic) 
28.6 g/kg green 
tea (nd) 
 
 
 
20 mg/kg 
6 
7, 30 
days 
% absorption 
(59Fe test 
meals), 
Hepatic non-
heme iron 
 
SDS-PAGE, 
MALDI-
MS/MS,DIGE 
 
 
 
Acute gastric 
gavage 
6 7 days 
Chronic 
gastric 
gavage 
6 30 days 
Acute tea 
powder 
6 
7 days 
 
Chronic tea 
powder 
6 30 days 
40 
 
 
 
 
Sprague 
Dawley rats 
Black tea 
Control 0.3 ± 0.0 35.9 ± 1.3 6 24 days 
% absorption 
(59Fe test 
meals), 
Hepatic non-
heme iron 
SDS-PAGE 
 
5% tea solids 
challenge 
tannin free 
diet 
8.9 ± 0.5 35.9 ± 1.3 6 24 days 
5% tea solids 
+ 6% gelatin 
challenge 
tannin free 
diet 
9.9 ± 0.7 35.9 ± 1.3 6 24 days 
5% tea solids 
chronic diet 
8.9 ± 0.5a 34.3 ± 1.5 6 24 days 
5% tea solids 
+ 6% gelatin 
chronic 
9.9 ± 0.7a 34.6 ± 1.0 6 24 days 
a. Supplied as 25 g/kg in diet.  
SDS-PAGE: sodium dodecyl polyacrylamide gel electrophoresis; MALDI-MS/MS: Matrix-assisted laser desorption/ionization/mass 
spectrometry; DIGE:difference gel electrophoresis 
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Table 4-7: Effect size of acute and chronic hepatic iron levels 
Study Treatment  Effect size (d) Lower CI (95%) Upper CI (95%) 
39
 Acute gavage 0.17 -0.96 1.31 
Chronic Gavage -0.20 -1.33 0.94 
Acute Powder -0.22 -1.36 0.91 
Chronic Powder -0.40 -1.55 0.74 
40 5% tea challenge -0.34 -1.48 0.80 
5% tea chronic 2.87a 1.26 4.48 
5% tea + gelatin 
challenge 
0.50 -0.64 1.65 
5% tea + gelatin 
chronic 
2.39a 0.91 3.87 
Total (CI % hepatic iron)  0.57 -0.64  1.84 
Total ( CI % chronic hepatic iron) 1.16 -0.18 2.51 
Total ( CI % acute hepatic iron) 0.03 -1.11 1.17 
a 
p < 0.05 (95% CI) 
 
Table 4-8: Effect size of acute and chronic % non-heme iron absorption 
Study Treatment  Effect size (d) Lower CI (95%) Upper CI (95%) 
39 Acute gavage 0.79 -0.38 1.97 
Chronic Gavage 0.14 -0.99 1.27 
Acute Oral 1.37a 0.11 2.62 
Chronic Oral -0.66 -1.81 0.51 
40 5% tea challenge -3.99a -5.94 -2.03 
5% tea chronic -1.62a -2.92 -0.31 
5% tea + gelatin 
challenge 
-4.11a -6.1 -2.11 
5% tea + gelatin 
chronic 
-2.29a -3.74 -0.83 
Total (CI % absorption)  -1.30 -2.73 0.13 
Total (CI % absorption chronic consumers) -1.11 -2.37 0.16 
Total (CI % absorption acute consumers) -1.61 -3.08 0.11 
a p < 0.05 (95% CI) 
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Table 4-9: PRP production in groups relative to control 
Study Treatment  PRP production/control 
39 Acute gavage 0.73 
Chronic Gavage 2.4 
Acute Oral 9.9 
Chronic Oral 4.1 
40 
 
5% tea chronic 1.22 
5% tea + gelatin 
challenge 
1.10 
PRP: salivary proline-rich protein 
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 Figures 
 
Figure 4-1: Condensed tannin Yikrazuul/ Wikimedia Commons / Public Domain and B: 
Tannic Acid Ronhjones/ Wikimedia Commons / Public Domain 
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Figure 4-2: Data analysis process for narrative review of tannin-non-heme iron and tannin-
PRP interactions adapted from the Center for reviews and dissemination 43. 
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Figure 4-3: Inclusion and exclusion criteria for review. Articles were excluded related to 
key terms, non-comparative studies, and biological modeling dissimilarities to saliva. PRP: 
proline-rich proteins. 
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Figure 4-4: Open and flexible conformations of a basic PRP molecule with proline residues 
49, with permission 
 
 
 
Figure 4-5: condensed tannin (white and brown) interaction with PRP peptide (green 
ribbon) during molecular dynamics run 52, with permission  
 
Tannins associate with PRP molecules and attach to proline-rich residues through hydrophobic 
bonds. On binding to PRPs, the multidendate nature of tannins allows for hydrophobic bond 
formation and conformational changes in the PRP molecule to stabilize the complex. 
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Figure 4-6: Relative PRP induction compared to non-heme iron absorption effect size.  
 
 
PRP expression follows iron absorption with the exception of oral bypass of tannins in gastric 
gavage groups. 
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 Abstract 
Background: Repeated consumption of phytic acid leads to iron absorption adaptation, 
but the influence of repeated condensed tannin consumption has not been well established. 
Salivary proline-rich proteins (PRPs) have been shown to protect iron absorption by precipitating 
tannins and reducing tannin-iron binding with repeated consumption in animal models. 
Upregulation of PRP synthesis may partially mediate the effects of tannin consumption on iron 
bioavailability.  
Objective: The primary objectives of the current tannin dose-response trial were to 
determine the effect of long term dose-response condensed-tannin supplementation on iron 
bioavailability, and status, and to understand the effect of salivary proteins on iron bioavailability 
during prolonged condensed tannin consumption. A secondary objective was to assess 
astringency as a potential marker for adaptation to tannins and iron bioavailability. 
Methods: Premenopausal women aged 18-35 yrs were enrolled in a double-blind three 
dose crossover trial (n = 11). During the 22-week study, one of three (1.5, 0.25, or 0.03 g) 
condensed proanthocyanidin tannin supplement doses was taken three times daily for four weeks 
in random order, with a two-week washout in-between. Dietary recalls were recorded for each 
supplementation period to assess dietary covariates for outcomes assessments. Before and after 
supplementation periods, meal challenges were employed to assess iron bioavailability, iron 
status, salivary PRP changes, and astringency perception.  
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Results: Tannin supplementation did not change iron bioavailability at any dose 
(incremental serum iron AUC: β = 0.022, p = 0.83; and % max iron absorption: β = -0.023, p = 
0.82) from Week 0 to 4 in any dose. Iron status (hemoglobin: β = 0.14, p = 0.126 and serum 
ferritin: β = -0.11, p = 0.83) was unchanged by tannin dose from Week 0 to Week 4. There were 
significant positive correlations between iron bioavailability (by % max iron absorption), basic 
PRP (r = 0.366, p = 0.003), and cystatin production (r = 0.27, p = 0.03) with tannin 
supplementation. Astringency ratings did not change significantly within or between tannin 
doses (ps > 0.126), but there were significant reductions in astringency ratings with 1.5 g tannin 
supplementation at the lowest astringency testing concentration (p < 0.047), and there were 
negative relationships between bPRP (rs < -0.32, ps < 0.21), cystatin (rs < -0.2, ps < 0.28) 
salivary protein production and astringency ratings. 
Conclusions: Condensed-tannin consumption did not affect iron bioavailability or status 
regardless of supplementation period in premenopausal women. Correlation analyses suggest 
that basic PRPs, and cystatins are associated with improved iron bioavailability, and that lower 
ratings of astringency may predict improved iron absorption with repeated tannin consumption. 
Keywords: tannins, iron bioavailability, salivary proline-rich proteins, adaptation, 
antinutritional factors, proanthocyanidins, iron deficiency anemia 
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 Background 
An estimated one billion people have iron deficiency anemia (IDA) worldwide 1. Most 
commonly, iron deficiency is found in women, children, vegetarians, and in people who have 
insufficient iron intake 1. Despite multiple initiatives aimed at reducing IDA in the past 20 years, 
an estimated 29% of non-pregnant women were anemic in 2011, constituting a 4% reduction 
since 1995 2. 
Tannins have been found to negatively impact iron bioavailability 3-8 by formation of 
insoluble antinutritional-mineral complexes 9, and this has deterred tannin-rich foods, such as 
sorghum, from being used for food-aid in regions that are largely undernourished10. Previous 
research suggests that long-term tannin consumption may not inhibit iron bioavailability as much 
as acute studies would estimate 11,12. For example, long term antinutritional factor consumption 
in animals 13-15 and humans 11,16 has resulted in improved non-heme iron bioavailability 
compared to single-meal studies. In these studies, the negative effects (reduced iron status or 
bioavailability) of antinutritional factor intake over time has not been sustained, these findings 
have been proposed to be due to adaptation. In studies that have found reductions in iron 
bioavailability with tannin consumption, individual iron absorption has been highly variable 17,18, 
and many individuals consuming diets with large concentrations of tannins maintain normal iron 
stores 19.  
Many studies finding reduced iron bioavailability with tannin consumption have used 
hydrolyzable tannic acid, which is not commonly consumed, or tea tannins, which may be 
metabolized differently than condensed tannins, which are commonly found in food 20. To the 
best of our knowledge, no studies have determined the long-term effects of tannin consumption 
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apart from other antinutritional factors such as fiber or phytates on iron bioavailability or status.  
In addition, it has not been determined whether long-term condensed tannin results in adaptation, 
or what mechanisms underlie adaptation if it does occur.  
Mechanistically, adaptation to tannins may start in the mouth 21. Saliva contains six main 
classes of salivary proteins: histatins, cystatins, statherins, acidic proline-rich proteins (aPRP), 
basic proline-rich proteins (bPRP), and glycosylated proline-rich proteins (gPRP) 22 that may 
exert independent effects on tannins. Proline-rich proteins (PRPs) in particular have been noted 
in sensory studies for their ability to precipitate condensed tannins, which results in an astringent 
oral sensation 21,22. Tannin-PRP complexes are insoluble within the GI tract 23,24, preventing 
tannin-iron chelation throughout digestion. There are a wide variety of PRP subtypes that make 
up different salivary profiles, which may be largely genetically determined 25,26. Genetic 
determination of salivary profiles favoring effective tannin precipitation may explain why some 
individuals have greater capacity to consume tannins than others without negative impacts on 
iron status. Upregulation of PRP secretion when consuming tannins has been shown to improve 
protein 27 and iron bioavailability in animal studies 14,28, and animals that do not upregulate PRP 
synthesis in response to tannin consumption have poor growth outcomes 29.  
Previously, PRP-tannin binding has been identified in sensory studies for creation of 
astringent taste sensation during interaction 22. Theoretically, identification of PRP “adapters” 
may then be possible through simple, inexpensive astringency testing 22. Further, changes in 
astringency sensation may indicate an upregulation of PRP production over time with repeated 
tannin consumption 30.  
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The primary objectives of the current tannin dose-response trial were to determine the 
effect of long term dose-response condensed-tannin supplementation on iron bioavailability, and 
status, and to understand the effect of salivary proteins on iron bioavailability during prolonged 
condensed tannin consumption. A secondary objective was to assess astringency as a potential 
marker for adaptation to tannins and iron bioavailability. 
In this study, we hypothesized that 1) Condensed-tannin supplementation would not change iron 
bioavailability (determined by iron absorption) or status (determined by hemoglobin and ferritin) 
regardless of dose over four weeks, 2) Salivary proline-rich protein production would not be 
induced by tannin consumption over time and by higher versus lower tannin doses, and 3) 
Proline-rich protein production would be positively associated with improved iron bioavailability 
after tannin consumption. Secondary hypotheses were that 1) Astringency perception would be 
changed with tannin consumption over time, 2) Salivary proline-rich protein production would 
predict astringency with tannin consumption, and 3) Astringency could be used as a surrogate 
marker for iron bioavailability with tannin consumption. 
 Methods 
 Inclusion/exclusion  
The study protocol was approved by the Institutional Review Board at Kansas State 
University (KSU; IRB #8121). Due to the length of the study, enrollment was rolling, and is 
outlined (Figure 5-1). An announcement requesting participants was sent to faculty and students 
through a University email digest, as well as disseminated though departmental social media 
channels. Total, 48 women responded, and potential participants were screened in person or via 
phone (Figure 5-1). Before screening, participants were required to read and sign an informed 
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consent document, and all procedures, risks and benefits of the study were reviewed verbally. 
During screening, participants were asked to complete a medical history questionnaire. 
Premenopausal women, aged 18-35, who were non-obese (body mass index, BMI ≤ 30.0 kg/m2), 
had no history of oral or gastrointestinal disease, were moderate (≤ 1 drink per day) or non-
alcohol consumers, and non-tobacco users we eligible for participation. Further exclusion criteria 
included blood disorders affecting iron status or absorption, current supplementation or 
medication that would impair iron status, food allergies to supplements, pregnancy or 
breastfeeding (see Appendix D for screening questionnaire and exclusion criteria). Participants 
were compensated for completing study activities. 
 Study Design  
 Blinding and randomization 
Participants were assigned participant ID numbers, and a researcher not involved in data 
collection randomized each participant number to a tannin supplement order (SAS, Carey, NC). 
Participants, the principle investigator, and the project coordinator were blinded to dose order.  
 Supplementation periods 
Supplementation periods consisted of Week 0 and Week 4 meal challenges, with four 
weeks of tannin supplementation in between (Figure 5-2). Each participant consumed a 
condensed-tannin (Nusci grape seed extract, 95% condensed proanthocyanidins) supplement, 
provided in an opaque bottle with a non-caloric flavor enhancer and sweetener (Mio Original) to 
improve its palatability, three times daily for four weeks. High (1.5 g), medium (0.25 g), or low 
(0.03 g) condensed-tannin doses were provided for consumption with three daily meals. These 
doses represented 100g of high tannin red sorghum, 1 cups of tea, or a meal with one serving of 
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fruit or vegetable, respectively, three times daily. Each Week 4 meal challenge was followed 
with a two-week washout period to allow normalization of iron absorption and ferritin values to 
the participant’s usual diet 31.  Two participants had a single washout period of three, instead of 
two weeks due to availability for meal challenges. 
 Tannin meal challenges  
At Week 0 and Week 4 of each supplementation period, participants completed meal 
challenges at the KSU Physical Activity and Nutrition Clinical Research Consortium (PAN-
CRC). Participants were asked to come in fasted (at least 8 hours) at 7:00 am, having abstained 
from teeth cleaning (2 hours) and exercise (24 hours) to minimize diurnal variations or other 
confounding factors in salivary production 32 and iron uptake 33 (Figure 5-2b). Pre-meal saliva 
was collected by passive drool (2 ml total) in cryovials, and samples were immediately stored in 
a freezer set at -71⁰ C. A 20-gauge indwelling peripheral IV (PIV) catheter was placed either in 
the median cubital, cephalic, or basilic vein for multiple blood samples, which was flushed and 
saline locked with 10 ml of 0.9% isotonic saline between blood collections. From the fasting 
blood draw, two separate samples were collected in 5 mL serum separator (SST) and 3 mL 
ethylenediaminetetraacetic acid (EDTA) vacutainer tubes to measure serum iron (by 
spectrophotometry), CRP (by nephelometry), ferritin (by immunoassay), and whole blood 
hemoglobin concentrations (by electronic cell cytometry).  After fasted blood collection, a 
challenge meal of a 95 g bagel with 12 g sugar-free strawberry jam, sprinkled with 15 mg ferrous 
sulfate and 75 mg ascorbic acid 11,34 supplements separately, and a 90 g banana, was consumed 
with the participant’s assigned dose (1.5 g, 0.25 g, or 0.03 g). Salivary samples were collected 15 
minutes following the final bite of the meal to determine salivary protein stimulation after tannin 
177 
 
 
 
 
consumption 35. Subsequent blood samples were collected in SST tubes and analyzed for serum 
iron at 180 and 240 minutes. After collection, serum samples were centrifuged at 2500 RPM for 
15 minutes after clotting for 20 minutes, and kept at room temperature for analysis. All blood 
samples were analyzed by a certified laboratory (Quest Diagnostics, Lenexa, KS) within 24 
hours.  
 Regression analysis of three-point time draw for % maximum iron absorption 
To minimize blood loss, validity of a three-time blood draws to determine iron 
bioavailability by serum iron was determined. In the first supplementation period of the study, 
four participants had blood drawn every thirty minutes for four hours to establish correlation 
with a three-time point draw (0, 180, and 210 minutes) system previously proposed 34. 
Regression of polynomial lines from data points were calculated on a computer data system 
(Microsoft Excel, 2013), and R2 values were calculated for goodness-of-fit. From these data, it 
was verified that time points proposed were representative of the full models previously used 
11,34. Correlations of 0.99+ were seen, thus blood samples were also drawn for serum iron at 
these three time points to determine % max iron absorption and incremental serum iron area 
under the curve (iAUC) 34.  
  
178 
 
 
 
 
 Incremental AUC and maximum percentage of iron absorption calculation 
Serum iron data were used to calculate percentage of maximum iron recovery and iAUC for 
iron bioavailability analysis.  
Percentage Iron Recovery: Percentage iron recovery was calculated as below 34. 
 
% 𝑖𝑟𝑜𝑛 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 max = (
𝑠𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛 max×𝑝𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒)
𝑡𝑜𝑡𝑎𝑙 𝑖𝑟𝑜𝑛 𝑖𝑛𝑔𝑒𝑠𝑡𝑒𝑑
×100 
Where:                    𝑖𝑟𝑜𝑛 max =
𝜇𝑚𝑜𝑙
𝐿
, 𝑝𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒 =
𝐿, 𝑎𝑛𝑑 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑟𝑜𝑛 𝑖𝑠 𝑖𝑛 𝜇𝑚𝑜𝑙  
𝑝𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒 (𝐿) =
𝐵𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙)×(1 − 𝑃𝑎𝑐𝑘𝑒𝑑 𝑐𝑒𝑙𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑑𝑒𝑐𝑖𝑚𝑎𝑙))
1000
 
And     𝑏𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 = 69.6
𝑚𝑙
𝑘𝑔
𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡   
 
iAUC by trapezoidal integration 
∫ 𝐴𝑈𝐶 = 
∆ 𝑡𝑖𝑚𝑒
2
×[∆𝑆𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛 𝑡𝑖𝑚𝑒 0−180 +  (2×∆𝑆𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛𝑡𝑖𝑚𝑒 0−210 )] 
 Astringency testing  
After the PIV was removed following each meal challenge, participants were asked to 
complete an astringency test 36,37. Each participant was given four different concentrations of 
alum powder in 10 ml distilled water (0.20, 0.15, 0.07, and 0.03%) in random order to sip. They 
were first given a verbal description of the sensation of astringency and were asked to rate each 
solution based on their perception of astringency on a 5 point Likert scale (1 = not astringent, 5 = 
extremely astringent). Participants waited for 30 seconds before testing the next sample. 
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 Dietary analysis in supplementation periods 
Within each supplementation period, 24-hour dietary recalls were collected on three 
different days (two weekdays and one weekend day) 38. At the beginning of week two of each 
four-week supplementation period, participants were emailed a unique username and password 
to complete 24-hour dietary recalls for 2 weekdays and 1 weekend day on the Automated self-
administered 24-hour recall (ASA24®). After all recalls were collected in each supplementation 
period, dietary data were extracted, and total caloric intake (kcal), protein (g), fat (g), 
carbohydrate (g), iron (mg), ascorbic acid (mg), meat protein (oz.), sugar (g), fiber (g), Zn (mg), 
and Cu (mg) content were averaged from system calculated amounts for each participant. Food 
intake logs were downloaded from the ASA24® for manual calculation of proanthocyanidins 
and polyphenols. During this process, a research assistant reviewed all dietary data for each 
participant using an electronic spreadsheet (Microsoft Excel). Food items were referenced from 
United States Department of Agriculture (USDA) tables pulled into an electronic spreadsheet, 
and total proanthocyanidin (condensed tannin) 39 and polyphenol 40 amounts were calculated and 
summated for each recall. From these summations, averages were calculated. All assessments 
and calculations were reviewed by the project coordinator before analyses were completed. 
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 Salivary PRP measurement:  
 Acidified saliva sample preparation 
Frozen salivary samples were thawed overnight in a refrigerator. Before sample analysis, 
consistency in chromatogram output with duplicate samples was verified, and samples were 
analyzed in a single run. For PRP extraction, 900 µl of saliva was mixed with 10 µl of 10% 
trifluoroacetic acid (TFA) in water, centrifuged for 5 min at 8000 RPM, and the supernatant was 
filtered through a 0.2 µm PVDF syringe filter as described previously 41. Before samples were 
analyzed, it was verified that there was no PRP peak loss with use of syringe filters by testing in 
trial HPLC runs. The supernatant was then analyzed by high performance liquid chromatography 
(HPLC). 
 HPLC parameters and equipment 
All reagents were analytical grade. Acetonitrile, TFA, and HPLC grade water were 
purchased from Fisher Scientific. Ninety µl of salivary supernatant was injected into a Fisher 
2.1x150 mm, 5µm BioBasic C8 analytical column at a flow rate of 0.3 ml/min for 49 minutes at 
40◦C with an autosampler (Shimadzu SIL) on a HPLC system containing a LC20AB pump 
(Shimadzu), and a Shimadzu SPD-M20A PDA system. Detection of PRPs was carried out at 214 
nm 41,42. Mobile phase consisted of 0.2% TFA in HPLC grade water (A) and 0.2% TFA in 80/20 
acetonitrile and HPLC grade water (B) 32,41-43. A linear gradient was applied from 0-39 minutes 
from 0-54% (B), then from 39-49 minutes at 54-100% B to elute late proteins 32,41-43. After each 
run, the column was washed and stabilized with initial conditions by increasing linear gradient 
back to 100% A over 10 minutes.  
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 Statistical analyses 
Data were analyzed using SAS statistical software (SAS Studio version 3.6, Cary, North 
Carolina), statistical significance was set at p < 0.05. All data are presented as mean ± standard 
deviation (SD). Before analysis, all data were analyzed for normality and homogeneity of data in 
Q-Q plots and with Levene’s tests. Variables that were non-normal (proanthocyanidin 
monomers, dimers, total proanthocyanidin, ascorbic acid, sugar, and iron intake) were log 
transformed, and determined to be normal before further analysis. Log-transformed variables 
were included in stepwise variable selection in adjusted model building (below). All log-
transformed data were back-transformed for results presentation.  
 Sample size  
A sample size calculation determined that four participants would be needed to detect a change 
in iAUC of 25% 11,34 (SAS studio version 3.6, Cary, NC) as statistically significant with 80% 
power and at an α-level of 0.05. 
 Demographic data, washout, and randomization order analysis 
Week 0 demographic and nutritional intake data were analyzed by analysis of variance 
(ANOVA) by supplementation period. Randomization order and previous dose effect were 
analyzed by Chi-square testing to assess for bias in supplementation period order, or previous 
effect of supplementation period. Changes between previous and next supplementation period 
during washout were analyzed for hemoglobin, ferritin, iAUC for serum iron, and % max iron 
absorption in ANOVA analysis.  
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 Hematological outcomes analysis 
 Regression analysis of hematological outcomes 
Linear regression of raw outcomes data was used to determine whether four weeks of 
multiple daily tannin supplementation would change iron absorption or status within nor between 
supplementation periods. In regression analysis, differences between supplementation periods 
were analyzed for % max iron absorption, ferritin, and hemoglobin at Weeks 0 and 4 (to analyze 
for within dose responses). Multiple regression was used to adjust models for repeated 
(participant) and random (ferritin, CRP, dietary intake, weight, and age) covariates after stepwise 
selection for variables. To maximize analysis of individual iron bioavailability and status within 
different supplementation periods, individual movements (increase, decrease, or maintain) in 
dose-responses (hemoglobin, ferritin, % max iron absorption, and serum iron iAUC) were 
analyzed with Chi-square testing and Fisher’s exact tests.  
 PRP and astringency outcomes analysis  
 PRP changes with tannin supplementation and correlations with iron bioavailability 
To determine whether salivary PRP production would be inducible by tannin 
consumption both over time and in a dose-dependent manner, salivary proteins were divided into 
type by retention times 32,41-43, peak mAu were recorded for each, and protein subtypes were 
aggregated to quantify total salivary proteins and PRPs. Salivary protein subtypes were further 
analyzed by proportion to total mAu from the equation:  
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𝑃𝑅𝑃 𝑠𝑢𝑏𝑡𝑦𝑝𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 = 𝑃𝑅𝑃 𝑡𝑦𝑝𝑒 (𝑎𝑟𝑒𝑎 𝑠𝑢𝑚) ÷ 𝑇𝑜𝑡𝑎𝑙 𝑃𝑅𝑃 𝑎𝑟𝑒𝑎 
 
Or 
𝑃𝑅𝑃: 𝐴𝑐𝑖𝑑𝑖𝑐 𝑠𝑎𝑙𝑖𝑣𝑎𝑟𝑦 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑠 = 𝑇𝑜𝑡𝑎𝑙 𝑃𝑅𝑃 𝑎𝑟𝑒𝑎 ÷ 𝑇𝑜𝑡𝑎𝑙 𝑠𝑎𝑙𝑖𝑣𝑎𝑟𝑦 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑟𝑒𝑎 
 
 
Differences in salivary protein production from Week 0 to 4 within doses were analyzed 
by MANOVA. To determine whether PRP production would impact iron bioavailability with 
tannin consumption, Pearson’s product-moment correlations were used to determine correlations 
between % max iron absorption, iAUC for serum iron, randomization order, and PRP types.  
 Astringency perception, connections to salivary protein production, and iron 
bioavailability 
We determined whether astringency perception was changed within or between tannin 
doses using Chi-square testing and Fisher’s exact tests by allocated, and previous dose. 
Connections between salivary protein production, iron bioavailability and astringency were 
analyzed by Pearson’s product-moment correlations.  
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 Results 
 Week 0 demographics 
Mean participant age was 26 ± 1.2 yrs, and ranged from 20-35. All participants were 
occasional (2-3 drinks/month) or moderate (2-3 drinks/week) alcohol consumers. Aside from one 
participant, who consumed a vegan diet, and took vitamin B12 supplements, no participants took 
vitamin or mineral supplements during the study period. The average BMI of participants was 24 
± 2.4 kg/m2 (range 18.2-28.9). Participant weights (kg) did not significantly change between 
tannin doses nor from Week 0 to Week 4 of each supplementation period.  
 
 Supplementation order and outcomes measures 
With our randomization procedure, six of the eleven participants were randomized to 1.5 
g tannin doses during the first supplementation period, and low doses during the second 
supplementation period. Incremental AUC for serum iron (p = 0.118), hemoglobin (p = 0.87), 
and ferritin (p = 0.15) were not different by order of tannin dose in any supplementation period. 
Supplementation order did significantly positively impact % max iron absorption following the 
1.5 g tannin dose when taken in the third versus the first supplementation order (p = 0.046), 
meaning that lower doses taken before the 1.5 g dose led to significantly improved iron 
bioavailability. There were no significant differences in Week 0 to Week 4 dose-responses for 
hemoglobin, ferritin, serum iron iAUC, or % max iron absorption when accounting for previous 
dose by Chi-square testing (results shown in Appendix E).   
There were no significant changes in hemoglobin (p = 0.993), ferritin (p = 0.982), iAUC 
for serum iron (p = 0.984), or % max iron absorption (p = 0.998) at each Week 0-time point, and 
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previous tannin dose did not affect outcomes changes during washout for hemoglobin (p = 0.68), 
ferritin (p = 0.511), % max iron absorption (p = 0.735), or iAUC for serum iron (p = 0.137). No 
salivary protein measurements were significantly correlated with tannin dose order (ps > 0.62).  
 Study dietary intake 
 There was wide variability in nutrient consumption during supplementation periods, but 
no significant differences in total calorie, macronutrient, meat, fiber, or micronutrient 
consumption between tannin doses (Table 5-1). Despite wide variability in nutrient 
consumption, individual macronutrient and micronutrient intake were not different between 
tannin doses. Iron intake was 7-18% less than the recommended dietary allowance (RDA) of 18 
mg in all supplementation periods, ascorbic acid exceeded the RDA by 15-80%. While not 
significant, proanthocyanidin intake trended towards lower amounts in the 0.03 g (69.1 ± 78.9 
mg) and 0.25 g (82.3 ± 85.1 mg) doses compared to the 1.5 g dose (123.2 ± 136.6 mg; ps > 
0.09). On average, 0.03 g, 0.25 g, and 1.5 g tannin supplements constituted 2, 8, and 35-fold the 
typical proanthocyanidin intake for their respective supplementation period.   
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 Supplementation period iron absorption, hematological indices of iron status 
 Unadjusted regression outcomes 
Individual level data are included in Appendix F. There were no changes in unadjusted 
iron bioavailability (by iAUC and % max iron absorption) within or between tannin 
supplementation periods (Table 5-2). In addition, there were no differences at Week 0 (p = 0.82) 
or Week 4 (p = 0.92) for unadjusted serum iron iAUC or % max iron absorption at Week 0 (p = 
0.82) or Week 4 (p = 0.62, Table 5-2) between tannin doses.  
Hemoglobin and ferritin values were not different at Week 0 or Week 4 for any tannin 
dose (Hb: p = 0.838, Week 0; 0.68, Week 4 and ferritin: p = 0.855, Week 0; 0.575, Week 4, 
Table 2). There were no significant differences in hemoglobin (p = 0.90), ferritin (p = 0.81), % 
max iron absorption (p = 0.39), or serum iron iAUC (p = 1.0) for improvement, deterioration, or 
maintenance by any tannin dose through Chi-square testing (Table 5-3). 
 Stepwise linear regression analysis and adjusted regression models 
To test the impact of dietary and individual physiological differences (iron status, 
anthropometric, salivary protein) on iron bioavailability and status, we employed stepwise 
regression analysis to establish significant covariates to build an adjusted model for 
hematological outcomes. Covariates that were significantly positively associated with serum iron 
iAUC and % max iron absorption included bPRP and cystatin production (Table 5-4). 
Significant covariates that were negatively associated with serum iron iAUC and % max iron 
absorption included aPRP and total salivary protein production, higher rating of 0.2 mg/dL 
astringency testing, and total meat consumption.  Significant covariates associated with ferritin 
levels included bPRP production, and zinc consumption.  
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Significant covariates for each outcome measure were added to the linear regression for 
adjusted outcomes analysis. Following the full adjustment for significant covariates, serum iron 
iAUC nor % max iron absorption were statistically different between or within each tannin dose 
(Table 5-4, Figures 5-3, 5-4). There were not significant differences in adjusted hemoglobin or 
ferritin values within or between tannin supplementation periods (Table 5-4).  
 Correlations between salivary protein production and iron absorption with tannin 
supplementation 
There were no significant correlations between total salivary protein production and iron 
absorption (by % max iron absorption and iAUC for serum iron) during the study. In all tannin-
doses, and when combining all data from 4-week supplementation periods, bPRP production was 
significantly and positively correlated with % max iron absorption at Week 0 and Week 4 (Table 
5-5). There were more positive correlations with Week 4 0.03 and 0.25 g dose-max iron 
absorption % and bPRP production than 1.5 g challenge (Table 5-5), suggesting that bPRP 
production was potentially important for lower, but not higher doses of tannins. Week 0 and 
Week 4 aPRP production was significantly negatively correlated with iron absorption in each 
supplementation period (Table 5-5). Total gPRP production was significantly negatively 
correlated with iron bioavailability at Week 4 in the 1.5 g supplementation period (Table 5-5). 
Statherin production was non-correlated with iron absorption, while cystatin was overall 
positively significantly correlated with iron absorption (Table 5-5).  
  
188 
 
 
 
 
 Astringency testing 
 Astringency ratings with tannin consumption 
Astringency ratings did not change among participants with changes in tannin doses, and were 
not statistically affected by order of tannin dose in Chi-square testing (ps > 0.09), except for the lowest 
astringency doses, which were rated significantly lower after 1.5 g tannin doses (p = 0.047; Table 5-
6). There were no significant effects from tannin dose on changes in ratings of astringency (ps > 
0.126), however, overall ratings of astringency were lower due to 1.5 g tannin dose compared to 0.03 g 
tannin dose for 0.07 and 0.15 mg/dL astringency doses (p = 0.0655 and 0.013, respectively).  
 Astringency ratings with PRP production 
Cystatin and bPRP production were correlated with lower sensation of astringency in all 
astringency doses. In correlations from individual participants with astringency ratings at the highest 
alum concentration (0.2 mg/dL) there were significant and positive correlations between total salivary 
proteins (7 of 11 participants, r > 0.49, p < 0.05) and astringency, and negative relationships between 
bPRPs (9 of11 participants, r = -0.32 to -0.81, p = 0.001 – 0.21), cystatins (9 of 11 participants, r = -
0.2 to-0.76, p = 0.03 – 0.28) and astringency.  
 Discussion 
The primary objectives of this trial were to determine the effect of long term dose-response 
condensed-tannin supplementation on iron bioavailability, and status, and to understand the 
effect of salivary proteins on iron bioavailability during prolonged condensed tannin 
consumption. Secondarily, the study assessed astringency as a potential marker for 
adaptation to tannins and iron bioavailability. 
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 Hematological outcomes and tannin supplementation periods 
Overall, our results support the hypotheses of no significant reductions in iron 
bioavailability or status with three supplementation periods of long-term, multiple-daily tannin 
supplements over four weeks. Despite non-significant negative trends in Week 0 iron absorption 
with 1.5 g (highest) compared to 0.25 and 0.03 mg (lowest) doses, hemoglobin and ferritin were 
maintained in all groups throughout supplementation periods (Table 5-2). There were no 
differences in ferritin or CRP measurements within individuals, or among tannin doses 
throughout the study (Table 5-2). To our knowledge, this is the first study that has quantified 
effects of long-term, dose-response condensed tannin effects on iron bioavailability and status.  
Our findings of no significant changes in iron bioavailability or status within or among 
tannin doses are contrary to previous single meal studies using black tea 6,44,45, which contain 
theaflavins and thearubigins 46 or tannic acid 3,4,45. Tannic acid and tea may bind to salivary 
proteins and chelate iron differently than condensed tannins (proanthycyanidins), which are 
typically larger in size and consumed within a complex food matrix 47,48. Condensed tannin 
models in humans and rats 49-52, also found no changes in iron bioavailability or status with 
tannin consumption over time are consistent. In contrast, dose-dependent inhibition of grape seed 
extract on iron bioavailability has been cited in Caco-2 cells 53. There have been similar 
discrepancies in in vivo and in vitro models cited previously. Iron status in pigs consuming red 
and white beans with different tannin levels resulted in no difference in iron status outcomes, 
while the Caco-2 cell model found higher iron bioavailability from white than red beans 54. 
Inconsistencies between long-term in vivo and in vitro studies noted may be partially a result of 
the complexity of factors contributing to human and animal digestion, including salivary 
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proteins, which may not be accounted for in simulated digestion. In addition, the acute nature of 
Caco-2 cells might have the same limitations as short-term bioavailability studies. The 
discrepancies between human, and Caco-2 findings may suggest that caution needs to be 
exercised when using the Caco-2 model to predict chronic consumption in vivo iron outcomes.   
The current study is the first that we know of that has quantified the effects of multiple 
daily, multi-dose condensed proanthocyanidins on iron bioavailability or status. While 
supplementation levels at 1.5 g were 50 x greater than 0.03 g and 10 x greater than 0.25 g tannin 
doses, iron absorption was only modestly reduced in the 1.5 g supplementation period 
(equivalent to consuming 100g of high tannin sorghum three times daily), and there were no 
significant reductions in iron status over time. There were no changes in iron absorption, ferritin, 
or hemoglobin over time in any adjusted or unadjusted models, suggesting that condensed tannin 
intake at any dose did not affect iron absorption. While other studies have noted reduction in iron 
bioavailability with condensed tannin intake 4,55, the current study is the first that we know of to 
isolate supplementation of proanthocyanidins outside of other antinutritional factors commonly 
consumed concurrently in vivo. 
 PRP production and iron bioavailability 
The current study is the first study, to the best of our knowledge, that has assessed 
correlations between salivary protein production and iron bioavailability, or measured long-term 
tannin supplementation effects on salivary profiles in humans. Overall, our hypotheses that 
salivary PRP production would be inducible in higher compared to lower tannin doses, and that 
PRP production would impact iron bioavailability with tannin consumption were partially 
supported. There were not significant changes in PRP or salivary protein production within or 
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among tannin doses, however, there were significant correlations between PRPs, non-PRP 
salivary proteins, and iron bioavailability suggesting that participants producing higher quantities 
of total salivary proteins, bPRPs, and cystatins had improved iron absorption with condensed 
tannin intake. Correlations between bPRPs, cystatins, and iron absorption tended to be stronger 
at Week 4 in lower doses, suggesting that salivary protein subtypes may change with regular 
tannin consumption to improve iron bioavailability, but are not likely the only physiological 
adaptation when consuming higher tannin doses. In caco-2 cells, bPRPs have been found to 
inhibit uptake of small tannin molecules through formation of insoluble complexes, but this 
process was mediated in part by sodium-glucose transporter-1 (SGLT-1) and multidrug 
resistance protein (MRP2) 56. It may be that bPRPs signal changes in these receptors that mediate 
tannin absorption and iron related sequelae.   
Binding of bPRP to polyphenols may be preferential versus other PRP subtypes 57, and 
production of larger bPRPs that would efficiently bind to tannins tends to be genetically 
determined 57-59. This idea may help to explain the wide variability in iron absorption among 
participants, and could help to explain age-related changes in iron absorption with tannin 
consumption. In pre-term infants, salivary protein profiles vary widely from adults 43, and bPRPs 
are almost non-existent.  
Contrary to findings that bPRP supported iron bioavailability with tannin consumption, 
gPRP and aPRP production, especially at Week 0 for each tannin dose, were significantly 
negatively correlated with iron bioavailability, possibly meaning that individuals producing 
higher levels of these proteins less efficiently absorb iron until other homeostatic protective 
mechanisms are employed. This is the first time, to the best of our knowledge, that aPRP and 
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gPRP interactions with tannins over time have been determined in vivo. Reasons for poorer iron 
bioavailability with increased aPRPs may be due to their predilection to bind calcium 60, which is 
also a divalent cation. It may be that these aPRP and gPRP are upregulated with tannin 
consumption, but do not bind to condensed tannins effectively, thereby increasing protein-iron 
chelation. Further, aPRP and gPRP may be effectively inhibited by carbohydrate consumption 61 
compared to bPRP, meaning that individuals producing higher quantities of these proteins may 
less effectively prevent tannin-iron chelation.  
 Astringency as a predictor of iron bioavailability with tannin consumption 
Our secondary hypotheses that: 1) Astringency perception would be changed with tannin 
consumption over time, 2) Salivary proline-rich protein production would predict astringency, 
and 3) Astringency could be used as a surrogate marker for iron bioavailability, based on PRP 
expression with consumption were also partially supported by our findings.  Astringency ratings 
did not change within or among tannin doses throughout the study, except for the highest (1.5g) 
tannin dose. Astringency ratings were lower with higher tannin concentrations, and were also 
significantly negatively correlated with bPRP and cystatin production, suggesting that reductions 
in ratings of very astringent or bitter foods may help predict iron bioavailability with tannin 
exposure. Despite this, we did not find consistent associations between iron bioavailability and 
astringency ratings within or between supplementation periods. 
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 Limitations  
There are several important limitations that must be considered when interpreting results 
from the current study.  It must be acknowledged that tannin-supplementation limits the 
generalizability of these findings to food tannins, which commonly co-exist with other 
antinutritional factors, such as phytic acid. This limitation constrains our findings to tannin-rich 
food commodities, which may confer different effects with antinutritional-food matrix 
interactions. In addition, the population assessed in this study consisted of non-anemic, pre-
menopausal adult women with a sufficient and varied diet. It may be problematic to generalize 
these findings to a clinical population, for example, anemic women and children, who may have 
a different response to tannin exposure. 
Participants noted that they experienced increased salivary flow rates during 1.5 g 
compared to 0.3 tannin doses, although flow rates were not measured quantitatively. It is also 
important to realize that while concentrations of PRPs themselves did not change through the 
study, subjective experiences of salivary flow rates among participants was greater at Week 4 in 
higher, 0.25 and 1.5 g, supplementation periods than at Week 0. Previous research findings have 
indicated that salivary flow along with PRP concentration have given more accurate estimates of 
total production than concentration alone 62. Salivary flow rate has been found to be an 
independent factor in reducing ratings of astringency along with salivary protein concentration 63 
suggesting that in our study, total PRP production may have been increased with increasing 
salivary flow rates. Lack of measurement of salivary flow rate is a limitation in PRP-iron 
outcomes analysis because we were not able to assimilate total PRP quantification from a pre-
determined 2 ml salivary sample (which was obtained over varying time spans). Lastly, we 
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grouped salivary types based on elution times. This has been previously employed 41, but is not 
an accurate representation of salivary protein quantification.  
 Future directions  
Foremost, better characterization of proanthocyanidin-phytic acid interactions on iron 
bioavailability and salivary protein production needs to be explored, including the effects of 
mixed antinutritional factor outcomes regarding iron bioavailability over time. Mixed diets have 
conferred different findings in the past 64 than those presented in the current research study, and 
understanding nutrient interactions may be key to understanding these discrepancies. In addition, 
effects of tannins in anemic populations, who may have disease burden or dietary deficiencies, 
need to be explored. 
Due to the complexity of PRP subtypes, determining which specific bPRP and cystatins 
improve iron bioavailability with tannin challenge may enable diet-specification in both children 
and adults 57. Determination of PRP genetic makeup in anemic and non-anemic tannin 
consumers may help to determine those with tannin-binding subtypes, and protein production 
could later be determined based on findings. More studies are needed to determine the effects of 
tannin supplementation on iron bioavailability in infants, and the effects of different tannin types 
(tannic acid, theaflavins and thearubigins) on salivary proteins. Further comparison of oral and 
enteric tannin exposure may help to determine non-salivary determinants of physiological tannin 
mediation.  
  
195 
 
 
 
 
 Conclusions  
Condensed tannins did not impair iron bioavailability, ferritin, or hemoglobin levels in 
non-anemic, premenopausal women after long-term supplementation. Iron absorption following 
tannin supplementation was positively correlated with bPRP and cystatin production, and tannin 
supplementation was associated with significantly reduced ratings of astringency over time. 
These findings suggest that individual physiology may need to be accounted for when 
considering nutritional impact on iron bioavailability and status. Given the lack of impact of 
tannins on iron status over time, these results suggest that further consideration may be justified 
to efforts to remove tannins from the diet, considering their potential health benefits.  
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 Tables 
Table 5-1: Dietary intake of calories, macronutrients, micronutrients, and 
proanthocyanidins by supplementation period  
Supplementation period 0.03 g 0.25 g 1.5 g 
 Mean ± SD Mean ± SD Mean ± SD 
N 11 11  11 
Kcal/day 2186.2 ± 570.9 2230.5 ± 640.6 1957.8 ± 348 
Protein (g/day) 80.8 ± 27.2 79.7 ± 21.6 71.6 ± 16.6 
Fat (g/day) 90.3 ± 30 93.5 ± 27.9 71.1 ± 19.5 
Carbohydrates (g/day) 259.3 ± 96.2 268.4 ± 109.9 252.1 ± 126.2 
Meat (oz/day) 3.61 ± 2.5 3.81 ± 2.6 3.6 ± 1.9 
Sugar (g/day) 122.8 ± 57.9 127.7 ± 69.3 120.0 ± 99.8 
Fiber (g/day) 21.2 ± 12 19.2 ± 10 21.6 ± 14.3 
Iron (mg/day) 15.1 ± 6.6 15.7 ± 7.2 14.7 ± 6.2 
Ascorbic acid (mg/day) 109.7 ± 87.9 80.9 ± 66.9 110.4 ± 142.8 
Zinc (mg/day) 12.6 ± 5 12.8 ± 5.6 10.2 ± 2.5 
Copper (mg/day) 1.5 ± 0.69 1.5 ± 0.91 1.4 ± 0.61 
Monomers (mg/day) 8.0 ± 7.5 18.2 ± 23.4 16.1 ± 21.8 
Dimers (mg/day) 8.6 ± 6.6 13.5 ± 15.7 14.8 ± 17.3 
Trimers (mg/day) 5.3 ± 4.5 6.7 ± 8.0 8.9 ± 12.5 
4-6 mers (mg/day) 15 ± 16.3 16.6 ± 19.4 27.5 ± 36.3 
7-10 mers (mg/day) 9.6 ± 12.7 9.0 ± 9.8 15.7 ± 18.7 
Polymers (mg/day) 22.7 ± 39.5 18.4 ± 25.7 40.3 ± 51.3 
Total proanthocyanidin 
intake (mg/day) 
69.1 ± 78.9 82.3 ± 85.1 123.2 ± 136.6 
Total polyphenol intake 
(mg/day) 
1106.6 ± 531.1 1139.6 ± 647.3 1108.9 ± 590 
No significant differences (p > 0.05) 
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Table 5-2: Unadjusted iron bioavailability, status, and inflammatory markers at Week 0 
and Week 4 of each supplementation period 
 0.03 g  
Week 0 
0.03 g 
Week 4 
0.25 g 
Week 0 
0.25 g  
Week 4 
1.5 g  
Week 0 
1.5 g  
Week 4 
 
Mean  
95% CI 
Mean  
95% CI 
Mean  
95% CI 
Mean  
95% CI 
Mean  
95% CI 
Mean  
95% CI 
% Max 
iron 
absorption 
12.7 
(7.5, 17.9) 
10.7 
(5.4, 15.9) 
12.1 
(6.9, 17.3) 
12.4 
(7.2, 17.6) 
11.2 
(6.0, 16.5) 
10.3 
(5.0, 15.5) 
iAUC for 
serum iron 
(µg/dL*hr) 
2155 
(612, 3696) 
2269 
(727, 3810) 
2461 
(919, 4003) 
2769 
(1228, 4311) 
2237 
(696, 3779) 
2277 
(735, 3819) 
Hemoglobi
n (g/dL) 
13.2 
(13.0, 13.4) 
13.3 
(13.1, 13.5) 
13.3 
(13.1, 13.5) 
13.4 
(13.2, 13.6) 
13.4 
(13.1, 13.5) 
13.3 
(13.2, 13.6) 
Ferritin 
(ng/ml) 
35.4 
(28.4, 42.4) 
42.3 
(35.3, 49.3) 
35.8 
(28.8, 42.8) 
37.3 
(30.3, 44.3) 
40.0 
(33.0, 47.0) 
44.5 
(37.5, 51.5) 
CRP 
(mg/dL) 
0.2 
(0.0, 0.5) 
0.3 
(0.0, 0.5)  
0.3 
(0.1, 0.5) 
0.2 
(0.0, 0.4) 
0.2 
(0, 0.4) 
0.3 
(0.1, 0.6) 
No significant differences (p > 0.05). 
iAUC: incremental area under the curve; CRP: C-reactive protein.  
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Table 5-3: Comparison of improvement, maintenance, or deterioration of iron 
bioavailability and status within each supplementation period 
 
Supplementation 
period 
Improvement Maintenance Deterioration 
Fisher’s exact 
(p) 
% max iron 
absorption 
0.03 g 5 0 6 
0.394 
0.25 g 8 0 3 
1.5 g 5 0 6 
Total 18 0 15 
iAUC serum iron 
µg/dL*hr 
0.03 g 6 0 5 
1.0 
0.25 g 6 0 5 
1.5 g 6 0 5 
Total 18 0 15 
Hemoglobin 
(g/dL) 
0.03 g 6 2 3 
0.896 
0.25 g 5 2 4 
1.5 g 4 4 3 
Total 15 8 10 
Ferritin (ng/dL) 
0.03 g 7 1 3 
0.816 
0.25 g 5 1 5 
1.5 g 6 0 5 
Total 18 2 13 
Significance: p < 0.05 
iAUC: incremental area under the curve; CRP: C-reactive protein.  
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Table 5-4: Estimation of iron bioavailability and status due to supplementation period, 
time, and significant covariates 
% max iron 
absorption 
 B SE B β t p 
Model  6.92 <0.0001 
Constant 48.9 22.7 0 2.16 0.004 
Supplementation 
period  
-0.36 1.5 -0.023 0.81 0.82 
Week 0 1.3 1.9 0.07 0.70 0.49 
Hemoglobin -4.2 1.7 -0.20 -1.54 0.034 
Ferritin -0.06 0.03 -0.23 -2.00 0.023 
CRP -26.1 3.7 -0.74 -5.91 <0.0001 
bPRP 10.22 3.02 0.25 2.00 0.023 
aPRP -16.9 6.5 -0.21 1.86 0.012 
Cystatin 0.0016 0.0004 0.06 2.51 0.0008 
iAUC serum 
iron µg/dL*hr 
Model  9.81 <0.0001 
Constant 10281 1869.2 0 5.5  
Supplementation 
period 
65.94 299.6 0.022 0.22 0.83 
Week 0 -210.6 379.4 -0.05 -0.56 0.58 
CRP -2091.3 514.5 -0.40 -4.06 0.0002 
bPRP 0.0042 0.001 0.31 3.12 0.003 
Total salivary 
protein 
-6606 1731 -0.38 -3.82 0.0004 
meat -185.7 78.3 -0.23 -2.37 0.022 
0.2 astringency -237.3 238.4 -0.31 -2.83 0.0066 
Hemoglobin 
(g/dL) 
Model  5.54 <0.0001 
Constant 12.4 0.27 0 41.55 <0.0001 
Supplementation 
period 
0.17 0.11 0.14 1.55 0.126 
Week 0 -0.05 0.13 -0.03 -5.12 <0.0001 
CRP -0.97 0.19 -0.47 4.14 0.0005 
Ferritin 0.007 0.001 0.36 3.32 0.0001 
Fat 0.008 0.002 0.32 -3.82 0.002 
Ferritin 
(ng/dL) 
Model  6.47 <0.0001 
Constant -213.7 69.5 0 -3.33 0.0016 
Supplementation 
period 
-5.44 5.64 -0.11 -0.97 0.83 
Week 0 -0.54 7.06 -0.01 -0.08 0.58 
Hemoglobin 22.95 4.49 0.50 4.60 0.0002 
bPRP 38.76 14.4 0.29 2.69 0.003 
%max iron -0.70 0.40 -0.19 -1.72 0.0004 
Zinc -2.24 0.85 -0.32 -2.63 0.022 
Significance: p < 0.05 SE: standard error; CRP: C-reactive protein; bPRP: basic proline-rich 
protein; aPRP: acidic proline-rich protein; iAUC: area under the curve; Zn: zinc 
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Table 5-5: Correlations between % max iron absorption and salivary proteins at Week 0 
and Week 4 of each supplementation period 
Dose 
Week 0/ 
Week 4 
N 
bPRP aPRP gPRP Statherin Cystatin Total 
R (p) R (p) R (p) R (p) R (p) R (p) 
0.03 
g 
Week 0 
11 
0.218 
(0.518) 
-0.18 
(0.596) 
-0.131 
(0.70) 
-0.241 
(0.475) 
0.290 
(0.387) 
-0.078 
(0.82) 
Week 4 
0.605* 
(0.049) 
-0.198 
(0.56) 
0.184 
(0.587) 
-0.055 
(0.872) 
-0.007 
(0.985) 
0.09 
(0.793) 
0.25 
g 
Week 0 
11 
0.25  
(0.46) 
-0.645* 
(0.03) 
-0.204 
(0.547) 
-0.245 
(0.469) 
0.326 
(0.328) 
0.047 
(0.892) 
Week 4 
0.489 
(0.07) 
0.057 
(0.876) 
0.111 
(0.76) 
0.112 
(0.757) 
0.138 
(0.704) 
0.158 
(0.66) 
1.5 g 
Week 0 
11 
0.297 
(0.438) 
0.075 
(0.861) 
0.391 
(0.298) 
0.01  
(0.80) 
0.201 
(0.60) 
0.46 
(0.182) 
Week 4 
0.173 
(0.611) 
-0.483 
(0.133) 
-0.595* 
(0.05) 
0.10 
(0.767) 
0.114 
(0.739) 
-0.076 
(0.825) 
Total   
0.366* 
(0.003) 
-0.20* 
(0.028) 
-0.23 
(0.06) 
0.07  
(0.57) 
0.27* 
(0.03) 
0.20  
(0.11) 
*p < 0.05 basic proline-rich protein: bPRP, acidic proline-rich protein: aPRP, glycosylated 
proline-rich protein (gPRP) 
 
Table 5-6: Mean astringency ratings, and changes from Week 0 to Week 4 of 
supplementation periods 
Dose* 
0.03 g Week 0 0.03 g Week 4 0.25 g Week 0 0.25 g Week 4 1.5 g   Week 0 1.5 g Week 4 
Fisher’s exact 
Week 0 to 4 
 
Mean  
(95% CI) 
Mean  
(95% CI) 
Mean  
(95% CI) 
Mean 
 (95% CI) 
Mean  
(95% CI) 
Mean  
(95% CI) 
p 
 
0.3 mg/dL 
1.4 
(1.1, 1.6) 
1.1 
(0.9, 1.3) 
1.2 
(0.9, 1.4) 
1.3 
(1.0, 1.5) 
1.2 
(0.9, 1.4) 
1* 
(0.8, 1.2) 
0.31 
 
0.7 mg/dL 
2.2 
(1.8, 2.5) 
2.3 
(1.9, 2.6) 
2 
(1.7, 2.4) 
1.9 
(1.6, 2.3) 
2.1 
(1.7, 2.4) 
1.8* 
(1.5, 2.2) 
0.50 
 
1.5 mg/dL 
3.3 
(2.8, 3.7) 
3.4 
(2.9, 3.8) 
3.2 
(2.7, 3.6) 
3.5 
(3, 3.9) 
2.4 
(1.9, 2.8) 
3.3+ 
(2.8, 3.7) 
0.126 
 
2.5 mg/dL 
4.2 
(3.7, 4.7) 
4.4 
(3.9, 4.8) 
4.3 
(3.8, 4.7) 
4.5 
(4, 5) 
3.3 
(2.9, 3.8) 
4.4 
(3.9, 4.8) 
0.55 
 
*p < 0.05. CI: confidence interval. *p < 0.05 Week 4 vs. Week 0. + p < 0.05 0.03 g vs. 1.5 g 
supplementation period. Tannin doses approximated consuming one fruit or vegetable, 3 cups of 
tea, or 100 g of sorghum, three times daily for four weeks. Scale 1 = not astringent, 5 = 
extremely astringent 
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 Figures 
Figure 5-1: Enrollment allocation 
   
 
 
 
 
 
 
 
 
 
Enrollment allocation. Forty-eight potential participants responded to the study call and were 
screened; the study was conducted on a rolling basis. Twelve participants were initially enrolled, 
and during study duration, two participants dropped out due to relocation, one due to time 
commitment in the study, another due to intolerance to blood draws, and one due to supplement 
intolerance. These participants all dropped out after supplementation period I of the study was 
completed, and another four participants were recruited on a rolling basis from the initially 
screened pool of 48.   
  
Initial response to 
recruitment: 48  
Originally 
interviewed and 
enrolled: 12  
Dropped out: 
Relocation = 2  
Time commitment= 1 
Side effect= 1 
Blood draws= 1 
Screened and 
enrolled from initial 
pool: 4  
Remaining: 7 Total: 11 
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Figure 5-2: Supplementation periods (A) and supplementation period activities (B). 
 
 
 
 
 
 
2b: 
 
 
The study consisted of three supplementation periods for each participant, a high (1.5 g), 
medium (0.25 g), or low (0.03 g) condensed tannin supplement was provided for four weeks. 
Two to three-week washout periods between supplementation periods aimed to stabilize salivary 
protein and iron biomarkers. Supplementation periods consisted of Week 0 and Week 4 meal 
challenges, salivary collection, and astringency testing. At midpoint of each supplementation 
period, there were 3 24- hour dietary recalls (2 weekday, and 1 weekend day) collected from 
each participant. 
 
2-week 
supplement 
 3 times daily 
2-week 
supplement 
 3 times daily 
Week 4: 
Meal challenge: 
Iron absorption 
curve 
Salivary collection 
Week 0: 
Meal challenge: 
Iron absorption 
curve 
Salivary collection 
Midpoint: 
 
3-24-hour diet 
recalls (2 weekdays, 
and 1 weekend day) 
Intervention:  
N= 11  
 high, medium, or 
low dose tannin 
supplement 
Intervention 2:  
N= 11  
 high, medium, or 
low dose tannin 
supplement 
Intervention 3:  
N= 11   
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Washout 
(2-3 
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Figure 5-3: Mean adjusted and unadjusted individual level iron absorption at Week 0 and 
Week 4 of each supplementation period. 
 
 
Adjusted for hemoglobin, ferritin, C-reactive protein, basic proline-rich proteins, and acidic 
proline-rich proteins, (red) and unadjusted (black) 
There were no significant differences (ps > 0.05) in iron absorption at any dose of condensed 
tannin before or after supplementation periods. 
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Figure 5-4: Individual level incremental area under the curve for serum iron at Week 0 
and Week 4 of each supplementation period  
 
 
Mean regression-adjusted for C-reactive protein, basic proline-rich protein, total salivary 
protein, meat consumption, and rating of highest level of astringency: red; and unadjusted: 
black.There were no significant differences (ps > 0.05) in iron absorption within tannin 
supplementation periods. 
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 Abstract 
Background: Repeated consumption of phytic acid has been shown to lead to iron 
absorption adaptation. Mechanistically, adaption is not well understood, but salivary proline-rich 
proteins have been shown to block iron chelation by antinutritional factors other than phytic acid 
in animal models. It is therefore possible that upregulation of salivary protein synthesis partly 
diminishes the antinutritional effects of phytic acid.  
Objective: The primary aims of this study were to determine whether salivary proteins 
bind phytic acid in vitro, and to understand the impact of daily phytic acid supplementation on 
individuals’ iron status, bioavailability, and salivary proline-rich protein (PRP) production. A 
secondary aim was to investigate the correlations between astringency ratings and iron status. A 
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post hoc objective was to determine whether cystatin SN levels were correlated with iron 
bioavailability after phytic acid supplementation. 
Method: In phase I, high performance liquid chromatography (HPLC) and matrix-
assisted laser desorption/ionization: time of flight (MALDI-TOF) were used to characterize in 
vitro salivary protein-phytic acid interactions. Phase II was a clinical arm where women (n = 7) 
aged 18-35 consumed 350 mg phytic acid supplements three times daily for four weeks. Post-
meal challenges were employed to determine iron bioavailability and status before and after 
supplementation periods. Three 24-hour dietary recalls were collected to assess for dietary 
covariates. At Week 0 and Week 4, phytic acid post-meal challenges were employed to assess 
iron bioavailability, ferritin, hemoglobin, salivary PRP changes, and astringency perception. In 
phase III, enzyme-linked immunosorbent assay (ELISA) analysis of purified protein fractions, 
and participant saliva from phase II were used to identify protein bound to phytic acid. 
Results: In vitro salivary protein-phytic acid interaction showed dose-dependent 
reductions in a protein peak which correlated with MALDI-TOF and phytase treated phytic acid-
salivary pellets. This peak was identified as cystatin SN through ELISA analysis. Neither iron 
bioavailability (p = 0.32), hemoglobin (p = 0.72), nor serum ferritin (p = 0.08) concentration 
were reduced from Week 0 to Week 4 after regular phytic acid supplementation. Basic proline-
rich proteins were associated with improved iron bioavailability by study end (r = 0.82, p = 
0.02). In post hoc analysis, cystatin SN concentrations were not significantly changed from 
Week 0 to Week 4 (R2: -0.55, 2.01, p = 0.23). There was a significant positive correlation 
between cystatin SN concentration at Week 4 and improved iron bioavailability from Week 0 to 
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Week 4 (r = 0.996, p < 0.001), suggesting that upregulation may improve iron bioavailability 
with phytic acid consumption. 
Conclusions: Proline-rich proteins did not bind to phytic acid in vitro. There were no 
changes in iron bioavailability, hemoglobin, or ferritin levels in participants consuming phytic 
acid supplements for four weeks. Basic proline-rich proteins were associated with improved iron 
bioavailability, while cystatin SN was found to be an independent predictor of poor iron 
bioavailability with phytic acid supplementation. Overall, these findings suggest that salivary 
proteins may play a role in protecting against phytic acid-iron chelation during digestion.  
Keywords: phytic acid, cystatin SN, iron bioavailability, salivary proline-rich proteins, 
adaptation, antinutritional factors, iron deficiency anemia 
 Background 
Phytic acid is the major phosphorous storage compound found in plants, including grains and 
legumes 1, which are commonly consumed in countries with high rates of iron deficiency. Phytic 
acid’s propensity to bind to metal cations and proteins reduces their nutritional bioavailability 1, 
and phytic acid is thus denoted as an ‘antinutritional’ factor when it forms a phytic acid-nutrient 
complex (denoted phytate). The amount of phytic acid consumed 2, the food matrix in which it is 
consumed 1, and food preparation 1 all determine its ultimate ‘antinutritional effect,’ but human 
single-meal studies have repeatedly found that phytic acid reduces iron bioavailability 3-5. 
Despite conventional views that support phytic acid’s contribution to marginal iron status, 
there are also studies that dispute this idea. The individual effect of phytic acid consumption on 
iron bioavailability has been found to be highly variable 6, and many individuals consuming diets 
rich in grains and legumes, and thus phytic acid content maintain normal iron stores 7,8, pointing 
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to possible gaps in the understanding of phytates’ antinutritional effects. Adaptation, or 
homeostatic maintenance of iron storage despite such antinutritional factor consumption, is one 
possible explanation. An experimental study showed that increased dietary phytic acid 
consumption over eight weeks improved iron absorption of a high phytate meal compared to a 
Week 0 meal and a low phytate control in marginally iron deficient women 9. Another study 
examining long-term consumption (10 weeks) of high and low bioavailability diets in iron 
replete men also suggested adaptation to low bioavailability diets from Week 0 to Week 4, and 
authors suggested that single meal bioavailability may have exaggerated long-term effects of 
antinutritional factors 10. In a 12-week crossover study that divided women into “high” (rich in 
heme protein and ascorbic acid) and “low” (rich in grains, legumes, and fiber) bioavailability 
diets, only women consuming a low bioavailability diet over time could absorb more non-heme 
iron from Week 0 to Week 4 with either a high or low bioavailable meal challenge, although iron 
storage was better correlated with a high bioavailability diet 11. 
Saliva is the first defense mechanism of the alimentary tract to toxins and pathogens 12, and 
salivary proline-rich proteins (PRPs) in particular have been noted in sensory studies because of 
their ability to precipitate tannins 12,13, thereby reducing tannin-iron chelation, and creating an 
astringent sensation. In saliva, there are six main classes of salivary proteins: histatins, 
cystatins, statherins, acidic proline-rich proteins (aPRP), basic proline-rich proteins (bPRP), and 
glycosylated proline-rich proteins (gPRP) 13 that may exert independent effects on 
tannins. Statherin and aPRPs are commonly known for their ability to 
regulate oral calcium 14,15. Cystatins have been linked to bitter sensation acceptance 16,17, and 
function to inhibit cysteine proteases 18. Basic PRPs (bPRP) are thought to protect against the 
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negative effects of polyphenols 19, while the function of gPRP 12 is not well characterized. 
Production of PRPs when consuming tannins has been shown to improve protein 20 and iron 
availability 21,22 in animal studies, while hamsters, that do not upregulate PRP synthesis in 
response to tannin consumption, have poor growth outcomes 23 when consuming tannins. While 
PRP binding to tannins has been characterized previously 24-28, PRP-phytate interaction has not. 
Phytates may not directly interact with salivary PRPs, but it is important to establish whether 
PRP synthesis can be upregulated by phytates, which often accompany tannin consumption. 
Therefore, the primary objectives of this study were to determine: 1) whether salivary proteins 
would interact with phytic acid in vitro 2) whether iron bioavailability, or markers or iron status 
would be affected with repeated phytic acid consumption, 3) whether there would be changes in 
salivary protein production with phytic acid consumption over time, and 4. ) whether salivary 
proteins could be associated with improved iron bioavailability during supplementation periods. 
Post hoc study objectives included determining whether cystatin SN could be correlated with 
improvements in iron bioavailability during the clinical study duration.  
 Methods 
Study activities were divided into three phases to explore answer study objectives. In phase I, in 
vitro analysis of phytic acid-salivary proteins was designed to determine whether these 
interactions occurred. In phase II, a clinical arm was designed to measure iron bioavailability 
with repeated phytic acid consumption over time, as well as salivary protein production with 
phytic acid consumption. In phase III, in vitro and clinical arm salivary protein samples were 
analyzed via ELISA for confirmation of phytic acid-protein interactions. 
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 Phase I: In vitro phytic acid-salivary protein interactions 
 Salivary PRP measurement  
 High performance liquid chromatography (HPLC) parameters and equipment  
All reagents were analytical grade. Acetonitrile, trifluoroacetic acid (TFA), and HPLC grade 
water were purchased from Fisher Scientific. 
 Acidified saliva sample preparation  
Frozen salivary samples from an individual donor, and later, clinical trial participants, were 
thawed in a refrigerator overnight. Before sample analysis, we verified consistency in 
chromatogram output with duplicate samples by HPLC, and because samples were analyzed 
relative concentrations, rather than for quantitative protein amounts, peak consistency allowed 
for samples to be analyzed in a single run. For PRP extraction, 900 µl of saliva was mixed with 
10 µl of 10% TFA in water, centrifuged for 5 min at 8000 RPM, and the supernatant was filtered 
through a 0.2 µm polyvinylidene fluoride (PVDF) syringe filter described previously 29. Before 
samples were analyzed, it was verified by investigators with HPLC analysis that there was no 
PRP peak loss with use of syringe filters. The supernatant was then analyzed by HPLC. 
Ninety µl of salivary supernatant was injected into a Fisher 2.1x150 mm, 5µm BioBasic C8 
analytical column at a flow rate of 0.3 mL/min for 49 minutes at 40◦C with an auto sampler 
(Shimadzu SIL) on a HPLC system containing a LC20AB pump (Shimadzu), and a Shimadzu 
SPD-M20A PDA system. Detection of PRPs was carried out at 214 nm 29,30. Mobile phase 
consisted 0.2% TFA in HPLC grade water (A) and 0.2% TFA in 80/20 acetonitrile and HPLC 
grade water (B) 29-32. A linear gradient was applied from 0-39 min from 0-54% (B), then from 
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39-49 min at 54-100% B to elute late proteins 29-32. After each wash, the column was stabilized 
with initial conditions by returning to 100% A over 10 min.  
 In Vitro Phytate-PRP testing  
 Matrix-assisted laser desorption/ionization: time of flight (MALDI-TOF) and HPLC 
determination of protein-phytate binding  
Acidic saliva PRP-fractions were prepared, and phytic acid (inositol hexaphosphate, ACOS 
Organics) was added to samples at concentrations of 0.000512 (physiological, equivalent to 2:1 
phytic acid supplement drink: saliva concentration, pH 4.5), 0.00512 (10:1, pH 2.3), or 0.0512 
(100:1X, pH 1) mg/100 µl saliva and compared with an acidic saliva sample (buffered to 100 X 
saliva-phytic acid sample pH of 1 with TFA), or a saliva-only control. All samples were prepared 
to equivalent sample dilutions by adding aliquots from a standard saliva sample. After 
preparation, samples were shaken for 30 seconds and allowed to sit at room temperature (20°C) 
for five minutes. Samples were spotted on MALDI-TOF/TOF in several fractions: 1) whole 
extracted saliva 2) washed supernatant from samples centrifuged at 8000 RPM for 5 min 3) 
pellet digestion. In pellet digestion, 2,2,2-trifluoroethanol was used to disassociate aggregated 
hydrophobic proteins before spotting samples to MALDI-TOF/TOF. Pellets were then digested 
with trypsin (Promega, Trypsin Gold) to verify that protein was bound in phytic acid salts. 
To reduce MALDI signal loss from phytic acid interference and quantify protein losses with 
phytic acid interaction, acidic saliva PRP-fractions were prepared at lower concentrations with 
phytic acid concentrations of 0.000512 (physiological), 0.000256 (0.5 X), or 0.000064 (0.125 X) 
mg/100 µl saliva, and a control saliva sample, to equivalent sample dilutions and buffered to pH 
of the physiological phytic acid supplement (pH 5.5). Samples were vortexed for 30 seconds, 
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then allowed to sit at room temperature (20°C) for five minutes, and finally centrifuged for 5 min 
at 8000 RPM. The supernatant was collected, filtered with a 0.2 µg PVDF syringe filter, and 
immediately run on HPLC. The remaining precipitate pellet was digested with addition of 10 µl 
wheat phytase (Sigma Aldrich) in hydrochloric acid buffered distilled water (62 mg/ mL phytase 
in water; pH 5.5) at 20⁰C for five minutes, filtered with a 0.2 µg PVDF syringe filter, and run on 
HPLC. Chromatograms were analyzed for peak reductions at 214 nm, HPLC purified peak loss 
fractions from phytic acid and control samples were collected from control saliva for tryptic 
digestion and MALDI-TOF/TOF analysis. A phytase standard was run on HPLC to assess peak 
changes in the phytase sample created by the enzyme or enzyme impurities. Protein peaks 
recovered from phytase digestion were also collected and run on MALDI-TOF/TOF for 
identification.  
 Tryptic digestion  
Pellets and HPLC fractions of interest were subjected to in-solution tryptic digestion. Trypsin 
(Promega, Trypsin Gold) was added to HPLC purified peaks and phytate pellets at a 1:200 
trypsin:protein ratio. Samples were digested in 50 mM ammonium bicarbonate overnight, and 
subsequently spotted to MALDI after acidification with 1% TFA.  
 MALDI TOF analysis 
 Intact mass and in-solution trypsin digestion were analyzed using a MALDI-TOF mass 
spectrometer (Bruker Daltonics Ultraflex III) in linear mode for intact proteins, and reflectron 
mode for peptides in the Biotechnology/Proteomics Core Facility at Kansas State University. 
Intact proteins were spotted with 20 mg/mL sinapinic acid in 1:1 0.1% TFA/acetonitrile. Peptide 
digest samples were spotted with 2,5 dihydroxybenzoic acid (50 mg/mL) in 1:1 0.1% 
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TFA/acetonitrile. Digested mass spectra were matched against a SwissProt database for proteins 
within the intact mass range using mMass software (http://www.mmass.org). 
 Phase II: Clinical Arm 
 Inclusion/exclusion 
The study protocol was approved by the Institutional Review Board at Kansas State University 
(KSU; IRB #8121). An announcement requesting participants was sent to faculty and students 
through a university email digest, as well as disseminated though departmental social media 
channels. Women who participated in a similar clinical trial were recruited for the current study, 
enrollment was rolling, potential participants were screened in person. Before screening, 
participants were required to read and sign an informed consent document, and all procedures, 
risk and benefits of the study were reviewed verbally. Premenopausal women, aged 18-35, who 
were non-obese (body mass index, BMI ≤ 30.0 kg/m2), had no history of oral or gastrointestinal 
disease, were moderate (≤ 1 drink per day) or non-alcohol consumers, and non-tobacco users we 
eligible for participation. Further exclusion criteria included blood disorders affecting iron status 
or absorption, current supplementation or medication that would impair iron status, food allergies 
to supplements, pregnancy or breastfeeding (see Appendix D for screening questionnaire and 
exclusion criteria). Participants were compensated for completing study activities. In total, seven 
participants were enrolled in the current study. Participants were compensated monetarily for 
completing study activities. 
 Study conditions  
The study consisted of Week 0 and Week 4 meal challenges, with four weeks of daily phytic acid 
supplementation in between. Each participant consumed 350 mg phytic acid supplements 
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(inositol hexaphosphate, ACOS organics), to mirror a dose from a previous trial 9. Supplements 
were provided in an opaque bottle with a non-caloric sweetener/flavoring (Mio Original) to 
improve palatability, three times daily for four weeks (Figure 6-1).  
 Phytic acid meal challenges 
At Week 0 and at the end of Week 4, participants completed meal challenges at the KSU 
Physical Activity and Nutrition Clinical Research Consortium (PAN-CRC). Participants were 
asked to come in fasted (at least 8 hours) at 7:00 am, having abstained from teeth cleaning (2 
hours) and exercise (24 hours) to minimize diurnal variations or other factors in salivary 
production 32, and iron uptake 33. Pre-meal saliva was collected by passive drool (2 mL total) into 
cryovials, and samples were immediately placed into a freezer set to -71⁰ C for storage. A 20-
gauge indwelling peripheral intravenous (PIV) catheter was placed either in the median cubital, 
cephalic, or basilica vein for multiple blood samples, which was flushed and saline locked with 
10 mL of 0.9% isotonic saline between blood collections. After fasted blood collection for serum 
ferritin, C-reactive protein (CRP), hemoglobin, and serum iron, a phytic acid challenge meal 
consisting of supplemented 15 mg ferrous sulfate and 75 mg ascorbic acid 9,34 (each sprinkled on 
a 95 g bagel with 12 g sugar free strawberry jam), and a 90 g banana, which were consumed with 
the phytic acid supplement. Salivary samples were collected 15 minutes following the final bite 
of the meal to determine salivary protein stimulation after phytic acid consumption 35. After a 
waste blood sample was drawn 36, blood samples were drawn from the PIV for serum iron at 180 
and 210 minutes to determine percentage of max iron absorption and incremental AUC for serum 
iron 34.  
 Astringency testing 
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After the PIV was removed at Week 0 and Week 4, participants were asked to complete an 
astringency test 37,38. Each participant was given four different concentrations of 10 mL alum 
powder in distilled water (0.20, 0.15, 0.07, and 0.03%) to sip in randomized order. They were 
given a verbal description of the sensation of astringency asked to rate each solution based on 
their perception of astringency on a 5 point Likert scale (1 = not astringent, 5 = extremely 
astringent). Participants waited 30 seconds between astringency tests. 
 Dietary Analysis  
At the beginning of week two of the study, participants were emailed a unique username and 
password to complete 2 weekdays and 1 weekend day, 24-hour dietary recalls on the Automated 
self-administered 24-hour recall (ASA24®). After all recalls were collected, dietary data were 
extracted, and total caloric intake (kcal), protein (g), fat (g), carbohydrate (g), iron (mg), ascorbic 
acid (mg), meat protein (oz.), sugar (g), fiber (g), Zn (mg), and Cu (mg) content were averaged 
from system calculated amounts for all participants. Food intake logs were downloaded from the 
ASA24® for manual calculation of proanthocyanidins, polyphenols, and phytic acid in the diet. 
During this process, a research assistant reviewed all dietary data for each participant kept in an 
electronic spreadsheet (Microsoft Excel). Food items were referenced from USDA tables 
transferred to an electronic spreadsheet, and total proanthyocyanidin 39, amounts were calculated 
and summated for each recall. Individual meal recalls were added into the Nutrition Data System 
for Research (University of Minnesota, Minneapolis, MN) post hoc to quantify phytic acid meal 
content. From these summations, group averages were calculated.  
 Hematological Parameters  
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From the fasting blood draw, two separate samples were collected 5 mL serum separator (SST) 
and 3 mL ethylene diaminetetra acetic acid (EDTA) vacutainer tubes to measure serum iron (by 
spectrophotometry), CRP (by nephelometry), ferritin (by immunoassay), and whole blood 
hemoglobin concentrations (by electronic cell cytometry). Subsequent blood samples were 
samples were collected in SST tubes and analyzed for serum iron. After collection, serum 
samples were centrifuged at 2500 RPM for 15 min after clotting for 20 minutes, and kept at room 
temperature for analysis. All blood samples were analyzed by a certified laboratory (Quest 
Diagnostics, Lenexa, KS) within 24 hours.  
 Incremental AUC and maximum percentage of iron absorption calculation 
Serum iron data were used to calculate percentage of maximum iron recovery and 
incremental AUC for iron bioavailability analysis.  
Percentage Iron Recovery: Percentage iron recovery was calculated as below 34. 
 
% 𝑖𝑟𝑜𝑛 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 max = (
𝑠𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛 max×𝑝𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒)
𝑡𝑜𝑡𝑎𝑙 𝑖𝑟𝑜𝑛 𝑖𝑛𝑔𝑒𝑠𝑡𝑒𝑑
×100 
Where:                    𝑖𝑟𝑜𝑛 max =
𝜇𝑚𝑜𝑙
𝐿
, 𝑝𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒 =
𝐿, 𝑎𝑛𝑑 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑟𝑜𝑛 𝑖𝑠 𝑖𝑛 𝜇𝑚𝑜𝑙  
𝑝𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒 (𝐿) =
𝐵𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙)×(1 − 𝑃𝑎𝑐𝑘𝑒𝑑 𝑐𝑒𝑙𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑑𝑒𝑐𝑖𝑚𝑎𝑙))
1000
 
And     𝑏𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 = 69.6
𝑚𝑙
𝑘𝑔
𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡   
 
Incremental serum iron AUC by trapezoidal integration 
∫ 𝐴𝑈𝐶 = 
∆ 𝑡𝑖𝑚𝑒
2
×[∆𝑆𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛 𝑡𝑖𝑚𝑒 0−180 +  (2×∆𝑆𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛𝑡𝑖𝑚𝑒 0−210 )] 
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 Phase III: ELISA confirmation of protein and protein-phytate binding  
To confirm MALDI-HPLC findings, peak loss fractions from in vitro phytic acid and control 
samples were tested for presence and absence of cystatin SN in samples, respectively, using an 
enzyme-linked immunosorbent assay (ELISA) kit (Raybiotech, Norcross GA). Samples were 
prepared according to manufacturer instructions by adding the instructed sample amount, and 
read on a 96-well plate reader (Biotek Synergy HT, Winooski, VT) at 450 nm immediately after 
adding stop solution. Participant saliva from the clinical arm of this study was analyzed to 
quantify cystatin SN before and after phytic acid supplementation at Week 0 and Week 4. One 
participant, whose iron bioavailability data was not obtained due to blood lysis in blood draws at 
180 and 240 minutes, was excluded from analysis. Separately, salivary-phytic acid samples 
obtained after phytic acid consumption (stimulated saliva) were interacted with phytic acid in 
vitro by to verify phytate formation with cystatin SN. During this experiment, phytic acid was 
added to saliva obtained after meal consumption at a concentration of 0.00512 mg/100 µl saliva 
(physiological). Samples were shaken and allowed to incubate for five minutes, saliva was then 
centrifuged at 8000 RPM for 5 min, the supernatant was separated from precipitate, then spotted 
to ELISA 96 well plates.  
 Statistical analysis 
Data were analyzed using SAS statistical software (SAS Studio version 3.6, Cary, North 
Carolina), statistical significance was set at p < 0.05, and are presented as mean ± standard 
deviation. Before analysis, all data were analyzed for normality and homogeneity of data in Q-Q 
plots and with Levene’s test.  
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Variables that were non-normal were log transformed, and determined to be normal before 
analysis. Log-transformed variables were included in stepwise variable selection in adjusted 
model building (below). All log-transformed data were back-transformed for results presentation. 
Week 0 demographic and nutritional intake data were analyzed by analysis of variance 
(ANOVA). 
 Sample size  
A sample size calculation determined that four participants would be needed to determine a 
change in incremental iron area under the curve (AUC) by 25% 9,34 (SAS studio version 3.6, 
Cary, NC) as statistically significant with 80% power and at an α-level of 0.05. With an 
anticipated dropout of 30%, it was determined that at least 6 participants were needed to enroll in 
the study.  
 Hematological outcomes analysis  
 Regression analysis of hematological outcomes 
Unadjusted percentage of max iron absorption, ferritin, and hemoglobin were analyzed 
by linear regression at Week 0 and Week 4 to answer our second primary research question, 
which asked whether iron bioavailability or status would be affected with repeated phytic acid 
consumption. Multiple regression was used to adjust outcomes (% max iron absorption, 
incremental serum iron AUC, hemoglobin, ferritin) for repeated (participant) and random 
covariates after stepwise selection for variables. Significant differences for all outcomes were 
determined using least significant differences. Post hoc sample size analysis was conducted 
using t-tests with a power of 0.90 and α of 0.05. 
 Astringency and salivary protein outcomes analysis 
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Our third primary research question asked whether changes in salivary protein production were 
induced by phytic acid consumption over time, and whether there were correlations between 
salivary proteins and improved iron bioavailability before and after phytic acid supplementation. 
To answer these questions, proline-rich proteins were divided into type by retention times; 
histatins were excluded from analysis 29-32, peak mAu were recorded for each. Proportions of 
acidic salivary subtypes were further analyzed. 
 
𝑃𝑅𝑃 𝑠𝑢𝑏𝑡𝑦𝑝𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 = 𝑃𝑅𝑃 𝑡𝑦𝑝𝑒 (𝑎𝑟𝑒𝑎 𝑠𝑢𝑚) ÷ 𝑇𝑜𝑡𝑎𝑙 𝑃𝑅𝑃 𝑎𝑟𝑒𝑎 
 
Or 
𝑃𝑅𝑃: 𝐴𝑐𝑖𝑑𝑖𝑐 𝑠𝑎𝑙𝑖𝑣𝑎𝑟𝑦 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑠 = 𝑇𝑜𝑡𝑎𝑙 𝑃𝑅𝑃 𝑎𝑟𝑒𝑎 ÷ 𝑇𝑜𝑡𝑎𝑙 𝑠𝑎𝑙𝑖𝑣𝑎𝑟𝑦 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑟𝑒𝑎 
 
Salivary proteins were analyzed by multiple factor ANOVA at Week 0 or Week 4; Pearson’s 
product-moment correlations were used to analyze correlations between iron absorption, 
incremental AUC for serum iron, astringency ratings, and PRP types. Changes in participant 
cystatin SN concentrations were analyzed at Week 0 and Week 4 by ANOVA, and effect sizes 
were calculated using the equations: 
Hedges’ g (unbiased estimator of Cohen’s d)15 
                        =  𝑴𝟏 − 𝑴𝟐/𝑺𝒑𝒐𝒐𝒍𝒆𝒅  
Where Sp = √
(𝑛𝑒−1)𝑆𝑒2+(𝑛𝑐 −1)𝑠𝑐2
𝑛𝑒+𝑛𝑐 −2
  and M1/M2 were the mean of experimental and control 
groups.  
95% confidence intervals were calculated using the equation: 
                                g*±1.96(𝜎𝑔 ∗) 
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𝜎𝑔 ∗= (
𝑛𝑒+𝑛𝑐
𝑛𝑒𝑛𝑐
+
g* 
2(𝑛𝑒+𝑛𝑐)
) and   g*= 𝑔 (1 −
3
4(𝑛𝑒+𝑛𝑐)−9 
) 
Astringency perception, connections to salivary protein production, and iron bioavailability 
We determined whether astringency perception was changed from Week 0 to Week 4 of phytic 
acid supplementation using Chi-square testing and Fisher’s exact tests. Correlations between 
salivary protein production, iron bioavailability and astringency were analyzed by Pearson’s 
product-moment correlations.  
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 Results 
 Phase I: In vitro phytic acid salivary protein interaction 
 HPLC analysis of phytic acid-saliva interactions 
To establish whether there was potential for meaningful mediation of iron-phytic acid chelation 
by salivary proteins, a single volunteer’s saliva was interacted with phytic acid at various 
concentrations. HPLC results from non-pelleted salivary supernatant extracted after interaction 
showed progressive peak reduction at 40.3 minutes, suggesting preferential binding of phytic 
acid to this HPLC fraction (Figure 6-2).  
 Saliva-phytic acid pellet MALDI outcomes 
Phytic acid-saliva pellets analysis resulted in peaks similar to those from purified protein 
fractions. Pellets were dissolved with tryptic digestion, indicating that the protein precipitated 
phytic acid. MALDI-TOF results found in vitro phytic acid supernatant sample peak reductions 
compared to control or acidified saliva (Figure 6-3). This lost fraction was recovered by tryptic 
digestion of MALDI-spots, also suggesting that phytic acid was directly precipitating specific 
protein fractions, rather than nonspecific precipitation of proteins due to pH reductions during 
experiments. 
 In vitro pellet tryptic digestion and purified protein fraction analysis 
In vitro tryptic digestion of the phytic acid-salivary pellet dissolved the complex, suggesting that 
proline-mediated bonds were not pellet components, and thus the protein identified on HPLC 
was not likely a proline-rich protein. MALDI spots of purified whole saliva and in vitro phytic 
acid fractions collected at 40.3 minutes recovered the same protein peaks as were identified on 
MALDI after tryptic pellet digestion, suggesting that HPLC peak reductions were the same as 
231 
 
 
 
 
MALDI pellet components (Figure 6-4). To match peptide components to proteins, in vitro 
phytic acid sample peaks were removed from control samples before searching the database. The 
best matches were for cystatins S, SN & SA fragments. All cystatins without signal peptides 
were mapped to the data, the match with the best fit was for cystatin SN (49.6%). 
 Phase II: clinical arm results 
 Participant demographics 
Participant ages ranged from 20-35, average age of participants was 26.2 ± 1.2 yrs. All 
participants were occasional (2-3 drinks/month) or moderate (2-3 drinks per week) alcohol 
consumers. Aside from one participant, who was vegan, and took vitamin B12 supplements, no 
participants took vitamin or mineral supplements during the study period. Average BMI of 
participants was 25.4 ± 5.8 kg/m2 (range 19.7-29.8). Participant weights (kg) did not 
significantly change between Week 0 and Week 4.  
 
 Participant dietary intake  
Mean caloric intake during the study was 2107 ± 672.8 kcal per day, 13.7± 3.2% of average caloric 
intake was from protein, 35.1 ± 12.1% and 51.2 ± 20.2 % came from fat and carbohydrates, 
respectively (Table 6-1). Average meat consumption ranged from 0-5.7 oz. per day. Average 
ascorbic acid intake exceeded the recommended daily value (RDA) by 15%, iron intake was on 
average 93% of the RDA. The average daily phytic acid intake was 863.8 ± 812.8 mg/ day (range 
199.8 – 2388 mg per day), phytic acid supplementation more than doubled the typical dietary phytic 
acid intake for five of the seven participants.  
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 Hematological indices and iron absorption 
 Unadjusted iron outcomes 
Iron absorption was not significantly different from Week 0 to Week 4 by either % max iron 
absorption or iAUC for serum iron (Table 6-2). The percentage of maximum iron absorption but 
not significantly different (p = 0.22, Tables 6-2, Figure 6-5) from Week 0 to Week 4. There 
were no significant differences in hemoglobin, ferritin, or CRP from Week 0 to Week 4 of the 
supplementation period (Table 6-2).  
Individual level data show that 57% of participants in the study experienced reductions in 
hemoglobin values from Week 0 to Week 4 ranging from 2-5% (Table 6-3). Three of those 
participants also had reduced ferritin levels from Week 0 to Week 4, the reduction range was 8-
37%. Four of seven participants experienced 1.1-4 times worse iron absorption measured by 
iAUC for serum iron at Week 4 compared to Week 0; of the three participants who had improved 
iron absorption, two also had reduced hemoglobin and ferritin levels. 
 Hematological covariate identification and adjustment 
To test the impact of dietary and individual physiological differences (iron status, 
anthropometric, salivary protein) on iron bioavailability and status, we employed stepwise 
regression analysis to establish significant covariates to build an adjusted model for 
hematological outcomes. Covariates that were significantly associated with serum iron iAUC 
included dietary fat and proanthocyanidin trimer intake, rating of 0.07 mg/dl astringency, aPRP, 
and cystatin production (Table 6-4). Significant covariates associated with %max iron 
absorption included hemoglobin and proanthocyanidin monomers. Ferritin and hemoglobin 
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covariates were CRP, dietary protein intake, and rating of 0.2 mg/dl (highest) astringency rating 
(Table 6-4).  
Significant covariates for each outcome measure were added to the linear regression for 
adjusted outcomes analysis. Following the full adjustment for significant covariates, % max iron 
absorption was significantly greater in Week 0 than Week 4 of the study (p = 0.02), but iAUC for 
serum iron was not statistically different from Week 0 to Week 4 (5019 ± 358.8 µg/dL*hr and 
4793 ± 345.4 µg/dL*hr, respectively; p = 0.32, Table 6-4). There were no significant differences 
between Week 0 and Week 4 % max iron absorption, hemoglobin, or serum ferritin after 
adjusted outcomes analysis (Table 6-4).  
 
 Correlations between salivary protein subtypes, iron absorption, and dietary phytic 
acid intake 
 
Week 0 % max iron absorption was not significantly correlated with acidic proline-rich protein 
(aPRP) and glycosylated proline-rich protein (gPRP) production (r = 0.535 and 0.48, 
respectively, ps > 0.22), while Week 4 absorption was significantly correlated with basic proline-
rich protein (bPRP) production (r = 0.819; p = 0.02, Table 6-5). Cystatin production was not 
significantly correlated at Week 0 (r = 0.525; p = 0.227) or Week 4 (r = 0.269; p = 0.56, Table 6-
5). Statherin was not-significantly correlated with % max iron absorption at Week 0 and Week 4. 
Dietary phytic acid intake was significantly correlated with bPRP (r = 0.89, p = 0.007), and 
cystatin (r = 0.79, p = 0.03) production at Week 0, and was not significantly correlated with % 
max iron absorption (r = 0.71, p = 0.11) or iAUC for serum iron (r = 0.77, p = 0.07) at Week 0.  
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 Astringency testing  
There were no significant differences in any astringency ratings from Week 0 to Week 4 of the 
study (ps > 0.18). At Week 0, there was a significant positive correlation between the 0.07 mg/dl 
(middle) astringency rating and iron bioavailability among participants (r = 0.996, p < 0.001, 
Table 6-6). Correlations at higher ratings of astringency were not significant. At Week 4, higher 
ratings of astringency perception with phytic acid consumption were significantly negatively 
correlated with iron absorption in all but the lowest concentration of alum powder, suggesting 
that lower ratings of astringency were associated with better iron absorption (Table 6-6).  
 Phase III: ELISA confirmation of purified protein peak findings and participant 
cystatin SN concentrations  
 Confirmation of cystatin SN-phytic acid interactions 
To confirm cystatin SN-phytic acid interaction, HPLC fractions for control and in vitro phytic 
acid purified protein saliva samples collected at 40.3 minutes were assessed using a cystatin SN 
ELISA. Total cystatin in the control was 132 ng; 8 ng was recovered in the same fraction from 
0.000512 mg/mL in vitro phytic acid interaction, suggesting that: 1) cystatin SN was the protein 
identified on HPLC and MALDI, and 2) that phytic acid interaction with saliva reduced cystatin 
SN in purified peak levels.  
 ELISA analysis of post-meal participant cystatin SN levels  
Post-meal participant cystatin SN levels were significantly reduced after in vitro interaction with 
phytic acid (p < 0.001), confirming purified protein ELISA results that cystatin SN was 
precipitated from saliva with phytic acid (Figure 6-6). Cystatin SN salivary concentration did 
not increase 15 minutes after meal consumption at Week 0 (R2 = 0.89, 95% CI [-0.55, 2.01], p = 
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0.23) and Week 4 (R2 = 2.14, 95% CI [-0.48, 2.10], p = 0.19) in all measured participants. In 
participant salivary samples, fasting cystatin SN concentrations did not change with long-term 
phytic acid consumption (R2 = -0.14, 95% CI: [-1.39, 1.09]), however, there was a non-
significant increase in cystatin SN at Week 4 (effect size 0.24, 95% CI [-1.08, 1.40]). From 
HPLC results, cystatin SN production at Week 0 was negatively correlated with iron absorption 
(r = -0.977, p = 0.006), but was positively correlated with iron absorption from Week 0 to Week 
4 (r = 0.996, p < 0.001).  
 Astringency ratings and cystatin SN levels 
Cystatin SN levels were significantly negatively correlated with astringency ratings (r = -0.82, p 
= 0.046). There was no correlation between cystatin SN and bPRP at Week 0 among participants 
(r = -0.10; p = 0.86), but a positive correlation at Week 4 (r = 0.56, p = 0.07, Figure 6-7). 
 Discussion 
The primary objectives of this study were to determine: 1) whether salivary proteins 
would interact with phytic acid in vitro 2) whether iron bioavailability, or markers or iron status 
would be affected with repeated phytic acid consumption, 3) whether there would be changes in 
salivary protein production with phytic acid consumption over time, and 4) whether salivary 
proteins could be associated with improved iron bioavailability during supplementation periods. 
Post hoc study objectives included determining whether cystatin SN could be correlated with 
improvements in iron bioavailability during the clinical study duration. 
 Phase I: In vitro phytic acid saliva analysis 
The experimental hypothesis in phase I of this study was that salivary PRPs would bind 
to phytic acid salts in vitro. To the best of our knowledge, this is the first study that has explored 
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the effects of phytic acid supplementation on salivary proteins. This hypothesis was supported in 
that PRPs did not bind to phytic acid, instead, phytic acid formed complexes with another non-
enzymatic salivary protein, cystatin SN. This finding was supported through tryptic and phytase 
digestion of phytate-saliva pellets formed after interaction, and co-analysis with supernatant 
fractions of whole and phytic-acid treated saliva. ELISA confirmation of cystatin SN in purified 
peak fractions and human participant saliva interacted in vitro with phytic acid suggests that this 
binding is consistent in a variety of participants. 
The findings that PRPs do not bind to phytic acid is an important one. Tannin-PRP 
binding is specific 24, and bonds may not dissociate during digestion 19. Because PRPs do not 
bind with phytic acid in addition to tannins, PRP mediated protection against tannin-iron 
chelation may be viable in phytic acid and tannin-rich foods. 
   Unlike other cystatin proteins, cystatin SN is only found in saliva. Its primary purpose is 
inhibition of cysteine proteolysis, but has been shown to be associated with enhanced tolerance 
of bitterness in infants and caffeine consumers 40,41, which is consistent with our findings that 
higher levels of cystatin SN were significantly correlated with lower ratings of astringency. In 
addition, induction of S-type cystatins with capscasin ingestion was found in rats, suggesting that 
these proteins may be stimulated with non-proteolytic oral irritants 42 like phytic acid.  
 Phase II: Clinical study arm 
 Hematological outcomes 
The first hypothesis for the clinical arm was that repeated phytic acid consumption would not 
change iron bioavailability, hemoglobin, or ferritin values in participants over four weeks. 
Although Week 0 % max iron absorption was significantly greater than Week 4 in the covariate 
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adjusted model (Table 6-4), phytic acid supplementation did not change iron absorption, 
hemoglobin, or ferritin when consumed three times daily for a month in other outcomes both 
adjusted and unadjusted for covariates (Tables 6-3, 6-4). Interestingly, while %max iron 
absorption was adjusted for several dietary and non-dietary factors (Table 6-4), it was not 
adjusted for hemoglobin, which may explain predicted iron absorption differences from 
incremental AUC for serum iron (Table 6-4). Overall, these findings are in contrast to a similar 
study that found improvement in bioavailability of a high phytate meal after consuming a phytate 
diet for 8 weeks 9. There is evidence that inulin improves iron bioavailability with phytic acid 
consumption over time 43, meaning that efficient adaptation may be due to combinations of 
homeostatic mechanisms, including changes in gut microbiota to resistant starch often found in 
phytate rich foods, rather than just with phytic acid alone. 
Contrary to findings in single meal 3-5, and in vitro Caco-2 44-46 models, we did not find 
that iron status, as indicated by ferritin or hemoglobin levels, was reduced with phytic acid 
supplementation over time. The current study findings are however, consistent with results from 
multiple rat studies 43,47-54. Findings from single meal studies, and Caco-2 cell models, may not 
predict adaptive mechanisms employed by certain populations to antinutritional factors like 
phytic acid over time 55. In support of this assertion, studies exploring long-term bioavailability 
in rat versus acute Caco-2 bioavailability, phytic acid inhibited iron bioavailability in in vitro, 
but not in vivo models 56,57. The Caco-2 cell model may not accurately simulate nuances of 
digestion and absorption, such as salivary protein profiles and their effect on antinutritional 
factors and absorption. 
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  Salivary protein production, correlations with iron bioavailability, and astringency 
The second hypotheses were that there would be no changes in salivary protein 
production with phytic acid consumption over time, and that salivary protein production would 
not be correlated with improved iron absorption with phytic acid supplementation. These 
hypotheses were partially rejected; there were no significant changes in salivary proteins over 
time, but while in vitro binding of PRPs with phytic acid did not occur, bPRP were significantly 
correlated with improved iron bioavailability at Week 4 (r = 0.819, p = 0.02). Interestingly, 
bPRP levels significantly correlated with dietary phytic acid intake at Week 0, suggesting that 
individuals commonly consuming phytic acid rich foods may produce more bPRP compared to 
those who do not. These findings may suggest that repeated phytic acid consumption triggers 
bPRP production.  
Perhaps supporting this idea, astringency ratings at Week 0 were positively correlated 
with iron bioavailability, while Week 4 astringency ratings were negatively correlated. A 
concurrent study from our lab group found that bPRP production is negatively correlated with 
astringency ratings as well, therefore these findings are consistent with previous bPRP-iron 
absorption correlations (unpublished data). Combined, these data suggest that in phytic acid 
naïve individuals, aPRP, gPRP, and total protein levels predict iron bioavailability in the short 
term, but that bPRP production better predicts iron bioavailability overall.  
 Part III: Cystatin SN and iron bioavailability 
The post hoc hypothesis was that cystatin SN would not change with phytic acid 
consumption over time, and that cystatin SN production would not be correlated with iron 
bioavailability from our clinical trial results. There were no significant differences in cystatin SN 
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production after daily phytic acid supplementation over four weeks. Regardless, Week 0 cystatin 
SN and iron absorption were negatively correlated (r = -0.97, p = 0.006). At Week 0, cystatin SN 
was not correlated with bPRP production, which suggests that cystatin SN may predict 
suboptimal iron bioavailability independent of bPRP production in non-regular phytic acid 
consumers. It is possible that production of cystatin SN, in lieu of other salivary proteins or 
protective mechanisms, is inefficient in protecting against phytic acid-iron chelation. Thus, 
elevated cystatin SN levels may be a marker of inefficient phytic acid protection. We found that 
tryptic digestion easily destroyed cystatin-phytic acid complexes, questioning stability during 
digestion, which would likely be poor. It is possible that cystatin SN does not trigger non-
salivary protective mechanisms to phytic acid as efficiently as other proteins. Higher levels of 
cystatin SN at Week 4 were positively correlated with bPRP production, which may explain the 
significant positive relationship between cystatin SN and iron bioavailability at Week 4. 
 Limitations   
This study was conducted in a small sample as an arm of another study. Due to the 
variability in iron absorption among participants, statistical power to detect significant findings 
was limited, including differences in cystatin SN from Week 0 to Week 4 of the study (effect 
size 0.24, 95% CI [-1.08, 1.40]). In addition, we used phytic acid, rather than food-source 
phytates for the model. There is evidence that tannic acid may bind to salivary PRPs differently 
than condensed proanthocyanidins found in food 55, and it is reasonable to believe that there may 
be different effects from phytates consumed in food compared to a highly ionized, liquid form. 
Additionally, compared to a similar clinical trial 9, our participants’ average Week 0 phytic acid 
consumption was higher (863 mg vs. 718 mg), more variable (199.8-2388 mg/day vs. 548-941 
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mg/day), and participant Week 4 consumption was greater (1913 vs. 1190 mg/day), which may 
have affected bioavailability over time. Our study only lasted four weeks, and although we 
anticipated that hemoglobin and ferritin would be impacted within this time frame, other studies 
have used longer supplementation periods that have produced significantly improved iron 
absorption from study start to end 9. It may be that long-term phytic acid supplementation 
induces non-salivary mechanisms not assessed with our study. It is also important to note that 
while concentrations of cystatin SN did not change through the study, lack of measurement of 
salivary flow rate is a limitation in protein production quantification. Our study used a pre-
determined 2 mL salivary sample (which was obtained over varying time spans), and thus 
participants with higher or lower salivary flow rates may have had different total cystatin 
production. 
Lastly, the current study was conducted in iron sufficient, pre-menopausal women, with a 
nutrient replete and varied diet. In Malawain children, a high-phytate diet resulted in increased 
zinc excretion in sick, but not well children, highlighting the complexity of metabolism 
potentially based on inflammatory status 58. Findings should be investigated in other populations 
of interest including children 40 and pregnant women 59, who have different salivary protein 
profiles than the current study population.   
 Future research  
Future studies are needed to determine effects of salivary proteins on phytic acid 
mediated reductions in iron bioavailability. In addition, more studies are needed to explore the 
non-chelating protective effects of bPRPs on iron bioavailability, and the potential effects of 
cystatins throughout the GI tract including potential interactions between salivary proteins and 
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microbiota. Studies exploring consumption of foods with multiple antinutritional factors are 
needed to understand the interactions between compounds commonly co-consumed and salivary 
profiles, including secondary effects from salivary proteins on enterocyte mediated iron 
bioavailability. Finally, further research is needed to determine the effects of developmental and 
hormonal changes on salivary protective mechanisms on antinutritional factors and iron 
absorption.  
 Conclusions  
To the best of our knowledge, this is the first time that salivary-phytic acid interactions 
have been investigated. Phytic acid does not specifically bind with PRPs, but does bind with 
cystatin SN, a non-proline-rich salivary protein. Iron bioavailability nor status were significantly 
affected with long term phytic acid consumption. Cystatin SN levels were significantly 
negatively correlated with iron absorption over time, suggesting that this protein may be an 
inefficient protein for protection against phytic acid, and production may identify individuals 
who do not adapt to phytic acid. Production of bPRP production positively influenced iron 
absorption with phytic acid consumption. Overall, these findings indicate that repeated phytic 
acid consumption may not negatively influence iron bioavailability and status, and that salivary 
proteins may help to protect against negative effects from phytic acid consumption.   
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 Tables 
Table 6-1: Participant macronutrient, select micronutrient, proanthocyanidin, and phytic 
acid intake during the study duration 
Outcome Totals 
 Mean ± SD 
N 7 
Caloric intake (kcal/day) 2107.7 ± 672.8 
Protein (g/day) 72.4 ± 15.6 
Fat (g/day) 82.2 ± 28.6 
Carbohydrates (g/day) 279.2 ± 109.0 
Meat (oz/day) 3 ± 1.8 
Sugar (g/day) 132.2 ± 88.4 
Fiber (g/day) 24.7 ± 13 
Iron (mg/day) 16.8 ± 7.1 
Ascorbic acid (mg/day) 69.5 ± 54.2 
Zinc (mg/day) 11.3 ± 3.2 
Copper (mg/day) 1.5 ± 0.66 
Total proanthocyanidin 
intake (mg/day) 
89.1 ± 45.5 
Total phytic acid intake 
(mg/day) 
863.8 ± 812.8 
SD:  standard deviation 
 
  
Table 6-2: Week 0 and Week 4 iron bioavailability, status, and inflammatory indicators 
 Week 0 Week 4 
 
Mean 
(95% CI) 
Mean 
(95% CI) 
% Max iron absorption 
12.8 
(-9.1, 34.1) 
8.3 
(-15.1-31.4) 
iAUC (µg/dL*hr) 2027 1525  
Hemoglobin (g/dl) 
13.7 
(13.4, 13.9) 
13.4 
(13.1, 13.6) 
Ferritin (ng/mL) 
48.9 
(40.1, 57.6) 
45.6 
(36.8, 54.3) 
CRP (mg/dL) 
0.21 
(-0.1, 0.49) 
0.20 
(-0.5, 0.94) 
iAUC: incremental area under the curve for serum iron. CRP: C-reactive protein 
No significant differences between Week 0 and Week 4 (p < 0.05) 
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Table 6-3: Hemoglobin, ferritin, % max iron absorption, iAUC for individual participants 
at Week 0 and Week 4 
 
Value 
  
 Week 0 Week 4 
 Hemoglobin (g/dL) 14.6 13.9 
 Ferritin (ng/mL) 53.0 46.0 
1 % max iron -25.8 0.0 
 iAUC (µg/dL*hr) -4845 -90 
 Hemoglobin (g/dL) 14.2 13.4 
2 Ferritin (ng/mL) 12.0 11.0 
 % max iron 19.1 16.0 
 iAUC (µg/dL*hr) 4725 4995 
 Hemoglobin (g/dL) 12.1 12.3 
3 Ferritin (ng/mL) 22.0 24.0 
 % max iron 4.2 -7.4 
 iAUC (µg/dL*hr) 510 -207 
 Hemoglobin (g/dL) 13.5 13.2 
4 Ferritin (ng/mL) 23.0 23.0 
 % max iron 28.4 30.3 
 iAUC (µg/dL*hr) 5325 4935 
 Hemoglobin (g/dL) 14.5 14.9 
5 Ferritin (ng/mL) 67.0 86.0 
 % max iron  not obtained* not obtained* 
 iAUC (µg/dL*hr) not obtained* not obtained* 
 Hemoglobin (g/dL) 13.3 12.6 
6 Ferritin (ng/mL) 28.0 43 
 % max iron 26.1 33.7 
 iAUC (µg/dL*hr) 4365 7530 
 Hemoglobin (g/dL) 13.4 13.3 
7 Ferritin (ng/mL) 137.0 86 
 % max iron 22.9 -22.9 
 iAUC (µg/dL*hr) 2085 -8101 
*Blood draws obtained at 180 and 210 minutes were severely lysed at Week 4 in this participant 
iAUC: incremental area under the curve for serum iron 
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Table 6-4: Covariate adjusted estimation of iron bioavailability and status due to phytic 
acid supplementation  
% max iron 
absorption 
 B SE B β t p 
Model   156.1 <0.0001 
Constant -95.3 3.82  0 -24.96 <0.0001 
Week 0  4.59 1.4  0.11  3.31  0.02 
Fat intake  0.68 0.04  1.2  19.04 <0.0001 
Trimer PA -2.95 0.20 -0.99 -14.59  0.023 
0.07 astringency  36.72 1.93  0.78  18.94 <0.0001 
aPRP -46.97 4.84 -0.53 -9.71  0.0002 
Cystatin  0.0005 0.0001  0.25  5.00  0.004 
AUC serum 
iron µg/dL*hr 
Model   10.4  0.0028 
Constant  815.0 583.4  0  1.4  0.196 
Week 0 -68.12 64.2 -0.18 -1.1  0.32 
Hemoglobin -60.6 44.9 -0.23 -1.35  0.58 
Monomer PA  16.35 3.1  0.88  5.35  0.0005 
Hemoglobin 
(g/dL) 
Model   5.95  0.016 
Constant  16.2 0.93  0  17.41 <0.0001 
Week 0  0.11 0.30  0.05  0.37  0.72 
0.2 astringency -0.63 0.21 -0.56 -3.01  0.017 
bPRP  0.56 0.56  0.18  1.34  0.22 
CRP -1.58 0.65 -0.50 -2.45  0.040 
Ferritin 
(ng/dL) 
Model   22.3  0.0002 
Constant 97.7 27.1  0  2.49  0.037 
Week 0 -5.09 6.91 -0.07 -0.74  0.48 
CRP -66.3 14.79 -0.46 -4.48  0.002 
Kcal -0.02 0.004 -0.42 -3.68  0.006 
Protein -0.93 0.18 -0.50 -3.77  0.006 
Total PRP 174.02 35.2  0.34  2.67  0.028 
Significance: p < 0.05 SE: standard error; CRP: C-reactive protein; PRP: proline-rich protein; 
AUC: area under the curve; aPRP: acidic proline-rich protein; bPRP: basic proline-rich protein 
PA: proanthocyanidin; Kcal: kilocalorie 
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Table 6-5: Correlations between proteins and iron bioavailability at Week 0 and Week 4 of 
phytic acid supplementation 
Phase 
Week 0/ 
Week 4 
N  bPRP aPRP gPRP statherin cystatin total 
    
r 
p 
r 
p 
r 
p 
r 
p 
r 
p 
r 
p 
phytate 
Week 0 
Week 4 
7 
% max iron 
0.334 
(0.464) 
0.525 
(0.227) 
0.48 
(0.276) 
0.246 
(0.594) 
0.525 
(0.227) 
0.537 
(0.214) 
%max iron 
 
0.819* 
(0.02) 
0.032 
(0.946) 
0.295 
(0.52) 
0.547 
(0.204) 
0.269 
(0.56) 
0.356 
(0.434) 
*p < 0.05; bPRP: basic proline-rich protein, aPRP: acidic proline-rich protein; gPRP: 
glycosylated proline-rich protein 
 
Table 6-6: Correlations between astringency and iron absorption (1 = not astringent, 5 = 
extremely astringent) 
Dose (95% CI) 
Week 0 Week 4 
Mean (95% CI) 
r 
Mean (95% CI) 
r 
0.03 mg/dL 
1 (0.7, 1.3) 1 (0.7, 1.4) 
0.0 0.0 
0.07 mg/dL 
2 (1.6, 2.4) 1.8 (1.3, 2.3) 
0.996* -0.959* 
1.5 mg/dL 
2.9 (2.3, 3.4) 3.0 (2.3, 3.7) 
0.492 -0.84* 
2.5 mg/dL 
4 (3.4, 4.6) 4.2 (3.5, 4.9) 
0.553 -0.768* 
Dose: astringency concentration testing at Weeks 0 and 4 of phytic acid supplementation. 
*Denotes significant correlation, p < 0.05 
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 Figures  
Figure 6-1: Study procedures 
 
Week 0 and Week 4 meal challenges were employed to assess iron bioavailability and salivary 
protein changes before and after phytic acid supplementation period (four weeks). At midpoint, 
participants recorded three 24-hour dietary recalls.  
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Figure 6-2: In vitro phytic acid- salivary interactions  
 
Progressive peak reductions were seen at 40.3 minutes with phytic acid concentration interaction 
independent of other peak reductions. At physiological doses (equivalent to phytic acid 
supplement in clinical study), there was total peak loss at 40.3 minutes. 
  
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 min
-500
-250
0
250
500
750
1000
1250
1500
1750
2000
2250
2500
2750
3000
3250
3500
mAU
min 
m
A
u 
3500 
2800 
2100 
1400 
700 
0 
5 10 15 20 25 30 35 40 45 
40.3 
Control 
0.00013 mg/mL 
0.00026 mg/mL 
0.000512 mg/mL (physiological) 
250 
 
 
 
 
Figure 6-3: MALDI-TOF whole saliva and phytic acid interacted salivary supernatant 
protein peaks 
 
Control saliva at 40.3 minutes and saliva fraction at 40.3 minutes after addition of 0.0128 mg/mL 
phytic acid. Noted peak losses at 13000-14000 kDA.  
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Figure 6-4: MALDI-TOF whole saliva, phytic acid interacted supernatant purified protein 
peak, and pytate pellet digest 
 
* mAu is correlated with signal strength, rather than concentration with MALDI-TOF analysis. 
Salivary pellet trypsin digest and purified peak MALDI-TOF results: From purified peak 
collected at 40.3 minutes, there is peak loss seen in phytic acid (B) compared to control (A) 
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samples that is also found in phytic acid-saliva samples subjected to tryptic digestion (C-D). This 
peak was also not found in the pellet sample acidified with TFA (E), suggesting selectivity of 
phytic acid to this protein. 
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Figure 6-5: Iron bioavailability at Week 0 and Week 4 phytic acid postabsorptive meal 
challenges 
 
 
 Unadjusted (black) and adjusted (red) iron absorption at Week 0 and Week 4 of 
supplementation. There was a significant reduction in covariate-adjusted iron absorption from 
Week 0 to Week 4 (p = 0.02). There were no significant differences in % max iron absorption 
from Week 0 to Week 4 in unadjusted (p = 0.22) models. 
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Figure 6-6: Cystatin SN before and after phytic acid meal challenges at Weeks 0 and 4 
 
Cystatin SN ELISA results. Phytic acid in vitro interaction with saliva significantly reduced 
cystatin SN concentrations from saliva supernatant. There were no significant changes in cystatin 
SN production before (R2 = -0.14, 95% CI: [-1.39, 1.09]), or after (R2 = 0.24, 95% CI [-1.08, 
1.40]) meals from Week 0 to Week 4.  
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Figure 6-7: Comparison of Week 4 bPRP and cystain SN quantities for individual 
participants 
 
Week 4 bPRP and cystatin SN for each participant. There is a positive (r = 0.56, p = 0.07) 
between Week 4 bPRP and cystatin SN levels.  
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Chapter 7 - CONCLUSION 
 Summary 
 Improving fortified-blended foods through nutritional formulation: 
 In vivo model findings 
In vitro FBF quality evaluation was designed to look closely at nutritional aspects of FBF 
blends, rather than for the potential nutritional effects during childhood complementary feeding. 
This controlled animal model allowed us to see FBF nutritional qualities that might otherwise 
have been muted by dietary variety or socioeconomic factors that contribute to nutritional status. 
Our findings supported that animal growth (as a surrogate for protein quality), vitamin A, and 
iron outcomes were similar between newly formulated FBFs. In CSB+, a roasted corn soy blend, 
protein quality was notably reduced compared to extruded, protein quality enhanced and oil 
fortified blends. Specific aspects leading to protein quality improvement, including pre-cooking 
in extrusion, oil fortification, and protein isolates, have not been explored. Nevertheless, blend 
reformulation improved protein outcomes, regardless of commodity used, suggesting that 
formulation, rather than specific legumes or grains was necessary.  These protein and 
micronutrient related outcomes may suggest that a variety of ‘low quality’ legumes or grains 
may be used as nutritious food sources when nutritional quality factors are accounted for in FBFs 
formulations. 
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 Limitations and future directions  
While using a rat model enabled new FBF evaluation in a controlled environment, several 
factors in the study design limit generalizability of results presented, especially in regards to 
protein quality and iron availability. Blends contained more iron than was necessary for growing 
rodents (nearly double AIN-93-G), making it is difficult to predict iron bioavailability for anemic 
children who could conceivably require more relative iron in their diets compared to rats from 
these findings. In addition, differences in protein quality due to extrusion versus roasting (in the 
case of CSB+) were not reflective of cooked FBFs, where CSB+ might be more fully ‘cooked.’ 
As noted above, it may be that protein availability changes with complete FBF cooking. Future 
directions for FBF evaluation could include using a rodent model where higher iron demand is 
present (perhaps with restricted intake), or a study design framed toward iron repletion with 
FBFs used in this work, could delineate FBF differences that could be important in the field. 
Beyond micronutrient availability, differences in plant and animal protein quality need to be 
further assessed, especially given the cost of animal protein and conflicting evidence regarding 
long-term effects of animal protein consumption on healthy weight and treatment of protein 
insufficiency.   
 Effects of tannins and phytates on iron bioavailability and status: 
Concerns regarding the influence of antinutritional factors over protein quality and 
micronutrient availability from grain and legume based diets have been limiting factors in the use 
of sorghum and like grains for FBF formulation, despite in-country benefits (including local and 
regional procurement), and potential health benefits of tannins and phytic acid. A narrative 
literature review conducted as a part of this discussion suggests that limitations in current 
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research exploring these issues include the use of single meal studies, the fact that a majority of 
evidence comes from in vitro experiments, and the use of models with non-typically consumed 
tannin and phytate supplements that may not represent human metabolism found in grain and 
legume based diets. A systematic literature review as a part of this dissertation suggests that iron 
bioavailability adaptation to tannins is possible through production of salivary proline-rich 
proteins. This analysis considered factors involved in iron bioavailability like tannin size, 
nutrient digestion, and PRP production changes after tannin consumption. Several rat 
experiments included in this systematic review suggest that PRP production improved iron 
bioavailability after long-term tannin consumption, suggesting adaptation. Through use of multi-
dose, long term supplements in a clinical trial, we approximated tannin and phytic acid 
supplemental influence on iron bioavailability over time. 
 Tannins 
We assessed the influence of food-tannin (proanthocyanidin, condensed tannin) 
supplementation on iron bioavailability with normal dietary intake in adult women. Multi-
concentration condensed tannin supplements did not change iron bioavailability or status with 
multi-meal supplementation over 4-week time periods in non-anemic adult women. In addition, 
basic salivary proline-rich proteins (bPRP) were positively correlated with iron bioavailability 
during tannin supplementation over time, consistent with hypothesized findings. Iron 
bioavailability and bPRP correlations increased from Week 0 to Week 4, suggesting that these 
proteins may be upregulated over time to improve iron bioavailability with tannin consumption.  
 Phytates 
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Overall, phytic acid consumption did not change iron bioavailability or status after a four-
week supplementation period. Unlike tannin research, phytic acid intake has been previously 
explored in multi-meal studies, but salivary protein-phytic acid interaction has not. In vitro 
modeling suggests that phytic acid does not bind with salivary proline-rich proteins, but does 
bind specifically with cystatin SN, a cysteine protease-inhibitor. Correlations from ELISA 
analyses and clinical trial iron bioavailability testing suggests that cystatin SN was negatively, 
but bPRP were positively, correlated with iron bioavailability after the supplementation period. 
This is the first time that salivary protein influence on iron bioavailability with phytic acid 
consumption has been explored.  
 Findings Synthesis and Limitations 
The preceding research studies suggest that neither tannin or phytic acid consumption 
influences iron status in healthy non-anemic women over time, even at concentrations more than 
double normal dietary intake. This research also suggests that certain salivary protein subtypes 
may improve iron bioavailability with chronic tannin or phytic acid consumption. Given that 
salivary protein production is genetically variable, and age-related, exploration of salivary 
protein production over the lifespan, and in anemic and non-anemic individuals, may lead to 
understanding of individualized nutritional outcomes. Understanding age and disease-related 
differences that contribute to tannin and phytic acid adaptation could better direct nutritional 
approaches to undernutrition including improved FBF formulation for complementary feeding, 
breastfeeding, or during pregnancy. Mechanisms outside of direct protein-tannin or protein-
phytate chelation could help with understanding correlations between bPRP production and iron 
bioavailability with phytic acid challenges presented in study #5, since phytates did not bind with 
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PRPs in vitro. Future studies could include iron bioavailability assessment after dietary 
challenges with tannin and phytate rich meals, and possibly an analysis of the influence of fiber 
on tannin and phytate antinutritional effects. Targeting a cohort of healthy and anemic 
participants could help to identify individuals with different salivary or gut anatomy that may 
inhibit adaptation. Studies employing food tannin and phytate-rich foods both in and out of the 
diet may reinforce findings from this research. Understanding factors that affect iron 
bioavailability throughout the lifespan may elucidate differences in childhood and adult 
metabolic effects from tannins and phytates. Finally, one could envision  studies exploring oral 
and gut isolated tannin or phytic acid meal challenges that could elucidate the direct impact of 
oral antinutritional exposure on iron absorption.  
 Future directions and development 
 Approaches to food aid formulation 
While biases of the scientific community toward effectiveness of models or ideas in 
nutrition abound, this body of work illustrates the effectiveness of using multiple models to 
describe phenomena through nutritional research. Complexities in nutrition and metabolism, 
including nutrient interactions related to formulation, the human system, environmental, and 
social factors, necessitate a variety of research methods to describe and understand multifactorial 
issues encountered, for example, in effective food aid formulation. Developing food aid, and 
perhaps understanding nutrition in general, benefits from understanding nuances in the models 
for research that are employed to describe phenomena. Regarding the present work, nutritional 
quality of blends themselves, outcomes in field trial consumption, and clinical studies exploring 
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nuances of formulation describe a holistic picture of what ‘nutrition’ means outside of any single 
study alone.  
 Considering individual approaches to antinutritional factor mediated reductions in 
iron bioavailability 
Understanding nuances from multiple model approaches to nutritional questions lends 
itself to moving forward into approaches favoring individualized or population specific nutrition. 
While our studies suggested that antinutritional factor intake influenced outcomes related to iron 
bioavailability; salivary proteins, for example, are also influenced genetically. Designing 
experiments that comprehensively look at the different factors in understanding antinutritional 
factors, salivary proteins, iron bioavailability genetics, epigenetics, and population differences 
will give context to the work found in models employed here. One could envision research 
approaches that would eventually explore interplay behind these factors, leading to a more 
comprehensive metabolic picture that could be employed in clinical and global undernutrition 
diagnostic and treatment modalities. Ultimately, targeted nutrition approaches may more 
effectively combat slowly improving issues, like iron deficiency, as compared to generalized 
knowledge. 
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Appendix A - Quality Assessment of Studies 
(Each criterion assessed as having high, unclear, or low risk) 
1.) Is there a clear purpose for study aims and research? 
2.) Is there relevant background information presented? 
3.) Methods assessment:  
a. Are methods employed appropriate? 
b. Were methods completely described or referenced? 
i. Studies described methods for allocation of samples or groups to 
treatments, if applicable 
1. Appropriate sample size or sample size justification 
 
ii. Are instruments used for data collection appropriate for outcomes 
assessed? 
iii. Methods allowed for randomization of study groups to minimize outcomes 
bias, if applicable 
c. Was the intervention independent of other changes (minimization or accounting 
of confounding variables)? 
4.) Outcomes measurement 
a. Were all outcomes measured reported? 
b. Completeness of outcome data:  
i. Are data presented clearly related to methodological design? 
ii. Did studies, if applicable, account for attrition or negative outcomes to 
intervention or control groups? 
iii. Is analysis of data reported, and appropriate for study design? 
iv. Are data transformations accounted for? 
5.)  Conclusions:  
a. Do conclusions and discussion match findings presented? 
b. Do findings contribute to current theory or future practice research? 
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Appendix B - Biochemical Study Characteristics 
Biochemical study Characteristics (references from Chapter 4) 
Study Topic 
Tannin-non-
heme iron 
binding (x) 
or tannin-
PRP binding 
(o) 
Tannic acid 
- 
Proanthocya
nidin 
comparison 
Tannins 
used 
Size of 
tannins 
compared 
Measureme
nt of 
mechanism 
Conditions 
for assay 
Findings 
(77) 
Effect of AA 
or EDTA on 
polyphenol 
non-heme iron 
binding 
x X 
tannic acid, 
gallic acid, 
catechin, 
coffee, tea 
monomers 
catechol/gallo
yl equivalent 
measurement 
of non-heme 
iron binding 
capacity 
900 µg/ml 
polyphenol 
bound less 
non-heme iron 
than at 40 
µg/ml (<50% 
vs. 100%); 
tannic acid 
more 
predilection to 
non-heme iron 
binding ability 
vs. gallic acid 
or catechin 
(51) 
IB-8c (basic 
PRP) and 
GSE 
interactions 
influenced 
by 
polysacchari
des in wine 
o  
proanthocya
nidins 
procyanidin 
tetramers, 
pentamers, 
gallate 
dynamic 
light 
scattering 
(amount of 
precipitation
) 
31.2 mg/L 
tannin: 0.6-
5mg/L IB8c 
and 
3.12mg/L 
IB8c: 19.5-
46.8 mg/L 
tannin; pH 
5.0, 12% 
ethanol, 20C 
20.8 uM 
needed for 
precipitation 
of PRPs. 
Plateau of 
PRP binding 
at 3.12 mg/L 
(tannin/IB8c 
molar ratio 
is 35); this 
means that 
at a given 
concentratio
n of tannin, 
PRP are 
bound to a 
maxima 
(multiple 
PRP per 
tannin) and 
then 
decrease at a 
certain 
concentratio
n- diffuse). 
At a higher 
tannin to 
protein 
ratio, there 
is also a 
plateau of 
precipitation
. At 
increasing 
ionic 
concentratio
ns, 
precipitation 
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increases; 
explained by 
increasing 
hydrophobic
ity 
(polyphenol 
rings stack) 
(54) 
Affinity of 
GSE twoard 
PRP in 
whole saliva 
o  
proanthocya
nidins 
dimers, 
trimer,tetra
mer 
(average 
polymerizati
on 3.2; mW 
936) 
HPLC, 
SDS-PAGE, 
tryptic 
digestion, 
Mass spec 
and top 
down 
analysis/MA
LDI-TOF 
pH 5.0, 20C, 
12% 
ethanol/saliv
a (0.00-1.5 
mM GSE in 
saliva) 
histatin, 
statherin, 
aPRP first 
bind, then 
bPRP and 
gPRP at 
higher 
concentratio
ns (min @ 
1.25) 
(55) 
binding 
affinity of 
different 
PRP to 
hydrolyzabl
e vs. 
condensed 
tannins 
o x 
Quebracho 
tannin vs. 
tannic acid 
not noted 
competitive 
binding 
assay at 
different 
concentratio
ns of tannin 
pH 7.4, 10 
µg protein 
and tannin, 
37C. 
Stability 
testing in 
HCL with or 
without 
pepsin for 
210 
minutes; 7.4 
c/trypsin/ch
ymotrypsin/
carboxypept
idase 
Plateau of 
precipitation 
at2- 3 µg of 
condensed 
tannin/tanni
c acid: more 
bound 
condensed 
tannin vs. 
tannic acid 
(40 µg 
/assay vs. 30 
µg /assay. 
No 
glycosylated 
binding of 
condensed 
PRP, some 
of tannic 
acid, most 
binding to 
BPRP. At 
pH 2.0, 93% 
of 
complexes 
were 
insoluble 
(condensed 
tannin) vs. 
71% 
hydrolyzabl
e; small 
intestine c 
enzymes 
72% 
insoluble vs. 
53% 
hydrolyzabl
e 
(67) 
comparison 
of 
bioavailabili
ty of tannins 
with and 
without PRP 
o  tannic acid 
tri, tetra, 
pentagalloyl 
glucose 
Caco-2 cell 
transport 
with/without 
PRP 
presence 
5-90 uM 
5GG 
concentratio
n 
Increased 
concentratio
n of 5GG 
decreased 
absorption, 
addition of 
Ib4 to 
fraction 
decreased 
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absorption 
8-9 fold 
(90uM 
5GG). 
Precipitation 
of 5GG 
4.5:10  
5GG:IB4 
(56) 
concentratio
n effects on 
binding; 
stereochemi
stry effects 
o x 
epigallocate
chin, gallic 
acid, 5GG 
pentagalloyl 
glucose, 
monomers 
tannin 
protein 
binding 
competition 
assay 
PRP isolated 
from whole 
saliva as 0.1 
µg/ml 
solution of 
saliva or 
with buffer 
(pH 9.6) 
with varying 
concentratio
ns for 5-20 
min. 
higher 
proline 
content to 
bPRP and 
gPRP (0.11-
1.22 µM 
displacemen
t constants- 
which 
means that 
there was 
not much 
required to 
bind; vs. 
0.54 um 
lowest in 
bacon and 
Rhodes 
1998; in 
proanthocya
nidin 
monomers 
to 350 µM 
for highest- 
hydrolyzabl
e are low); 
galloylation 
decreases 
displacemen
t constants 
(46) 
dimer (B2)  
vs. 
pentagalloyl
glucose vs. 
trigalloylglu
cose vs. 
proanthocya
nidin 
monomer 
vs. 
epicatechin 
vs. propyl 
gallate 
o x see topic see topic NMR 
40 mM B2, 
50 mM 
PGG/epicate
chin: 0.5ml 
4mM PRP 
or 2mM 
PRP pH 3.8 
N terminal 
proline 
shifts this is 
calculated 
by chemical 
shifts 
(binding site 
for tannin); 
the 
hydrolyzabl
e tannins 
had H 
bonding 
(protons in 
tannins 
bound to 
protons of 
PRPs); not 
true of 
condensed 
tannins 
(non-heme 
iron binding 
is 
protonated); 
Ka B2 = 
300/M vs. 
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PGG 241, 
TGG 28, 
epicatechin 
39; 
increased 
ring 
structure 
and size 
leads to 
cross linking 
of 
polyphenols 
bound to 
PRP; does 
not occur in 
hydrolyzabl
e tannins= 
also, larger 
size of 
polyphenol 
reduces N 
terminal 
sites that 
can bind on 
PRP but 
increase 
hydrophobic 
interactions 
(increasing 
precipitation
), and the 
proline 
residues at 
the N 
terminal 
then 
functions to 
not only 
bind galloyl 
group, but to 
allow for 
secondary 
interactions 
with other 
galloly 
functions. 
Predominant 
force for 
binding is 
hydrophobic
; essential 
polyphenol 
site for 
binding is a 
proline 
residue with 
an amide 
bond and 
amino acid 
residue; 
polyphenols 
form 
multidentate 
bonds: the 
TGG PGG 
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B2 
polyphenol 
curves 
showed that 
there is 
cooperative 
binding 
between 
aromatic 
functions on 
polyphenols 
and the 
neighboring 
polyphenol 
sites that are 
on the PRP 
peptides; 
noted that 
polyphenols 
start to self-
associate 
when 
bound: 
larger 
compounds 
more than  
smaller 
(47) 
B1, B3, C2 
procyanidin
s and PRPs 
to look at 
the process 
of binding 
o  
B1/B2 
dimers, C2 
trimer 
B1/B2 
dimers, C2 
trimer 
NMR 
pH 3.5; 0.5-
20mM PRP 
(exp 1) 
15.7mM 
tannin, 
1.7mM 
protein 
At below 
tannin 
concentratio
n 10 mM the 
interaction 
is specific, 
then second 
phase at 10 
mM there is 
a linear 
chemical 
shift with 
tannin 
addition 
(non-
specific 
interaction 
where 
tannins exist 
in 
aggregates); 
longer 
proteins are 
better, due 
to wrapping 
of the PRP 
around the 
tannin. 
Again, Kd 
C2 > B1 > 
B3. PRP 
IB9 binds to 
2-3 tannins 
each 
(68) 
types of 
tannins and 
the quality 
o x 
proanthocya
nidins 
dimers (B1-
9) and 
trimer C1, 
B2 3-O 
nephelometr
y 
(stereochem
istry)- 
12% ETOH, 
pH 5.0 or 
3.5; 760 µg 
procyanidin
Stabilization 
of 
precipitates 
at 40 
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of binding 
with PRPs 
gallate, 
epicatechin 
from GSE 
tannin 
specific 
activities 
(TSA), 
nephlos 
turbidity 
units (NTU) 
s, 48 µg 
PRP (15:1) 
minutes; 
stereo 
specificity 
mattered for 
binding: c6 
vs. c8 
binding; 
gallic acid 
esterificatio
n (Table 1: 
TSA) 
explored. 
NOTED 
THAT 
SMALL 
POLYPHE
NOLS 
BIND BUT 
DO NOT 
CROSSLIN
K; THAT 
THE 
PYRANIC 
RING 
STRUCTU
RE OF 
FLAVAN 3-
OL 
INCREASE
S ABILITY 
TO 
INTERACT 
WITH 
PROTEINS. 
BIGGER 
POLYMER
S BIND 
WITH 
MORE 
AFFINITY. 
ALSO, C8 
BONDS > 
AFFINITY 
THAN C6 
BONDS. 
(48) 
understandi
ng effect of 
gallolylation
, 
polymerizati
on, and B 
ring 
hydroxylatio
n on PRP 
binding 
o x 
EgC, ECG, 
B2, B2 3-O 
gallate 
dimers, 
monomers 
ESI-MS 
protein 
polyphenol 
1:10, 24C, 
pH 3.2 
Galloylation 
favors 
binding. 
Binding is 
specific to 
tannins (did 
not bind to 
compound 
similar in 
structure); 
binding in 
phases: 1) 
dissociation 
is minimal 
2) log-linear 
dissociation 
3) plateau 
(how strong 
is the bond): 
dimers > 
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monomers; 
OH group 
on the B 
ring = 
improved 
stability. 
Importance 
of features: 
B ring 
hydroxylate
d < 
galloylation 
< degree of 
polymerizati
on; 
procyanidin
s are mostly 
composed of 
epicatechin 
and catechin 
units 
(57) 
BPRP with 
various 
wavelengths 
against 
polyphenols 
o  
flavonoids, 
oligomeric 
flavan-3-ols 
flavonoids, 
oligomeric 
flavan-3-ols 
ESI-MS 
1:1 peptide 
polyphenol 
conditions 
(gas) 3:1 
peptide: 
polyphenol 
in 10% 
ETOH for 1 
hour 
C2 > B2 > 
quercetin > 
B1 > B4 > 
B3 > 
epicatechin 
> catechin; 
larger 
molecules 
display 
greater 
affinity; 
stereochemi
stry at C3 
makes a 
difference 
(epicatechin 
(2R, 
3R)/catechin 
(2R, 3S); 
dimers > 
monomers; 
C2 
stereochemi
stry matters 
(2R > 2S); 
OH groups 
on the B 
cycle > not 
hydroxylate
d; B cycle 
branching 
position (B 
cycle bound 
to 2C of 
flavonoid 
skeleton 
greatest); 
increased 
length of the 
PRP peptide 
increases 
binding; 
they 
hypothesize
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d that OH 
groups and 
stereochemi
stry of the 
OH groups 
promoted H 
bonding, 
increasing 
interaction 
with PRPs 
(65) 
influence of 
gastric 
digestion on 
PRP tannin 
complexes 
o  GSE 
catechins, 
gallic acid, 
procyanidin 
dimers, 
trimers, 
tetramers, 
pentamers, 
hexamers/ 
galloyl 
derivatives 
HPLC, in 
vitro 
digestion 
saliva: wine 
ratio of 2:1 
(well 
justified) pH 
3.5; pepsin c 
pH 1.7 for 2 
h 
Tannin/SP 
complexes 
that are 
monomers, 
dimers, 
trimers are 
disrupted by 
gastric 
digestion. 
Tetramers, 
pentamers 
are more 
resistant; 
statherin, 
aPRP bind 
more 
potently, 
then gPRP, 
then bPRP 
(49) 
influence of 
EgCG on 
IB5 
o  EgCG EgCG 
MS/ SAXS, 
DLS 
pH 5.5 ; 
protein = 
.336mM (1-
3.5 mg/ml), 
stimulated 
to mimic 
saliva 
Threshold 
concentratio
n of tannins, 
below this, 
the DLS 
intensities 
were the 
same as the 
pure protein 
solution; at 
threshold, 
there was an 
almost 
exponential 
increase in 
precipitation 
with 
increased 
concentratio
n. At a 
higher 
concentratio
n, it took 
much more 
EgCG to 
precipitate 
proteins; 
PRP can 
bind 1-8 
tannins 
depending 
on the 
concentratio
n, at higher 
concentratio
n of tannin, 
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1 PRP can 
bind up to 
14 tannin 
molecules 
meaning 
that the 'n' 
binding sites 
does not 
correlate to 
tannin 
binding at 
higher 
tannin 
concentratio
ns because 
the tannin 
'stacks'. E50 
K 1-8 are 
similarly 
stable, 
greater than 
this is a 
different 
interaction 
(tannin 
stacking- 
hypothesize
d by 
authors); 
binding sites 
are 
independent 
and have 
free energy; 
found that 
even when 
not 
precipitated, 
PRP were 
binding a 
significant 
amount of 
tannin (up to 
3 per 
molecule- 
could be 
why 
precipitate 
analysis 
does not 
show bPRP 
although 
these seem 
to bind more 
potently in 
other 
experiments
- not hitting 
threshold); 
at 
precipitation
, there is 
aggregation 
that may be 
attributed to 
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the 
multidendat
e nature of 
tannins 
(crosslinkin
g) that 
conserves 
PRP 
measures; 
the 
limitation in 
aggregation 
continuing 
are 'poison' 
PRP that do 
not carry 
enough 
tannins to 
continue 
aggregation 
(cannot 
crosslink); 
tannins 
move fairly 
easily on the 
PRP 
polypeptide 
chain, and 
thus will 
dissociate 
easily when 
population 
has not been 
met; in fact, 
at low ionic 
concentratio
ns, tannins 
and PRP 
repel each 
other 
(61) 
influence of 
pH on 
tannin 
salivary 
protein 
binding 
o x 
hydrolyzabl
e and 
condensed 
extracts, 
catechin, 
tartaric acid, 
gallic acid 
mixed in 
extracts, not 
specified 
diffusion 
precipitation 
interaction 
assay 
pH 3.5 vs. 
pH 7.0 
pH 3.5 
precipitates 
tannins > 
pH 7.0 
(53) 
influence of 
tannin 
binding on 
PRP 
conformatio
n 
o  EgCG EgCG 
mass 
spectrometr
y coupled 
with ion 
mobility 
IB5 and 
12% ETOH, 
pH 3.5; 
molar ratio 
of 1:20 
IB5:EgCG 
Poisson 
binding 
(continuous 
and 
independent 
binding in 
favor of 'non 
cooperative 
sticking 
process') 
binding 1-9 
tannins; at 
binding of 
1-7 tannins, 
IB5 
structure is 
stable (in its 
still 
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unstructured 
state) at 10 
ligands, a 
more 
compact 
conformatio
n is formed 
that is 
smaller than 
the 
unstructured 
protein; 
several 
tannins are 
required to 
stabilize the 
folded state. 
Folding is 
favored by 
H bonds 
between 
PRP and 
tannin OH 
groups on 
tannins that 
stack 
together 
(66) 
influence of 
polymerizati
on on 
precipitation 
(as a 
surrogate of 
affinity) 
o  GSE 
monomers, 
dimers, 
trimers 
HPLC DAD 
37C 
incubation, 
1,2,8 ml of 
saliva mixed 
with 40 ml 
GSE or 
20/40 ml 
GSE sipped 
increased 
tannin 
concentratio
n increased 
precipitation
; of LMW 
tannins, 
ECG 
precipitates 
effectively; 
at low-
EGCG -
protein 
ratios, 
binding is 
progressive 
in 
suspension 
without 
binding, at 
higher 
ratios, 
precipitates 
(4) 
glycosylatio
n and 
influence on 
tannin 
binding 
o  GSE 
monomers 
and 
galloylated 
units 
SDS-PAGE 
10% ETOH, 
20 µg 
purified 
protein or 
40 µl saliva, 
different 
concentratio
ns of tannins 
20.57% of 
GSE had 
galloylated 
units; 
compared 
astringency 
trained and 
untrained 
individuals: 
gPRP more 
prevalent in 
trained 
saliva; 30% 
of tannins 
were 
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precipitated 
by the 
astringency 
trained 
individual 
(most 
remained in 
supernatant)
, 85% in the 
astringency 
untrained 
(all 
precipitated)
; precipitate 
was dose 
dependent 
and 
selective; 
the 'nature 
of the saliva' 
significantly 
predicted 
the 
precipitation 
of tannins as 
well; 
polymerizati
on of 
tannins 
positively 
correlated 
with 
precipitation
; however, 
trained 
saliva was 
able to 
precipitate 
smaller 
polymers 
than the 
untrained 
despite 
similar 
AMOUNTs 
of protein in 
saliva; bPRP 
most 
commonly 
precipitated 
and the 
trained 
participant 
had higher 
quantity 
than the 
untrained; 
there were 
no proteins 
in the 
untrained 
supernatant; 
there were 
abundant 
glycosylated 
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PRP in the 
trained 
supernatant. 
PRP 
themselves 
(purified) 
are more 
effective at 
binding 
tannins than 
whole saliva 
however, 
PRP affinity 
greater than 
alpha 
amylase. At 
low tannin 
concentratio
n, all 
polymers 
were bound, 
at higher 
concentratio
n, selective 
to higher 
order 
polymers. 
Glycosylatio
n seems to 
stabilize the 
complex to 
tannin 
outside of 
precipitation
. At low 
tannin 
concentratio
n, 
glycosylatio
n may stay 
soluble by 
decreased 
hydrophobic
ity, while at 
higher 
concentratio
ns, 
hydrophobic
ity is 
reduced, and 
the complex 
precipitates. 
(42) 
interactions 
of IB5 with 
EGCG 
o  EgCG EgCG 
DLS, 
isothermal 
titration 
microcalori
metry, 
dichroism 
pH 3.5 ionic 
strength at 
100 mM 
(same as 
saliva mixed 
with wine) 
6.4 or 12.8 
mM EgCG 
solution 
with 0.25-2 
mg/ml IB5 
PRP are 
random and 
unfolded; At 
low protein 
concentratio
n, no 
aggregates 
occurred 
until a high 
tannin ratio 
then would 
slowly start. 
At a next 
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saturation, 
there was a 
rapid 
increase in 
aggregation 
and further 
increases in 
tannin led to 
immediate 
precipitation
. If the 
solution was 
started at 
very high 
tannin 
concentratio
n, 
immediate 
aggregation 
and 
precipitation
. At a lower 
tannin ratio 
(more 
protein), the 
precipitation 
occurred at 
a lower 
threshold. 3 
stages at 
low 
concentratio
n: 1) 
saturation of 
protein 
residues 
with tannin 
2) bridging 
of the 
proteins by 
tannin and 
hydrophobic 
stacking of 
tannins 3) 
aggregation 
and phase 
separation. 
Protein folds 
around the 
tannin and 
then later 
tannin 
bridges the 
condensed 
protein 
aggregates. 
(58) 
influence of 
tannin 
stereochemi
stry on PRP 
binding 
o  GSE 
monomer 
free; mostly 
catechin, 
epicatechin, 
epicatechin 
3-O-gallate 
ITC 
10% ETOH, 
40 µl saliva 
and different 
amounts of 
tannins 
Individual 
salivary 
profiles 
differed 
greatly 
throughout 
the day and 
by 
individual; 
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PRP came 
out of 
supernatant 
as tannin 
concentratio
n increased. 
Glycosylatio
n increased 
threshold for 
precipitation 
but did not 
impede 
affinity. 
Larger 
proanthyocy
anidins 
precipitate 
first, LMWP 
stayed in 
supernatant 
longer. 
(59) 
influence of 
glycoprotein 
on binding 
o  
sorghum 
and 
Quebracho 
multiple 
polymers of 
PACs 
 
pH 4.8, 
methanol, 
acetate 
buffer 
< binding to 
sorghum 
than 
Quebracho, 
deglycosylat
ed proteins 
with less 
affinity 
suggesting 
that is 
important; 
glycosylatio
n increased 
solubility 
(increased 
tannin 
binding in 
solution) 
(62) 
influence of 
pH, 
fructose, 
ethanol on 
precipitation 
of salivary 
proteins 
x x 
tannic acid 
or wine 
multiple 
polymers of 
PACs 
SDS PAGE 
25C with 
either tannic 
acid or wine 
(pH 3.6/3.6) 
with 2-4-6 
g/L fructose, 
manoprotein
s, tartaric 
acid. 11% 
ETOH 
Lower pH 
increased 
binding > 
decreased 
hydrophobic
ity and 
increased 
hydrophobic 
binding; this 
is more 
prominent in 
wine than in 
tannic acid 
(increase in 
21.7 vs. 11, 
9 
respectively
). 
ETOH/fruct
ose 
negatively 
effects 
precipitation 
(disruption 
of H bonds 
between 
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polyphenols 
and 
proteins; 
ETOH may 
change 
conformatio
n of PRP 
and 
solubility of 
tannin and 
change 
reactivity; 
carbohydrat
e molecule 
CH2OH 
may also 
reduce 
binding sites 
to proteins 
by binding 
to NH3 
proline 
surfaces on 
proteins; as 
pH 
decreases, 
wine more 
commonly 
precipitates 
before 
tannic acid 
(50) 
PRP 
alleviation 
of intestinal 
enzyme 
binding by 
tannins 
o  EgCG EgCG 
in vitro 
digestion 
stability, 
absorbance 
for 
reactivity, 
SDS PAGE, 
HPLC 
gastric juice 
pH 2.07 c 
pepsin; 
duodenal 
juice pH 7.8 
c/ lipase, 
pancreatin 
with PRP: 
IC50 of 
chymotrypsi
n, trypsin, 
lactase 
increased 2-
3x; 
maximum 
pH effect of 
PRP at ~5-6, 
lower had 
increased 
protein 
binding, 
higher 
reduced 
(Figure 3); 
PRP bound 
and 
recovered 
EgCG >2x 
in duodenal 
digestion, 
no effect in 
gastric or 
control 
solutions; 
PRP are 
resistant to 
proteolytic 
digestion 
(60) 
saliva and 
hydrophobic 
o x wine tannins 
multiple 
polymers of 
PACs 
TRAP 
1:5 saliva to 
wine ratio 
with acidic 
Moderate 
removal of 
polyphenol 
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interactions 
with tannins 
extraction 
(1% TFA) 
with 1 ml 
saliva 
(45) 
binding 
mechanism 
tannins 
o x 
EGCG, 
EGC, PGG 
penta and 
tetra 
gallotannins 
NMR, 
diffusion, 
dynamic 
light 
scattering 
20mM 
polyphenol 
solutions 
2mM PRP 
(mouse 
PRP); pH 
3.8 
Preferential 
binding to 
polyphenols 
at the 
proline 
residues; but 
interactions 
also occur at 
the arginine 
and 
phenylalani
ne side 
chains; 
polypeptides 
self-
associate 
and so the 
number of 
binding sites 
does not 
equal the 
concentratio
n of 
solution. 
The 
strongest 
self-
association 
is PGG; 
ECG and 
EGCG same 
self-
association 
suggesting 
that H 
bonding is 
not primary 
mode of 
self-
association, 
but 
hydrophobic 
bonds are. 
Most 
binding sites 
on PRP can 
be filled 
simultaneou
sly; arginine 
strengthens 
the bonds of 
tannin-
phenylalani
ne/proline, 
but does not 
independent
ly bind. 
Longer PRP 
'wrap' 
around 
tannins 
(higher 
affinity); at 
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lower temp, 
multidendat
e binding. 
Binding 
affinity: 
PGG>TGG
>TG>EGC
G~EGG. 
Stages of 
binding: 
reversible 
hydrophobic 
binding of 
polyphenol 
that gives a 
soluble 
complex due 
to stacking, 
particularly 
of 
hydrophobic 
galloyl 
rings. 2 
addition of 
polyphenol, 
and two 
peptides are 
crosslinked 
by two 
polyphenol 
protein 
interactions, 
and the 
complex 
becomes 
insoluble; 
this is 
different for 
different 
polyphenols, 
for example: 
3:1 EGCG 
vs. 0.5:1 
PGG 3) 
phase 
separation 
and 
aggregation 
of insoluble 
complexes 
determined 
by the 
surface 
charge 
(EGCG: pH 
3.8; 50% 
monomers, 
2.3/3 
binding sites 
occupied 
(monomer 
and dimer 
binding) vs. 
PGG 64% 
monomeric, 
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0.4/3 
binding sites 
are occupied 
at 
precipitation
. 
(52) 
type of 
polyphenol 
tannin 
binding 
o  
catechin, 
epicatechin, 
B2, C1 
dimers, 
trimers, 
monomers 
RPHPLC 
pH 3.2 
either 1:1 or 
1:2 v/v 
mixture; 
37C 90 min 
incubation 
Flavone 
type and 
concentratio
n of protein 
effect 
precipitation
, but there is 
also a 
significant 
interaction 
between the 
compound 
and saliva; 
not all 
flavones 
behave the 
same way in 
saliva; C1 < 
epicatechin 
< catechin < 
B2; protein 
concentratio
n> = more 
precipitation
. Increased 
concentratio
n of 
polyphenol 
= more 
precipitation
. More 
protein had 
pronounced 
effect on 
polyphenols 
with less 
affinity (C1 
and 
epicatechin)
; most 
pronounced 
reduction in 
affinity with 
smaller 
molecules. 
In lower 
concentratio
ns of 
monomers, 
increased 
precipitation 
of protein 
(64) 
interaction 
of PRP with 
galloyl ring 
and 
pyrrolidine 
ring 
x  tannic acid 
monomers, 
dimers, 
trimers 
NMR 
1:0-1:5.6 
ratio of PRP 
to 
polyphenol 
Increase in 
temp or 
decrease in 
pH 
solubilize 
complexes. 
Changes in 
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chemical 
shifts 
suggested 
binding 
rather than 
conformatio
nal changes; 
proline is 
key binding 
site. More 
complexes 
bound = less 
dissociation. 
(63) 
stereochemi
stry of 
tannins 
o  EgCG EgCG NMR 
pH 3.5; 100 
mM and 5 
mM NaCl 
Ionic 
concentratio
n changes 
conformatio
ns of PRP to 
be more 
structured at 
100 mM, 
although 
both have 
unfolded 
conformatio
n and there 
is a higher 
level of 
disorder in 
the PRP at 
100 mM. On 
binding to 
EGCG, 
secondary 
structure of 
the protein 
was changed 
at 100mM 
but not 5 
mM; NMR 
modeling 
suggests 
beta sheet 
structure of 
Proline 
residues 
after tannin 
binding; 
residual 
sites are 
preferential 
for binding 
(43) 
mechanism 
of binding 
o  
EgCG, B2, 
B23OG 
dimers, 
EgCG 
MS-SAXS 
Interaction 
of IB5 with 
various 
tannins; 
water/ETO
H 88:12 at 
pH 3.3. 10 
µM IB5 to 
tannin 
solution for 
ratio of 1:10 
protein: 
polyphenol 
Polyproline 
helix and 
repeat 
proline 
sequences 
are most 
preferentiall
y bound, 
they are 
surrounded 
by glycine 
and alanine 
which give 
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more 
flexibility 
and 
establish 
increased 
number of H 
bonds. 
While PRP 
are 
unstructured
, the 
polyproline 
regions are 
rigid and 
provide 
anchoring 
points to 
tannins. 
Shorter 
PRPs do not 
change 
conformatio
n around 
tannins. 
Noted that 
extended 
tannin 
structure 
also 
precipitated 
binding 
(44) 
mechanism 
of binding 
o  B3 Trimer 
MS-circular 
dichroism 
pH 3.5 
tannin 
binding does 
not modify 
peptide 
folding; at 
low 
concentratio
n, 34% TII 
helix, 66% 
extended 
and random 
colloid 
conformatio
n; there are 
extended 
conformatio
ns with a 
type II helix 
with 7 
residues 
(IB7); initial 
H bonding 
to proline 
residues; the 
PRP studied 
was 
amphiphilic, 
tannin 
binding to 
the 
hydrophilic 
face (H 
bonds) 
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Appendix C - Inclusion Criteria 
 
1. Studies that include long-term effects of tannin consumption on PRP outcomes and non-
heme iron bioavailability 
2. Studies that include at least two key words, tannin AND salivary proline-rich protein OR 
non-heme iron 
AND 
3.) Studies that explore biochemical modeling for binding mechanisms of tannins and 
PRPs  
4.) Studies that explore binding affinity for PRP and tannins  
5.) Studies that compare mechanism of non-heme iron-tannin chelation to Tannin-PRP 
binding 
Exclusion criteria: 
1.) Validity studies for measurement tools 
2.) Assessment studies of food tannin content or food non-heme iron content 
3.) Studies that include surrogate PRP proteins (albumin, BSA, amylase, gelatin) 
4.) Studies that explore PRP without tannin or non-heme iron binding 
5.) Ruminant modeling 
6.) Specialized conditions: cancer, Sjogren’s syndrome, burning mouth syndrome, 
hemochromatosis 
7.) Studies did not present comparative findings (descriptive or qualitative studies describing 
astringency or optical tongue without biochemical mechanisms/affinity studies) 
8.) In vivo animal studies that did not explore non-heme iron bioavailability with PRP and 
tannins 
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Appendix D - Clinical Screening Questionnaire 
Tannin-Dose Response Trial Screening Questionnaire  
 
Name:                                                                                   DOB: 
Height:                                                                                  Weight: 
 
 
1.) Medical history: 
Are you currently taking any prescribed medications? (please list the name, how often you take, and the dose) 
 
 
 
Are you currently taking any non-prescribed medications, including multivitamins, herbs, mineral supplements, 
vitamin supplements? (please list the name, how often you take, and the dose) 
 
 
 
 
Are you currently taking any iron supplementation (including prescribed or over the counter iron supplements)? 
(please list what you are taking, and your current dose) 
 
 
 
Do you have any food allergies? (please list your food allergies, and reaction to the food) 
 
 
 
 
 
 
 
 
Are you currently pregnant, planning to become pregnant, or breastfeeding? 
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Are you a current tobacco (smoking, chewing) user?  
 
How often do you consume alcohol (circle one)? 
Daily  Weekly  Monthly  Never 
If you consume alcohol, how much do you consume, per occasion? One drink equals 1 oz of  liquor, 12 
ounces of beer, or 4 oz of wine (circle one). 
1 drink   2-3 drinks 3 or more drinks 
 
Please check the following medical conditions that you may have: 
History of gastrointestinal illness, including:  
_____ Irritable bowel syndrome 
_____ Irritable bowel disease (Chrohn’s, Ulcerative Colitis) 
       _____ History of colostomy/colectomy 
       _____ Diagnosed condition of malabsorption (including diagnosis of chronic diarrhea) 
       _____ Other, please list:  
 
History of oral illness, including:  
_____ Sjogren’s syndrome 
_____ Burning mouth syndrome 
       _____ Active mouth bleeding, oral ulcerations 
       _____ Periodontal or gum disease 
      _____ Multiple or severe cavities 
      _____ Other, please list: 
 
History of blood disorders, including:  
_____ Sickle cell anemia 
_____ Alpha or Beta Thalassemia 
       _____ Anemia of chronic disease 
       _____ Other, please list:  
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Appendix E - Effect of previous dose on dose-response 
Hemoglobin: 
Table of Hb by previous 
Hb(Hb) previous(previous) 
Frequency 0 0.03 1.5 Total 
drop 1 3 0 4 
improve 1 3 1 5 
maintain 0 0 2 2 
Total 2 6 3 11 
 
Statistic DF Value Prob 
Chi-Square 4 6.9667 0.1377 
Likelihood Ratio Chi-Square 4 7.8869 0.0958 
Mantel-Haenszel Chi-Square 1 5.2673 0.0217 
Phi Coefficient  0.7958  
Contingency Coefficient  0.6227  
Cramer's V  0.5627  
WARNING: 100% of the cells have expected counts less 
than 5. Chi-Square may not be a valid test. 
 
Fisher's Exact Test 
Table Probability (P) 0.017
3 
Pr <= P 0.225
1 
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Ferritin 
 
Table of Ferritin by previous 
Ferritin(Ferritin) previous(previous) 
Frequency 0 0.03 1.5 Total 
drop 2 3 0 5 
improve 0 2 3 5 
maintain 0 1 0 1 
Total 2 6 3 11 
 
Statistic DF Value Prob 
Chi-Square 4 6.6000 0.1586 
Likelihood Ratio Chi-Square 4 8.4281 0.0771 
Mantel-Haenszel Chi-Square 1 1.2447 0.2646 
Phi Coefficient  0.7746  
Contingency Coefficient  0.6124  
Cramer's V  0.5477  
WARNING: 100% of the cells have expected counts less 
than 5. Chi-Square may not be a valid test. 
 
Fisher's Exact Test 
Table Probability (P) 0.0216 
Pr <= P 0.1775 
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% Max iron absorption 
Table of iron_abs by previous 
iron_abs(iron 
abs) previous(previous) 
Frequency 0 0.03 1.5 Total 
drop 0 1 2 3 
improve 2 5 1 8 
Total 2 6 3 11 
 
Statistic DF Value Prob 
Chi-Square 2 3.4375 0.1793 
Likelihood Ratio Chi-Square 2 3.6651 0.1600 
Mantel-Haenszel Chi-Square 1 2.9584 0.0854 
Phi Coefficient  0.5590  
Contingency Coefficient  0.4880  
Cramer's V  0.5590  
WARNING: 100% of the cells have expected counts less 
than 5. Chi-Square may not be a valid test. 
 
Fisher's Exact Test 
Table Probability (P) 0.1091 
Pr <= P 0.2061 
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iAUC: 
Table of AUC by previous 
AUC(AUC) previous(previous) 
Frequency 0 0.03 1.5 Total 
drop 0 4 1 5 
improve 2 2 2 6 
Total 2 6 3 11 
 
Statistic DF Value Prob 
Chi-Square 2 2.9333 0.2307 
Likelihood Ratio Chi-Square 2 3.7009 0.1572 
Mantel-Haenszel Chi-Square 1 0.1980 0.6563 
Phi Coefficient  0.5164  
Contingency Coefficient  0.4588  
Cramer's V  0.5164  
WARNING: 100% of the cells have expected counts less 
than 5. Chi-Square may not be a valid test. 
 
Fisher's Exact Test 
Table Probability (P) 0.0974 
Pr <= P 0.4156 
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Appendix F - Individual level iron absorption data 
Participant Value 
0.03 g 0.03 g 0.25 g 0.25 g 1.5 g 1.5 g 
Week 0 Week 4 Week 0 Week 4 Week 0 Week 4 
1 
Hemoglobin (g/dL) 12.9 12.9 13.8 13.8 13.6 13.6 
Ferritin (ng/mL) 30.0 28.0 27.0 36.0 35.0 44.0 
% max iron abs 1.7 2.7 9.2 9.6 -1.6 3.7 
iAUC (µg/dL*hr) 2.0 19.2 44.3 53.8 4.0 18.5 
2 
Hemoglobin (g/dL) 13.6 13.9 13.1 12.7 13.6 14.2 
Ferritin (ng/mL) 7.0 8.0 8.0 7.0 10.0 9.0 
% max iron abs 16.2 24.2 9.3 17.5 13.9 17.3 
iAUC (µg/dL*hr) 1208.6 652.8 789.9 1146.9 382.8 417.4 
3 
Hemoglobin (g/dL) 13.7 14.1 13.7 13.7 13.6 13.6 
Ferritin (ng/mL) 24.0 28.0 19.0 38.0 22.0 28.0 
% max iron abs 21.7 16.9 24.6 14.2 16.0 13.2 
iAUC (µg/dL*hr) 270.8 63.3 171.0 55.7 103.1 129.0 
4 
Hemoglobin (g/dL) 13.6 12.9 13.2 13.4 12.9 13.0 
Ferritin (ng/mL) 23.0 27.0 29.0 26.0 22.0 19.0 
% max iron abs 9.2 0.9 7.9 -6.5 11.5 -2.7 
iAUC (µg/dL*hr) 82.3 3.7 114.1 -49.6 141.8 -26.0 
5 
Hemoglobin (g/dL) 12.1 12.1 12.0 12.1 11.7 11.6 
Ferritin (ng/mL) 23.0 21.0 26.0 20.0 26.0 30.0 
% max iron abs -11.5 0.9 -2.6 3.6 -7.1 2.1 
iAUC (µg/dL*hr) 0.0 -29.2 0.0 45.3 -60.5 27.6 
6 
Hemoglobin (g/dL) 14.0 13.2 13.1 12.9 13.2 12.7 
Ferritin (ng/mL) 38.0 38.0 27.0 24.0 27.0 43.0 
% max iron abs 23.9 22.2 23.9 25.0 18.9 15.6 
iAUC (µg/dL*hr) 123.1 201.2 214.1 253.1 331.9 53.4 
7 
Hemoglobin (g/dL) 14.0 14.7 14.9 14.2 15.0 15.5 
Ferritin (ng/mL) 88.0 70.0 94.0 66.0 111.0 109.0 
% max iron abs 3.8 10.3 6.0 15.8 1.0 2.2 
iAUC (µg/dL*hr) 7.9 35.0 10.8 26.0 -4.2 4.3 
8 
Hemoglobin (g/dL) 12.7 13.6 12.6 13.2 12.8 12.8 
Ferritin (ng/mL) 19.0 26.0 22.0 22.0 24.0 22.0 
% max iron abs 28.8 5.2 20.4 23.5 17.4 15.3 
iAUC (µg/dL*hr) 389.4 47.2 300.6 319.4 231.3 342.6 
9 
Hemoglobin (g/dL) 12.8 13.0 13.1 13.2 13.0 13.0 
Ferritin (ng/mL) 23.0 44.0 30.0 34.0 30.0 21.0 
% max iron abs 25.6 17.5 17.0 8.9 26.8 24.2 
iAUC (µg/dL*hr) 1770 600 1515 2835 1065 1440 
10 
Hemoglobin (g/dL) 12.9 13.6 13.9 13.8 13.1 12.9 
Ferritin (ng/mL) 14.0 18.0 17.0 19.0 14.0 22.0 
% max iron abs 9.4 19.2 9.0 12.9 22.7 15.4 
iAUC (µg/dL*hr) 62.8 327.2 91.9 91.3 336.3 85.5 
11 
Hemoglobin (g/dL) 12.8 12.6 13.0 14.1 14.3 14.4 
Ferritin (ng/mL) 100.0 157.0 95.0 118.0 119.0 142.0 
% max iron abs 10.9 -3.0 8.2 12.1 4.0 6.5 
iAUC (µg/dL*hr) 23.6 3.3 24.9 29.3 8.8 14.1 
iAUC: incremental iron under the curve 
 
